Entries added 2026-08-26: Central Motor-Drive Fatigability Cascade (Bedard 2026)

Chapter Abstract

This chapter presents detailed protocols for research studies designed to test hypotheses derived from pediatric ME/CFS outcomes and to advance understanding of recovery mechanisms. These proposals range from observational cohort studies to randomized controlled trials, each with explicit hypotheses, design specifications, and expected outcomes.

The evidence tables that motivate and constrain these proposed studies are consolidated in Appendix G (Research Synthesis Tables), and the supporting literature is annotated in Appendix H (Annotated Bibliography of ME/CFS Literature).

Chapter Roadmap: How to Use This Chapter

For patients: skim the early-intervention-trial and pediatric-adult-study sections to see how recovery-focused trials are being designed, and the HRV-pacing section for a pacing approach you could relate to daily management.

For caregivers: read the periodization and infection-decline study sections for designs relevant to pacing and relapse.

For clinicians: review the LSR-biomarker-validation and wound-healing-biomarker study sections as near-term candidate diagnostics, and the treatment-sequence-RCT section for a paradigm-shaping trial design.

For researchers: this chapter is a protocol library — start with the replication and prodromal sections, then the highest-value protocols (biomarker validation, PEM-recovery-duration, viral-clearance-longitudinal, pharmacogenomics).

Speculation p=0.20Null Subtype 1 — Absent: Receptor or Enzyme Never Present

Evidence: Receptor occupancy theory establishes that a null agonist response does not equate to receptor absence — it only indicates insufficient occupancy at that concentration. Bypass agonist logic (direct downstream activator confirming downstream machinery intact) is pharmacologically sound but never tested in ME/CFS. (Finlay, Duffull, and Glass 2020)
Citations: (Finlay, Duffull, and Glass 2020)
Mechanism: Receptor, ion channel, enzyme, or transporter never existed in patient’s tissue — or lost irreversibly. Drug never had a target. Bypass probe: give downstream agonist; if bypass produces response, receptor was absent. If bypass fails, downstream machinery also broken.
Chapter ref: ch33: null subtyping — absent vs blocked vs overwhelmed
Prediction: In patients with TRPM3 null response to pregnenolone, calcium ionophore (A23187 or ionomycin) produces calcium flux in PBMCs — confirming TRPM3 is specifically absent while calcium signalling machinery is intact. Falsified if ionophore also produces null, though this would suggest broader calcium signalling defect rather than TRPM3-specific absence.
Treatment: None — absent target cannot be targeted. Treatment shifts to downstream pathways or unrelated mechanisms.
Limitation: No published ME/CFS study has tested bypass-agonist logic systematically. Probe requires in vitro or ex vivo setup (PBMC calcium flux, functional receptor assay) not available in standard clinical settings.

Speculation p=0.20Null Subtype 2 — Blocked: Receptor Present but Orthosteric Site Inaccessible

Evidence: GPCR autoantibodies can act as orthosteric antagonists, allosteric modulators, biased agonists — well-established pharmacology (Skiba and Kruse 2021). GPCR AAb documented in POTS (allosteric modulation (Sunami, Sugaya, and Takahashi 2025)) and ME/CFS (detection methods contested — Germain2025 REAP/Luminex null vs CellTrend ELISA positive). β-arrestin-biased AAb signalling produces chronic functional blockade distinct from simple orthosteric antagonism (Dodge-Kafka et al. 2026).
Citations: (Skiba and Kruse 2021) (Sunami, Sugaya, and Takahashi 2025) (Dodge-Kafka et al. 2026)
Mechanism: Receptor structurally present but orthosteric site occupied — by autoantibody, competitive endogenous ligand, or PTM locking inactive conformation. Probe: allosteric ligand binding different site may produce response when orthosteric agonist fails. If allosteric works → blocked, not absent. If both fail → absent or allosteric site also disrupted.
Chapter ref: ch33: null subtyping — absent vs blocked vs overwhelmed
Prediction: In β2-AR AAb-positive ME/CFS patients (by validated functional assay), allosteric β2-AR modulator (e.g. Cmpd-6 or biased ligand) produces measurable cAMP response in PBMCs while orthosteric agonist (isoproterenol) does not — confirming orthosteric-site blockade. Falsified if both produce null, suggesting receptor absence or broader signalling defect rather than site-specific blockade.
Treatment: Immunoadsorption or plasmapheresis to remove AAb, then retest orthosteric drug. B-cell depletion for AAb source elimination. Allosteric bypass as alternative strategy when AAb removal is impractical.
Limitation: GPCR AAb detection in ME/CFS is contested — largest screen (Germain2025 n=172) null. Probe requires validated functional GPCR AAb assay not clinically available. No published study has tested allosteric bypass in AAb-positive ME/CFS patients. If GPCR AAb in ME/CFS are non-pathogenic or measurement artefacts, this null subtype collapses.

Speculation p=0.15Null Subtype 3 — Overwhelmed: Receptor Outcompeted by Endogenous Antagonist

Evidence: KYNA as endogenous NMDA antagonist binding glycine co-agonist site is well-established neuroscience (Schwarcz et al. 2012). Kynurenine pathway dysregulated in ME/CFS (Behrouz Kavyani et al. 2024) but KYNA direction inconsistent — some studies show elevation, others depletion. KYNA binding site (glycine co-agonist, not glutamate site) means concentration-competition probe must control for glycine levels (Hazrati et al. 2024).
Citations: (Schwarcz et al. 2012) (Behrouz Kavyani et al. 2024) (Hazrati et al. 2024)
Mechanism: Receptor present, structurally intact, capable of signalling — but outcompeted by supraphysiological endogenous antagonist at orthosteric or co-agonist site. Probe: escalate drug dose above therapeutic range; if drug works at high dose → overwhelmed (higher concentration displaced endogenous antagonist). If fails at all doses → absent or blocked.
Chapter ref: ch33: null subtyping — absent vs blocked vs overwhelmed
Prediction: In ME/CFS patients with confirmed elevated plasma KYNA (>2 SD above healthy controls), escalating ketamine dose over 3 sessions (0.1 → 0.5 → 1.0 mg/kg) produces dose-dependent symptom improvement linear with dose — while NMDA-agonist-naive patients show flat dose-response. Falsified if high-dose ketamine produces no improvement or produces psychosis/dissociation before therapeutic effect — suggesting KYNA elevation is compensatory (neuroprotective) rather than causal for NMDA hypofunction.
Treatment: Kynurenine pathway inhibition (IDO/TDO inhibitor) to lower KYNA, allowing standard-dose NMDA drugs to work. Alternatively, glycine-site agonist (D-serine) to competitively displace KYNA without NMDA overstimulation risk. Dose escalation of NMDA-targeting drug with safety monitoring.
Limitation: KYNA direction inconsistent in ME/CFS — applies only to elevated-KYNA subset (minority). Probe requires measurement of both KYNA and glycine levels. Concentration-competition probe (escalating doses of psychoactive drugs) carries clinical risk (dissociation, psychosis). No published study has tested this probe. Framework may apply to a negligible fraction of ME/CFS patients.

Open Question p=0.20Null Ladder Extension — Tripartite Null Taxonomy with Distinguishing Probes

Evidence: Synthesises receptor occupancy theory (Finlay, Duffull, and Glass 2020), GPCR AAb pharmacology (Skiba and Kruse 2021), GPCR AAb in POTS (Sunami, Sugaya, and Takahashi 2025), β-arrestin-biased AAb signalling (Dodge-Kafka et al. 2026), and kynurenine pathway dysregulation in ME/CFS (Behrouz Kavyani et al. 2024) into a unified framework for distinguishing absent/blocked/overwhelmed null responses. Zero empirical validation in ME/CFS — all probes are proposed and untested.
Citations: (Finlay, Duffull, and Glass 2020) (Skiba and Kruse 2021) (Sunami, Sugaya, and Takahashi 2025) (Dodge-Kafka et al. 2026) (Behrouz Kavyani et al. 2024) (Hazrati et al. 2024)
Mechanism: Binary null logic (null → mechanism eliminated) is incomplete. Three distinct null types exist with mutually exclusive diagnostic implications and distinguishing probes. Absent: receptor never present (bypass agonist probe). Blocked: receptor present but orthosteric site occupied by AAb/ligand/PTM (allosteric probe). Overwhelmed: receptor present but outcompeted by endogenous antagonist (concentration-competition probe). Each null type changes treatment strategy differently — blocked nulls should be unblocked, not abandoned; overwhelmed nulls should be dose-adjusted, not abandoned.
Chapter ref: ch33: null subtyping — absent vs blocked vs overwhelmed
Prediction: In a cohort of 100 ME/CFS patients with documented null responses to ≥3 drugs, systematic null-subtyping using the three probes identifies ≥5% of nulls as BLOCKED or OVERWHELMED (not ABSENT) — confirming that binary null logic produces false eliminations in a measurable minority. Falsified if all nulls resolve to ABSENT on probing, meaning the tripartite framework adds no clinical value over binary null logic.
Treatment: Framework-level — no direct treatment recommendation. Informs interpretation of existing null responses and design of future pharmacodiagnostic protocols.
Limitation: All probes untested in ME/CFS. BLOCKED subtype contingent on validated pathogenic GPCR AAb detection (contested). OVERWHELMED subtype contingent on KYNA elevation (minority of patients). Framework may add conceptual precision with zero practical impact if blocked/overwhelmed null prevalence is negligible.

Speculation p=0.25Menstrual Cycle as Endogenous Pharmacodiagnostic Probe — Drug Response Tracking Across Cycle Phases

Evidence: Oestrogen rapidly potentiates NMDA signalling via ER transactivation of MAPK/ERK and PI3K/Akt (review, largely animal data (Sellers, Raval, and Srivastava 2015), cert 0.36 discounted). Progesterone-derived allopregnanolone enhances GABA-A tonic current, with receptor subunit composition shifting drug sensitivity (review, preclinical (Locci and Pinna 2017), cert 0.36 discounted). Oestrogen modulates serotonin synthesis, release, and receptor sensitivity (review (Shadani et al. 2024), cert 0.44 discounted). Menstrual cycle hormones produce measurable whole-brain structural changes in humans (n=30 (Rizor et al. 2024), cert 0.53 discounted). Thomas et al. 2026 explicitly call for menstrual-cycle-aware sampling in ME/CFS research (review (Thomas et al. 2026), cert 0.60 discounted). PET null findings constrain but do not falsify: 5-HT1A binding unchanged across cycle (n=13 (Jovanovic et al. 2009)), D2 availability unchanged (n=16 (Petersen et al. 2021)). CYP450 expression stable across rat oestrous cycle (S.-Y. Lee et al. 2012) suggests PD over PK interpretation. PK data in humans mixed (review (Bosch, Sommer, and Touw 2025)). Zero human studies testing cycle-phase-dependent drug response as receptor-system probe. Origin: brainstorm — menstrual cycle dopaminergic mast cell probe, extended to pharmacodiagnostic drug-response tracking.
Citations: (Sellers, Raval, and Srivastava 2015) (Locci and Pinna 2017) (Shadani et al. 2024) (Rizor et al. 2024) (Thomas et al. 2026) (Jovanovic et al. 2009) (Petersen et al. 2021) (S.-Y. Lee et al. 2012) (Bosch, Sommer, and Touw 2025)
Mechanism: Menstrual hormone fluctuations (oestrogen at follicular/ovulatory peak → potentiates NMDA, D2, 5-HT1A signalling; progesterone/allopregnanolone at luteal peak → potentiates GABA-A) provide a predictable, endogenous oscillation of receptor function. Tracking drug response across two full cycles maps the drug’s mechanism to hormone-gated receptor families: follicular benefit → oestrogen-coupled (NMDA/D2/serotonergic); luteal benefit → progesterone/GABA-coupled; flat response → hormone-independent. The probe relies on functional sensitivity differences (downstream signalling cascade potency), not receptor density changes (PET-null for D2/5-HT1A binding). PK confound (oestrogen modulation of CYP) must be controlled via serum drug level measurement.
Chapter ref: ch34 sec-10 subsec-07: endogenous probes — menstrual cycle pharmacodiagnostic
Prediction: In a prospective N-of-1 trial, premenopausal ME/CFS patients track a drug with known receptor pharmacology across 3+ cycles. Cycle-phase response variation >30% with follicular-phase benefit → D2 is oestrogen-coupled. Falsified if (a) drug serum levels vary by cycle phase (PK confound), (b) same variation with placebo, or (c) D2/5-HT1A functional output (cAMP response to agonist in PBMCs) shows zero cycle-phase variation in humans.
Treatment: None — observational probe, not a treatment recommendation. Formalises cycle-phase drug-response tracking as a zero-cost diagnostic method. Applies only to menstruating patients with regular cycles (excludes postmenopausal, continuous hormonal contraception, prepubertal, male, amenorrhoeic).
Limitation: No human study has directly tested the probe concept in any disease. The >30% threshold is arbitrary. Two-timepoint sampling (follicular vs luteal) may miss periovulatory oestrogen peak. Cycle-phase symptom patterns confounded by non-hormonal factors (menstrual pain, sleep disruption). Requires minimum 8 weeks for reliable inference. All mechanistic evidence for oestrogen→receptor modulation from general-population and animal studies; no ME/CFS-specific validation. Risk of over-interpretation, though risk of harm is negligible (observational only). Origin: brainstorm.

Speculation p=0.20Menstrual Cycle Phase at Drug Initiation as Confound in N-of-1 Trial Design

Evidence: Logical corollary of Menstrual Cycle as Endogenous Pharmacodiagnostic Probe. If cycle-phase hormone levels modulate receptor sensitivity, a D2 agonist started during high-oestrogen follicular phase will produce a different initial response than the same drug started during low-oestrogen luteal phase — creating a systematic confound in N-of-1 trial interpretation that reads as tachyphylaxis (if started at follicular peak followed by luteal decline) or inefficacy (if started at luteal nadir). Zero human data. Origin: brainstorm — Phase 5 extension.
Citations: (Sellers, Raval, and Srivastava 2015) (Petersen et al. 2021) (Rizor et al. 2024)
Mechanism: Cycle phase at drug initiation → initial receptor state (oestrogen-potentiated vs baseline) → initial drug response magnitude. Follicular-start trials produce higher initial efficacy for oestrogen-coupled drugs → subsequent luteal-phase decline misinterpreted as tachyphylaxis or tolerance. Luteal-start trials produce lower initial efficacy → drug abandoned as ineffective. Standardising initiation to day 1 of menses (hormone nadir) OR recording cycle phase as covariate eliminates the confound.
Chapter ref: ch34 sec-10 subsec-07: endogenous probes — menstrual cycle pharmacodiagnostic
Prediction: In pooled N-of-1 trial data from premenopausal ME/CFS patients, cycle phase at drug initiation predicts response magnitude for dopaminergic drugs (follicular-start higher initial response than luteal-start). Null result would suggest cycle-phase-independent initial response, removing the confound.
Treatment: Methodological recommendation: standardise drug trial initiation to a specific cycle phase (day 1 of menses) or record phase as covariate and test for phase × response interaction. No treatment recommendation.
Limitation: No prospective data. Requires coordinating drug trial initiation with menstrual phase — adds logistical burden. If confirmed null, this recommendation is unnecessary. If confirmed positive, applies only to oestrogen-coupled drugs (D2 agonists, SSRIs, NMDA modulators), not all medications. Origin: brainstorm.

Open Question p=n/aCan Cycle-Phase Drug Response Patterns Stratify ME/CFS Patients by Mechanism?

Evidence: Entirely inferential — builds on Menstrual Cycle as Endogenous Pharmacodiagnostic Probe. If cycle-phase-dependent drug response identifies patient subgroups with oestrogen- or progesterone-coupled pathophysiology, these subgroups may differ in prognosis, treatment trajectory, or biomarker profile. Zero data.
Mechanism: Cycle-phase response pattern → patient-level mechanism identification → treatment stratification: oestrogen-dependent responders may benefit from hormonal modulation or continuous-cycle contraceptives; hormone-independent responders would waste time on hormonal strategies. The concept is that cycle-phase variation is not just diagnostic for the drug’s mechanism but for the patient’s disease pathophysiology.
Chapter ref: ch34 sec-10 subsec-07: endogenous probes — menstrual cycle pharmacodiagnostic
Prediction: If cycle-phase drug response is prospectively tracked across a cohort, patients with >30% follicular response variation will differ from those with less than 15% variation in: (a) response to hormonal modulation, (b) D2 agonist efficacy, (c) oestrogen receptor gene expression in PBMCs. Falsified if no patient-level differences emerge beyond the drug-level mechanism inference.
Treatment: Research-stage only — not a basis for current clinical decisions.
Limitation: Requires validation of the base probe concept first. Patient stratification by cycle-phase response is a second-order inference. Entirely untested. Origin: brainstorm.

FH p=0.65OXPHOS–V̇O₂ₘₐₓ Uncoupling Reflects Disease-Intrinsic Mitochondrial Dysfunction, Not Deconditioning

Evidence: Charlton et al. (2026, Nature Communications) (Charlton et al. 2026): n=105 total (26 ME/CFS, 25 Long COVID, 30 healthy controls, 24 pre-/post-bed-rest). OXPHOS capacity (high-resolution respirometry) correlated with V̇O₂ₘₐₓ (maximal CPET) in healthy controls (r>0) and pre-/post-bed-rest, but not in either patient group. Intrinsic mitochondrial function (OXPHOS/SDH, E/L coupling) impaired in patients but not after bed rest. Corroborated by Joseph 2021 (invasive CPET: impaired O₂ extraction in ME/CFS (Joseph et al. 2021)), Germain 2025 (plasma proteomics: disrupted proteomic-VO₂max associations in ME/CFS (Germain et al. 2025)), and Eggelbusch 2024 (bed rest: preserved OXPHOS–performance coupling despite atrophy (Eggelbusch et al. 2024)).
Citations: (Charlton et al. 2026) (Joseph et al. 2021) (Germain et al. 2025) (Eggelbusch et al. 2024)
Mechanism: Mitochondrial respiratory capacity normally scales with whole-body aerobic performance. In ME/CFS, the coupling breaks: patients have low V̇O₂ₘₐₓ regardless of how much mitochondrial machinery they retain, and intrinsic mitochondrial function is impaired (lower OXPHOS/SDH, lower E/L coupling). This is not a deconditioning effect — bed rest reduces both OXPHOS and V̇O₂ₘₐₓ but preserves their correlation. The limiting factor is either downstream of the mitochondrion (O₂ delivery failure, microvascular obstruction) or upstream (CNS-mediated motor output restriction).
Chapter ref: ch20: universal mechanisms — Family 17 structural integrity / (fhyp-oxphos-vo2max-uncoupling?)
Prediction: Interventions that increase mitochondrial content (pyruvate dehydrogenase activation, NAD⁺ precursors) should restore the OXPHOS–V̇O₂ₘₐₓ correlation if the uncoupling is a modifiable mitochondrial failure. If V̇O₂ₘₐₓ remains uncoupled despite raised OXPHOS capacity, the limiting factor is upstream (CNS motor output) or delivery-side (microvascular obstruction). Interventions improving O₂ delivery (volume expansion, pyridostigmine) that restore the correlation would localise the bottleneck to the microvasculature.
Treatment: Research-stage only. Implications for clinical approach: “reconditioning” is not a rational therapeutic strategy — the molecular machinery needed to adapt to exercise is itself impaired. Mitochondrial support strategies (CoQ10, NAD⁺ precursors) and microvascular therapies are rational targets.
Limitation: Single cohort, single lab (Wüst/VU Amsterdam). No independent replication of the OXPHOS–V̇O₂ₘₐₓ dissociation specifically. Mild–moderate patients only (daily steps 733–8609). Organelle-level finding; no patient-reported outcome data. Correlation design (change in V̇O₂ₘₐₓ after raising OXPHOS has not been tested prospectively).

A p=0.85Sixty-Day Bed Rest Fails to Reproduce ME/CFS Muscle Phenotype — Deconditioning Not the Explanation

Evidence: Charlton et al. (2026, Nature Communications) (Charlton et al. 2026) compared 60-day strict head-down tilt bed rest (n=24 healthy volunteers) against 26 ME/CFS patients, 25 Long COVID patients, and 30 healthy controls across multiple independent measurements: fibre typing (IHC), fibre-type-specific atrophy, mitochondrial respirometry, capillary morphology, whole-body CPET, ventilatory patterns. Five phenotypic dimensions diverged between bed rest and patients, each excluding deconditioning as the sole explanation.
Citations: (Charlton et al. 2026)
Mechanism: Bed rest produces: (1) generalised atrophy of all fibre types without shift; patients show Type I-selective atrophy and glycolytic shift. (2) Preserved OXPHOS–V̇O₂ₘₐₓ coupling; patients lose it. (3) Increased capillary density (atrophy outpaces capillary loss); ME/CFS shows lower capillary-to-fibre ratios. (4) Altered ventilatory pattern (increased V̇E/V̇CO₂ slope); patients’ ventilation is largely normal. (5) No intrinsic mitochondrial function impairment; patients show reduced OXPHOS/SDH and E/L coupling. The qualitative divergence at five independent levels makes deconditioning an insufficient explanation.
Chapter ref: ch20: Sixty-Day Bed Rest Fails to Reproduce the ME/CFS Muscle Phenotype — Deconditioning Is Not the Explanation; ch07: PEM connection (subsec-16); ch11: cardiovascular summary
Prediction: Future studies that include activity-matched sedentary controls (not bed rest but matched daily step counts to ME/CFS patients) should reproduce the qualitative divergence found by Charlton et al. — the patient phenotype is not reproducible by activity reduction alone. Falsified if an activity-matched sedentary control group (not bed rest) develops the same glycolytic shift, Type I atrophy, or OXPHOS–V̇O₂ₘₐₓ uncoupling as patients.
Treatment: Structural evidence that deconditioning is not the primary driver of exercise intolerance. Supports the concept that PEM is a disease-intrinsic phenomenon requiring targeted treatment of its underlying mechanisms (mitochondrial support, microvascular therapy, CNS energy budget), not “reconditioning.” Does not provide specific treatment evidence.
Limitation: Cross-sectional in patients (no longitudinal patient cohort). Bed rest participants younger than patient-matched controls. Head-down tilt is an imperfect model of ambulant deconditioning. All ambulant patients (mild–moderate). Single-lab findings awaiting independent replication. Correlation study — causation inferred from laboratory-controlled bed rest comparator, not directly tested in patients prospectively.

M p=0.25Contraindication Ladder: 4-Level Mechanism-Based Drug Interaction Classification

Evidence: Pharmacological classification derived from receptor pharmacology (Level 1), CYP metabolism (Level 2 — fluvoxamine+duloxetine: 460% AUC increase (Knadler et al. 2011)), autonomic physiology + 1 case report (Level 3 — (Dayal et al. 2025)), and metabolic-stress modelling + 1 ME/CFS stimulant RCT (Level 4 — (Blockmans et al. 2006), (Eckey et al. 2025)). Level 1 pairs are textbook pharmacology. Level 2 best-documented pair (fluvoxamine+duloxetine) has dedicated manufacturer PK study; cimetidine+aripiprazole is predicted from CYP pharmacology with zero PubMed interaction studies. Level 4 stimulant-PEM risk has direct ME/CFS evidence; rapamycin+metformin is mechanistic inference only. No existing DDI framework organizes interactions by mechanism type — the ladder is a novel organizational contribution.
Citations: (Knadler et al. 2011) (Blockmans et al. 2006) (Eckey et al. 2025) (Dayal et al. 2025) (Due Bruun et al. 2024) (Palma and Kaufmann 2020) (Everly, Heaton, and Cluxton 2004) (Lipworth and Grove 1997) (Ponticelli, Moroni, and Reggiani 2023)
Mechanism: Four ladder levels: (L1) Direct receptor antagonism — competitive occupation of same receptor for opposing purposes → pharmacologically certain, absolute contraindication. (L2) Pharmacokinetic catastrophe — Drug A inhibits CYP enzyme that Drug B needs for clearance → Drug B accumulates to toxic levels. (L3) Pharmacodynamic opposition — opposing physiological goals at systems level, not same receptor → temporally mitigatable. (L4) Metabolic PEM risk — drug increases metabolic demand, masks fatigue signal, or induces autophagy in an energy-compromised system → PEM amplification. Contraindication table: patient-experience-based permanent class-wide contraindications (e.g., LDN dysphoria → avoid all opioid-modulating drugs). (Origin: brainstorm)
Chapter ref: ch34: Diurnal Response Window as Circadian Pharmacodiagnostic Probe
Prediction: Falsifiable per-level: (L1) If a patient known to be on an opioid agonist tolerates LDN without blunted opioid effect or precipitated withdrawal → LDN did not achieve μOR occupancy at dose — the antagonism is dose-dependent, not absolute. (L2) If duloxetine at standard dose is co-administered with fluvoxamine and duloxetine AUC remains within normal range → patient is a CYP1A2 ultrarapid metaboliser (genotype-dependent bypass). (L3) If clonidine 0.1 mg + midodrine 5 mg co-administered simultaneously produces stable BP within 10% of baseline → the sympathetic-α1 axis has sufficient reserve to absorb dual modulation. (L4) If stimulant-treated ME/CFS patients show no increase in PEM frequency over 3 months vs placebo → activity masking is not the dominant PEM mechanism in that subpopulation.
Treatment: Structural safety framework — defines what NOT to combine. No new treatment proposed. Clinical utility: each contraindication is also a diagnostic signal — the adverse response reveals which system is load-bearing for that patient’s homeostasis. The table translates adverse events into mechanism-specific diagnostic inferences.
Limitation: L2 cimetidine+aripiprazole predicted-only (0 PubMed hits). L4 rapamycin+metformin predicted-only (0 adverse-interaction papers). L3 supported by 1 case report in a non-ME/CFS population. L1 pairs lack dedicated interaction studies (pharmacology-level evidence only). Contraindication table entries lack formal rechallenge data. No prospective validation of the ladder structure. Origin: brainstorm — pharmacological inference from receptor physiology + CYP metabolism + autonomic physiology + metabolic constraint modelling.

Speculation p=0.20Diurnal Response Window as Circadian Pharmacodiagnostic Probe

Evidence: Circadian receptor expression established in chronopharmacology: GR peak 04:00–08:00, TLR4 peak 18:00–00:00, H1 peak 02:00–06:00, D2/D3 striatal peak 12:00–16:00 (Levi 2024 review (Lévi et al. 2024)). ME/CFS: blunted cortisol awakening response, exaggerated HPA feedback (meta-analysis, n=1,388, 46 datasets (Woo et al. 2026) — discounted cert 0.88). Chronotherapy proof-of-concept: evening-timed prednisone improves fatigue in RA (CAPRA-2 RCT, n=350, FACIT-F +3.8 vs +1.6, p=0.0032 (Alten et al. 2015)). Diurnal cytokine-symptom coupling: PMR IL-6/IL-8/TNF-α peak 04:00–08:00, prednisolone chronotherapy abolishes symptoms (Galbo and Kall 2016). Post-infectious fatigue: clock gene dysregulation (CLOCK, BMAL1, PER2), epigenetic clock changes (Livieratos, Lockley, and Tsiodras 2025). CYP450/transporter circadian regulation (Okyar et al. 2024). Trial methodology guidelines (Hermida et al. 2021). (Origin: brainstorm)
Citations: (Lévi et al. 2024) (Woo et al. 2026) (Alten et al. 2015) (Galbo and Kall 2016) (Livieratos, Lockley, and Tsiodras 2025) (Okyar et al. 2024) (Hermida et al. 2021) (Cutolo 2019) (Zaki et al. 2019) (Ohdo 2021) (Guarnotta, Amodei, and Giordano 2021)
Mechanism: Drug at 08:00 vs 20:00 produces >30% benefit difference if target follows circadian rhythm; flat → constitutively expressed or downstream. Three patterns: (1) morning-only → GR/cortisol-coupled; (2) evening-only → melatonin/sleep-dependent (TLR4 peak 18:00–00:00); (3) flat → non-circadian. PK vs PD disambiguation via plasma drug levels at both time points. ME/CFS blunted HPA may amplify diurnal signal.
Chapter ref: ch34: Diurnal Response Window as Circadian Pharmacodiagnostic Probe
Prediction: Crossover trial (08:00 vs 20:00, 2 weeks each, n≥1, ≤7 days washout): drug with circadian target shows >30% difference. If all drugs lt.eq 30% in patient with normal circadian phase → probe assumption falsified. If non-circadian drug shows >30% difference → PK confound unless plasma levels controlled. Falsified if pilot (n≥10, 2 drugs with known circadian vs non-circadian targets) finds no drug with >30% diurnal difference in any patient with confirmed circadian phase.
Treatment: No treatment recommendation — pure pharmacodiagnostic methodology. If validated, zero-cost clinical test: 08:00 vs 20:00 response difference reveals receptor circadian coupling, guiding dosing timing without lab work.
Limitation: No ME/CFS chronopharmacology trial exists — concept untested in this population. Assumes circadian phase aligned with clock time (false for DSPD/ASPD). Diurnal symptom variation confounds drug effect. Requires actigraphy + plasma drug levels for PK/PD disambiguation. All evidence analogical (general chronopharmacology + autoimmune chronotherapy). Origin: brainstorm.

Speculation p=0.25Response Onset Latency as Mechanism Kinetics Classifier

Evidence: Onset latency well-documented for drug classes but never systematised for ME/CFS mechanism inference. SSRI onset 2–4 weeks (postsynaptic adaptation), stimulant hours (DAT inhibition), IVIG 48–72h (immune complex) vs 2–4 weeks (immunomodulation). Existing ch34 content covers LDN, aripiprazole, IVIG, duloxetine, gabapentin, DORA latency inferences. No trial validates latency-to-mechanism mapping. (Origin: brainstorm)
Citations: Existing ch34 references; no dedicated ME/CFS latency studies
Mechanism: Before 48h → ion channel gating, receptor agonism/antagonism; 2–7 days → enzyme induction/acute phase protein; 1–4 weeks → receptor upregulation, microglial M1→M2 shift; 4–12 weeks → epigenetic remodelling, mitochondrial biogenesis. LDN at 48h: TRPM3/TLR4 direct (too fast for endorphin). LDN at 3–6 weeks: endorphin or microglial shift.
Chapter ref: ch34: subsec-04 subsubsec-03 response onset latency
Prediction: Prospective LDN latency tracking: ~30% respond by day 2 (TRPM3/TLR4), ~40% at weeks 3–6 (endorphin/microglial), 30% non-responders. Falsified if unimodal distribution.
Treatment: If validated, onset latency classifies fast vs slow responders, avoiding futile 8-week trials. No clinical recommendation without validation. Origin: brainstorm.
Limitation: No prospective latency study. Confounded by placebo (also ~48h onset), concurrent changes, disease fluctuation. Bimodal hypothesis theoretical. Inter-individual PK variability produces pseudo-latency differences.

Speculation p=0.20Sequential Ordering Principle — Five-Rule Drug Trial Priority Order

Evidence: Mechanistic inference framework combining pharmacology (drug half-life, metabolic cost, receptor breadth) with clinical heuristics (cost, accessibility). No prospective study validates the ordering principle for ME/CFS. Existing ch34 content covers individual drug mechanisms and synergy/antagonism pairs; the 5-rule framework synthesizes them into a clinical decision sequence. (Origin: brainstorm sec 13c)
Citations: (Eckey et al. 2025)
Mechanism: Five priority rules: (1) Restorative > Corrective > Threshold-modulatory > Substrate > Symptomatic — trial drugs in descending therapeutic depth. (2) Broad > Narrow — each trial should eliminate the most hypotheses. (3) Energy-neutral > Energy-consuming — conserve PEM budget. (4) Reversible > Irreversible — short-washout drugs allow rapid reinterpretation. (5) Cheap/OTC > Expensive/Prescription — access principle, applied when mechanistic criteria are equal. Integrated sequence: LDN → mast-cell stabilisers → LDA → mitochondrial cofactors → valacyclovir → stimulants cautiously → IVIG/rituximab.
Chapter ref: ch34: Diurnal Response Window as Circadian Pharmacodiagnostic Probe
Prediction: Prospective 7-drug sequence trial: cumulative diagnostic resolution (proportion with >30% improvement + mechanism validated by synergy probe) ≥60% by step 5 (LDN through valacyclovir). Falsified if cumulative resolution <40% or ≥30% of resolution occurs after step 5 (stimulants/IVIG — the end-of-sequence drugs).
Treatment: Clinical decision scaffold — provides a defensible “which drug next?” algorithm. Reduces trial-and-error PEM cost. No validated treatment recommendation. Origin: brainstorm.
Limitation: No prospective validation. Ordering conflicts possible — broad but expensive (IVIG) vs narrow but cheap (NAC). Population-specific: ordering assumes patient has the energy budget for 7+ drug trials; severe patients may exhaust PEM budget before step 3. POTS-dominant cluster may need autonomic probes (midodrine, pyridostigmine) earlier.

Speculation p=0.20Do Not Disturb Rule — Four Stopping Conditions for Pharmacodiagnostic Trials

Evidence: Clinical heuristics derived from side-effect diagnostic patterns (Patterns 1–5) and PEM budget constraint. None validated prospectively for ME/CFS pharmacodiagnostic trialling. Existing ch34 sec-10 documents all 6 side-effect patterns; this entry formalizes their clinical stopping implications. (Origin: brainstorm sec 13d)
Citations: Existing ch34 references; no dedicated stopping-rule literature
Mechanism: Four stopping conditions: (C1) Any drug causes severe PEM (>24h self-care-blocking crash or >50% more severe than typical) → stop, do not escalate. PEM obscures diagnostic signal. (C2) Energy-neutral drug causes fatigue → stop, the fatigue IS the diagnostic signal (Pattern 1 — zero reserve in target system). (C3) Three consecutive nulls in same mechanism class → eliminate the class. (C4) >50% improvement from any drug → pause, fully characterise the response before adding a second drug. Each stop IS a diagnostic outcome.
Chapter ref: ch34: do not disturb rule
Prediction: Per-condition falsifiable: (C1) Early-resumers after drug-induced PEM (<1 week) show higher false-positive rates than late-resumers (≥2 weeks). (C2) Dose reduction to 50% eliminates energy-neutral fatigue. (C3) <10% of patients respond to a fourth same-class drug after three nulls. (C4) Fast-sequencers (<1 week after >50% improvement) show lower cumulative resolution than characterisation-first sequencers (≥6 weeks + washout).
Treatment: Safety framework — prevents cumulative PEM from futile pharmacodiagnostic trialling. Reduces risk of false-positive attribution and class-wide adverse event discovery. Clinical utility: conserves PEM budget and redirects toward validated mechanisms. Origin: brainstorm.
Limitation: All conditions are heuristic — no prospective validation. C3 threshold (3 nulls) is arbitrary. C2 (energy-neutral → fatigue = Pattern 1) not validated. C4 (>50% improvement) may miss additive benefits from combining with a second drug. Severe patients may trigger C1 from drugs well-tolerated in moderate patients — severity-level interaction effect unknown.

Speculation p=0.35Waking Local Sleep as a Convergent Electrophysiological Mechanism for ME/CFS Brain Fog

Evidence: Well-established local-sleep phenomenon: sleep-like slow waves (1–4 Hz delta) in localized cortical patches during wakefulness cause attention lapses, RT variability, and subjective sleepiness (Pinggal et al. 2026) (Andrillon and Oudiette 2023). Catecholamines gate waking slow waves: noradrenaline/dopamine suppress, serotonin promotes (Pinggal et al. 2022). ME/CFS involves: (a) central noradrenergic deficiency (Walitt et al. 2024), (b) chronic neuroinflammation increasing local sleep probability (Leemburg et al. 2025), (c) energy-metabolic limitation reducing ion-pump capacity for maintaining waking membrane potentials (Alfonsa et al. 2023). Zero studies have applied the waking slow-wave EEG paradigm to ME/CFS patients. The entire inferential chain is cross-disease extrapolation from ADHD, post-COVID, healthy-volunteer, and animal models. PDE: 0.35 – speculative, not hypothesis-level. (Translation gap: general-population/adult-ADHD → ME/CFS. Not validated in ME/CFS patients.)
Citations: (Pinggal et al. 2026) (Pinggal et al. 2022) (Andrillon and Oudiette 2023) (Alfonsa et al. 2023) (Leemburg et al. 2025) (Van Dongen 2025) (Fatt et al. 2020) (Neu et al. 2015) (Ortelli et al. 2022) (Walitt et al. 2024)
Mechanism: Upstream ME/CFS pathology (noradrenergic deficiency + neuroinflammation + ATP deficit → impaired cortical maintenance of waking desynchronisation) → individual cortical columns enter sleep-like slow-wave oscillations during wakefulness → functional disconnection of those circuits from ongoing cognitive processing → attention lapses, slowed RT, increased RT variability, subjective brain fog. Convergent endpoint of three disrupted gatekeeping factors: noradrenergic suppression failure, inflammatory priming, and ion-pump energy depletion.
Chapter ref: ch18: Waking Local Sleep as a Convergent Mechanism for Brain Fog; research protocol: Waking Slow-Wave Density as a Direct Electrophysiological Biomarker of Brain Fog in ME/CFS
Prediction: ME/CFS patients performing sustained attention task under EEG show higher waking SW density (SW/min, parieto-temporal electrodes) vs controls, correlating with brain fog severity, omission errors, and RT variability. Density increases 24–48h post-CPET. Atomoxetine/methylphenidate acutely reduces SW density. Falsified if no group difference, no cognitive correlation, or no catecholaminergic modulation.
Treatment: No clinical treatment recommendation – mechanism unverified in ME/CFS. If confirmed: (a) waking slow-wave density becomes objective electrophysiological biomarker of brain fog; (b) adrenergic support (atomoxetine, guanfacine) and anti-neuroinflammatory strategies (LDN, PEA) target measureable endpoint; (c) sleep-quality interventions (SWS enhancement, sleep hygiene) indirectly reduce waking slow-wave pressure. Research-stage only.
Limitation: Zero ME/CFS waking slow-wave data. Entire mechanism is cross-disease extrapolation. Behavioral signature (RT slowing, lapses) is generic – present across many neurological conditions, not specific to local sleep. Competing mechanisms (glymphatic failure, orthostatic hypoperfusion, kynurenine neurotoxicity, sleep fragmentation) produce same behavioral endpoint and may be dominant. BDNF findings mixed in ME/CFS. Catecholamine deficiency group-level only; intra-individual catecholamine–SW correlation unmeasured. Severity applicability: unknown. (Origin: /integrate-topic local-sleep-waking-slow-waves.)

Prediction —Waking Slow-Wave Density as Direct Electrophysiological Biomarker of Brain Fog – Proposed EEG Study Protocol

Evidence: Prediction only – test not yet performed. Grounded in established paradigms: Pinggal 2026 waking slow-wave EEG (n=63), Pinggal 2022 pharmacological SW modulation (n=32 RCT crossover), Walitt 2024 noradrenergic deficiency in ME/CFS (n=17), Ortelli 2022 post-COVID attention deficits (n=117), Leemburg 2025 LPS→waking SW in animals. No component requires novel technology.
Citations: (Pinggal et al. 2026) (Pinggal et al. 2022) (Walitt et al. 2024) (Ortelli et al. 2022) (Leemburg et al. 2025)
Mechanism: Prediction of the waking local-sleep model: ME/CFS cognitive dysfunction results from elevated waking slow-wave density, which in turn results from catecholamine deficiency + neuroinflammation + metabolic limitation. The study protocol tests each link: resting-state SW density (baseline), task-related SW density (attention paradigm), post-CPET SW density (PEM timecourse), pharmacological modulation (atomoxetine crossover), and negative controls (absence of correlation with motor slowing or sleep latency).
Chapter ref: ch18: Waking Slow-Wave Density as a Direct Electrophysiological Biomarker of Brain Fog in ME/CFS
Prediction: All predictions specified in the protocol below. Falsified if: (1) no group difference in waking SW density ME/CFS vs controls; (2) SW density does not correlate with cognitive performance; (3) atomoxetine/methylphenidate does not reduce SW density; or (4) post-CPET SW density does not track subjective brain fog timecourse.
Treatment: If positive, identifies atomoxetine and methylphenidate as first-line pharmacological probes targeting the waking local-sleep mechanism with a quantifiable electrophysiological endpoint. Research-stage only until confirmed.
Limitation: No ME/CFS waking slow-wave EEG data exist – the entire protocol is a prediction. EEG hardware and analysis pipeline are standard but require operator training for waking slow-wave detection. CSF DHPG measurement requires lumbar puncture – only feasible in research settings, not routine clinical monitoring. Cross-sectional first; longitudinal PEM timecourse adds scheduling complexity. Atomoxetine and methylphenidate carry sympathomimetic side effects that may be poorly tolerated in ME/CFS patients with POTS. (Origin: /integrate-topic local-sleep-waking-slow-waves.)

Speculation p=0.40The Inflammatory-Mediated Neurodegeneration Template: Bidirectional Mental-Illness–Inflammation Link

Evidence: Meta-analyses testing the inflammatory-mediated-neurodegeneration hypothesis found (a) Alzheimer’s disease associated with elevated IL-17A, IL-1$\alpha$, IL-10, G-CSF, GM-CSF, IL-3 independent of comorbid psychiatric/physical inflammatory conditions (Kuring et al. 2026); (b) depression, anxiety, PTSD each associated with inflammation independent of such comorbidities (Kuring et al. 2023). IL-17A elevated in both AD and depression; G-CSF in AD, depression, PTSD. Excluding comorbid inflammatory conditions removed classically-reported IL-6/TNF-$\alpha$ elevations in AD (Kuring et al. 2026). Cross-disease (dementia/mental-illness → ME/CFS inference); specific AD markers do not match ME/CFS profile (TNF-$\alpha$/IL-4/TGF-$\beta$/CRP per (Strawbridge et al. 2019)), so only the general template, not the specific markers, transfers.
Citations: (Kuring et al. 2026) (Kuring et al. 2023) (Strawbridge et al. 2019)
Mechanism: Pre-existing mental-illness-associated inflammation → IL-17A/IL-1$\alpha$/G-CSF signaling → CNS neuroinflammation and neuroinflammatory-mediated CNS pathology. In ME/CFS this runs REVERSE to the “neuroinflammation as common upstream driver” model (depression as secondary); the two imply a bidirectional inflammation–mental-state loop with causality direction unresolved. Comorbidity masking: excluding comorbid inflammatory conditions changes which cytokines appear elevated (a methodological caution applicable to ME/CFS inflammatory-marker research).
Chapter ref: ch14d-cross-disease: bidirectional mood inflammation template; ch08 pro-inflammatory cytokines: Comorbidity Masking of Cytokine Signals — A Cross-Disease Caution; ch19 causal hierarchy: chronicity criterion cross-disease precedent
Prediction: Within ME/CFS, a depression/anxiety-comorbid subgroup (excluding other inflammatory conditions) will show a distinct inflammatory-marker profile (higher IL-17A, G-CSF) correlating with depressive-symptom severity, with mental-symptom onset preceding the marker rise in longitudinal sampling. Falsified if mental symptoms are uniformly secondary (marker rise follows mental-symptom onset in all patients) or if the sub-group marker profile is not distinct.
Treatment: No clinical treatment recommendation. If confirmed, the bidirectional link would imply anticytokine/anti-neuroinflammatory strategies and mental-health treatment may each partially address the other — but this is speculative and not currently actionable.
Limitation: Cross-sectional included studies cannot establish causality vs prodrome vs epiphenomenon. Direction of mental-illness→inflammation arrow unresolved. Specific dementia markers not transferable to ME/CFS. Severity applicability unknown (dementia populations not ME/CFS-severity-stratified). No comorbidity-screened ME/CFS replication yet. (Origin: /integrate-topic dementia-inflammation.)

Speculation p=0.30Shared Th17/Myeloid-Axis Signal Between ME/CFS and Inflammatory CNS Conditions

Evidence: G-CSF and GM-CSF are severity-correlated inflammatory markers in ME/CFS (Montoya PNAS 2017 cohort (Montoya et al. 2017)) and are elevated in Alzheimer’s disease independent of comorbidity (Kuring et al. 2026). IL-17F (Th17) is part of early-disease ME/CFS signatures (Hornig 2015); IL-17A is elevated in both Alzheimer’s and depression (Kuring et al. 2023). This specific Th17/myeloid-hematopoiesis axis (G-CSF/GM-CSF/IL-17 family) converges across conditions, in contrast to the overall divergent ME/CFS (TNF-$\alpha$/IL-4/TGF-$\beta$/CRP (Strawbridge et al. 2019)) vs AD (IL-17A/IL-1$\alpha$/IL-10/G-CSF/IL-3) profiles.
Citations: (Kuring et al. 2026) (Kuring et al. 2023) (Strawbridge et al. 2019) (Montoya et al. 2017)
Mechanism: Chronic inflammatory-CNS conditions may show a shared, co-elevated set of G-CSF/GM-CSF/IL-17 markers (grouped by observed correlation, not a proven shared regulatory node — G-CSF/GM-CSF are myeloid growth factors, IL-17A/F are T-cell-derived) even when their broader inflammatory profiles diverge. In ME/CFS this marker set may track fatigue/cognitive severity.
Chapter ref: ch14d-cross-disease: th17 myeloid shared signal
Prediction: A comorbidity-screened ME/CFS cohort will show elevated G-CSF and GM-CSF with a Th17-correlated profile (raised IL-17F/IL-17A) tracking fatigue/cognitive severity. Falsified if comorbidity-screened ME/CFS cohorts show neither elevated G-CSF/GM-CSF nor a Th17-correlated signal.
Treatment: No clinical recommendation. If confirmed, identifies a specific measurable immune axis for biomarker and stratification use; anti-Th17/anti-IL-17 biologics would be research-stage probes only with no ME/CFS data.
Limitation: Cross-study marker panels differ; none run on comorbidity-screened ME/CFS cohorts. Inference from cross-disease panels, not direct ME/CFS replication. Severity applicability unknown. (Origin: /integrate-topic dementia-inflammation — brainstorm.)

Hypothesis p=0.30Dysbiotic Microbiome-Immune-Metabolome Crosstalk with a Benzoate-to-Hippurate Axis in ME/CFS

Evidence: BioMapAI (n=249; 96 controls, 153 ME/CFS; 4-year longitudinal; 515 timepoints) integrated gut metagenomics, plasma metabolomics, immune profiling, blood labs, and 12 symptoms; classification AUC=0.99 with held-out + four external-cohort validation (Xiong et al. 2025). Connectivity map: decreased butyrate/BCAA pathways, increased tryptophan/benzoate pathways, heightened MAIT/gamma-delta T-cell IFN-gamma + granzyme A, increase in benzoate-to-hippurate linked to sleep/emotional/fatigue symptoms. Pillars individually supported: butyrate deficiency (Xiong et al. 2023); tryptophan/kynurenine diversion (Z. Kavyani et al. 2022); T-cell remodeling (Shahbaz2026single?)-cell-immune (J.-S. Lee et al. 2025). The benzoate-to-hippurate axis itself has only indirect, neighbouring-population support (hippuric acid elevated in post-infectious syndromes (Brigo et al. 2025) and fibromyalgia (Malatji et al. 2017) — both tiny pilots, not ME/CFS replication). Symptom attributions and direction are model output, not held-out validated; the integrated axis is constrained by review (adversarial) to 0.30.
Citations: (Xiong et al. 2025) (Xiong et al. 2023) (Z. Kavyani et al. 2022) (Shahbaz2026single?)-cell-immune (J.-S. Lee et al. 2025) (Brigo et al. 2025) (Malatji et al. 2017)
Mechanism: Hypothesis (direction of causation unresolved; simpler shared-driver alternative not excluded): gut dysbiosis may alter microbial-metabolite output (decreased SCFA/BCAA, increased tryptophan/benzoate) read by the immune system and reflected in plasma lipids/bile acids, with inflammatory innate-like T-cell activity (MAIT/gamma-delta IFN-gamma, granzyme A) contributing to symptom burden; benzoate-to-hippurate (hepatic glycine conjugation of microbial benzoate) as a possible readout. Reverse causation and dietary benzoate intake are unaddressed confounds.
Chapter ref: ch15: Dysbiotic Microbiome-Immune-Metabolome Crosstalk with a Benzoate-to-Hippurate Axis; BioMapAI: Explainable AI Integration of Five Omics Layers; ch12: Replication Status: Partially Replicated
Prediction: Independent ME/CFS cohort with paired metagenomics + plasma/urine metabolomics: (a) reduced butyrate/BCAA-producing taxa + reduced metabolites; (b) increased benzoate and hippurate; (c) significant positive correlation between urinary/plasma hippurate (or benzoate-pathway score) and fatigue/sleep/emotional severity — after adjusting for dietary benzoate intake and overall dysbiosis burden. If the axis is only a global-dysbiosis (or diet) marker, it should not independently predict symptom severity after those adjustments.
Treatment: No clinical treatment recommendation. If replicated after diet- and dysbiosis-adjustment, benzoate-to-hippurate could become a research readout of the microbial-immune interface — not yet a clinical monitoring metric.
Limitation: Symptom-specific biomarkers computed on the full dataset, not held-out validated. Single-country (US) cohort, n=249. Associative, not causal. Benzoate axis rests on one model plus small neighbouring-population pilots (Brigo n=41, Malatji n=18; not replication). Unaddressed reverse-causation and dietary-benzoate confound. Tension: model shows MAIT/gamma-delta ACTIVATION (per-cell function) while single-cell data show DEPLETION (frequency) in Long-COVID ME/CFS — possibly orthogonal readouts. Severity applicability unknown — cohort not stratified. (Origin: /integrate-topic ai-multiomics-mecfs-xiong2025.)

Hypothesis p=0.35A Cross-Layer Coordination Signature, Not Any Single Marker, Defines ME/CFS

Evidence: BioMapAI PCoA: each omics layer alone leaves patients largely indistinguishable from controls; only integration separates groups with high accuracy (Xiong et al. 2025). Consistent with discrepancy framework (single-resting-measurement domains miss the disease The Subjective-Measurable Discrepancy as a Diagnostic Index). BUT integration can win via a technical concatenation of individually-weak main effects, requiring no cross-layer coordination; the paper does not report an interaction-versus-concatenation test. The strong “coordination rewiring” reading is contingent and unreplicated.
Citations: (Xiong et al. 2025)
Mechanism: Contingent hypothesis: ME/CFS may be a pathological coordination (association) structure across compartments — normal correlated relationships between microbiome, immune system, and metabolome rewired even though each layer’s marginal distribution is largely preserved. Alternative (simpler): a flat feature-concatenation model reproduces the integrated result with no interaction. The model alone cannot discriminate these.
Chapter ref: ch15: A Cross-Layer Coordination Signature, Not Any Single Marker, Defines ME/CFS
Prediction: Independent multi-omics ME/CFS cohort, two baselines required: (a) each single omics layer alone fails to separate; (b) a FLAT feature-concatenation model is meaningfully worse than a model explicitly modeling cross-layer interactions. If concatenation matches the interaction model, the coordination reading collapses to additive main effects and is rejected; if a single layer discriminates as well as integration, the disease is better described by a single-compartment signature.
Treatment: No clinical recommendation. If confirmed after the concatenation control, biomarker strategy shifts from a single blood marker toward algorithms reading cross-layer relationship patterns; until then only “integration works better than any single layer” is defensible.
Limitation: The “coordination structure” is partly defined by the model architecture (may not be a natural-kind property); no interaction/permutation control reported; not severity-stratified; the observed integrated-vs-single-layer advantage is not evidence of coordination per se. Severity applicability unknown. (Origin: /integrate-topic ai-multiomics-mecfs-xiong2025 — brainstorm.)

Speculation p=0.25Longitudinal Symptom Stability Is Symptom-Specific: Stable Fatigue Core, Labile Emotional Component

Evidence: BioMapAI 3-4 year longitudinal data: fatigue persistently severe across years; emotional dysregulation highly variable/unstable (Xiong et al. 2025). Single (US) cohort, model-reconstructed/observed timecourse, not independently replicated. A non-biological alternative — coarse ordinal fatigue scales near ceiling (measurement artifact) and symptom-circularity — is not excluded.
Citations: (Xiong et al. 2025)
Mechanism: Contingent: IF the pattern survives range-normalization and scale-artifact control, different symptoms may be driven by different biological timescales: stable driver (chronic metabolic or neuroimmune deficit) for fatigue; labile driver (fluctuating gut-metabolic state, autonomic reactivity, state-dependent inflammatory tone) for emotional symptoms. Measurement artifact (scale ceiling/coarseness) is the primary alternative.
Chapter ref: ch15: Longitudinal Symptom Stability Is Symptom-Specific: A Stable Fatigue Core with a Labile Emotional Component
Prediction: Prospective longitudinal cohort with continuous, range-normalized fatigue AND emotional scales over 12+ months: test-retest stability (ICC) significantly higher for fatigue than emotional items AFTER controlling for scale range; a stable biological measure correlates significantly more strongly with the time-stable fatigue score than the fluctuating emotional score. Falsified as biological if fatigue is as labile as emotional symptoms after scale control (i.e., the stability was a ceiling artifact).
Treatment: No clinical recommendation. If confirmed biologically, affects trial-design sampling frequency (stable vs fluctuating endpoints); does NOT justify single-visit clinical assessment of an individual patient.
Limitation: Single-cohort, model-derived; severity unknown; measurement-artifact explanation (scale ceiling/coarseness, symptom-circularity) not excluded; not replicated. (Origin: /integrate-topic ai-multiomics-mecfs-xiong2025 — brainstorm.)

Hypothesis p=0.50Distinct Brain Neurochemical Signatures Distinguish ME/CFS from Long COVID (7T MRS)

Evidence: 7T MRS head-to-head (24 ME/CFS, 25 long COVID, 24 HC): ME/CFS brain lactate elevated in both pgACC (p=0.004) and dACC (p=0.006); long COVID showed reduced total choline in dACC (p=0.0002); resting calf-muscle metabolites did not differ between groups (Godlewska et al. 2025). The ME/CFS brain-lactate elevation is consistent with a 3-organic-lab replication cluster (Mount Sinai: (Murrough et al. 2010), (Natelson et al. 2017); UAB: (Mueller et al. 2020)).
Citations: (Godlewska et al. 2025) (Murrough et al. 2010) (Natelson et al. 2017) (Mueller et al. 2020)
Mechanism: ME/CFS and long COVID show separable anterior-cingulate neurochemistry (lactate elevation vs choline reduction) despite overlapping clinical symptoms; consistent with distinct underlying neurobiological mechanisms rather than a single pooled post-infectious fatigue. Brain lactate does not uniquely localise a cause (mitochondrial vs astrocyte-lactate-shuttle vs hypoperfusion vs inflammatory-cell glycolysis).
Chapter ref: ch14d-cross-disease: Distinct Brain Neurochemical Signatures Distinguish ME/CFS from Long COVID (7T MRS); ch09: existing brain-lactate glial-cell environment (Godlewska et al. 2025) baseline
Prediction: A head-to-head 7T MRS replication will reproduce the divergence (ME lactate elevated, long COVID lactate not; vice versa for choline). Long COVID patients who later meet full ME/CFS criteria will shift toward the ME/CFS lactate-elevation signature. Concurrent perfusion imaging will resolve whether ME/CFS lactate tracks hypoperfusion (vascular) or persists with normal perfusion (mitochondrial/anabolic).
Treatment: No clinical recommendation. If confirmed, argues against pooling ME/CFS and long COVID in treatment trials and supports MRS as a stratification/mechanistic-readout tool (research-stage).
Limitation: Single-site 7T cohort, not yet independently replicated at 7T; cross-sectional (no causation); choline direction is region/age/condition-dependent (Pajuelo corpus-callosum increase (Pajuelo et al. 2024); Mueller cingulate increase (Mueller et al. 2020)) so should not be generalised. Severity applicability unknown – cohort not severity-stratified. (Origin: /integrate-topic godlewska-7t-mrs-brain-muscle.)

Speculation p=0.35Long COVID Dorsal-Cingulate Choline Reduction: Coagulation and “Brain Fog” Substrate

Evidence

Reduced total choline (tCho) in dorsal anterior cingulate of long COVID patients (p=0.0002) (Godlewska et al. 2025). Author-linked to the blood-clot/brain-fog association and to animal work showing choline can prevent intravascular coagulation. Purely associative and cross-sectional; no in-cohort coagulation assay and no causal demonstration. Direction heterogeneity: Pajuelo corpus-callosum choline increase in older patients (Pajuelo et al. 2024); Mueller cingulate choline increase in ME/CFS (Mueller et al. 2020).

Citations

(Godlewska et al. 2025) (Pajuelo et al. 2024) (Mueller et al. 2020)

Mechanism

Brain-region-specific choline deficit in long COVID may reflect altered membrane phospholipid metabolism; speculative link to a pro-coagulant local milieu relevant to cognitive symptoms via choline’s role in the one-carbon/anticoagulation axis.

Chapter ref

ch14d-cross-disease: Long COVID Dorsal-Cingulate Choline Reduction: Coagulation and “Brain Fog” Substrate

Prediction

Long COVID patients with low dACC choline will show elevated coagulation/fibrinolysis markers (D-dimer, fibrinogen, microclot assay) relative to those with normal choline. (2) If choline’s anticoagulant role were causal, dietary choline supplementation would raise dACC choline and lower coagulation markers. Falsified if dACC choline is unrelated to coagulation markers and cognitive severity.

Treatment

No clinical recommendation; no evidence choline supplementation changes long COVID brain chemistry or symptoms.

Limitation

Associative, cross-sectional, single cohort; no coagulation co-measure; choline direction heterogeneous across regions/ages/conditions. Severity applicability unknown. (Origin: /integrate-topic godlewska-7t-mrs-brain-muscle.)

Hypothesis p=0.40Neuroinflammation-Activated Dedicated Sickness and Torpor Neural Circuits — a Hypothesis for ME/CFS Symptom Generation

Evidence: Komaroff & Dantzer 2025 (Cell Reports Medicine) propose the sickness-behavior and torpor framework (Komaroff and Dantzer 2025): dedicated neural circuits – area postrema to brainstem (suppresses eating/drinking/movement), organum vasculosum to ventromedial preoptic area (appetite suppression, warmth seeking, fever), and median preoptic nucleus to torpor (hypometabolic) – are activated by neuroinflammation and generate stereotyped symptom bundles. The rodent circuits are well-established (Hrvatin et al. 2020), (Machado et al. 2025), but application to chronic human ME/CFS is inferential and rests on a single review by the framework’s originator, with no independent ME/CFS-cohort evidence; multiple rival readings (deconditioning, neural plasticity, the model not extending to inflammation-negative patients) are not currently distinguished.
Citations: (Komaroff and Dantzer 2025) (Hrvatin et al. 2020) (Machado et al. 2025) (Tuomaala et al. 2026)
Mechanism: Neuroinflammation (whose presence in established ME/CFS is uncertain – Omdal peripheral null, regional-not-global TSPO) could activate dedicated sickness/torpor circuits whose output is the ME/CFS symptom set. An important rival: the closest human neuroinflammatory data (limbic) do not correspond to the named area-postrema/preoptic circuits, so the human signal is indirect support at best.
Chapter ref: ch18: Dedicated Sickness and Torpor Neural Circuits as a Hypothesis for ME/CFS Symptom Generation; ch18: Constraints on, and Rival Readings of, the Torpor/Sickness-Circuit Model
Prediction: The discriminating test must resolve a specific circuit (area-postrema→brainstem) tracking symptoms under a modality able to resolve millimeter-scale nuclei (ultra-high-field fMRI or higher-resolution tracers; current TSPO-PET cannot). Absence of any circuit-specific activation change with symptoms would falsify the dedicated-circuit (versus diffuse-inflammation or plasticity-maintained) claim. The neuroinflammation-input claim is separately refuted by consistent absence of neuroinflammatory signal in ME/CFS cohorts.
Treatment: Research-stage. Principal implied target is neuroinflammation (existing anti-neuroinflammatory rationale unchanged); no new test or drug follows from the dedicated-circuit framing. No ME/CFS dosing or efficacy data.
Limitation: Rodent-only circuits; zero direct human ME/CFS evidence; torpor-with-hypothermia phenotype not reproduced in ME/CFS; severity applicability unknown; all proposed tests research-only and unsuitable for severe patients. (Origin: /integrate-topic komaroff-dantzer-symptom-persistence.)

Hypothesis p=0.45Symptom Persistence Arises from Self-Reinforcing Vicious Cycles Across Underlying Abnormalities

Evidence: Komaroff & Dantzer 2025 synthesize bidirectional reinforcement among abnormalities (mitochondrial injury <-> inflammation; redox <-> energy; redox <-> endothelial; endothelial+NK+neuroinflammation; spike/fibrin pro-inflammatory epitope) as vicious cycles that perpetuate pathology and symptoms (Komaroff and Dantzer 2025). Each individual connection is supported by the primary literature the review cites; the unified vicious-cycle model is the review’s integrative claim and is consistent with but not directly proven as a closed loop in patients.
Citations: (Komaroff and Dantzer 2025) (Baraniuk, Eaton-Fitch, and Marshall-Gradisnik 2024)
Mechanism: Chronicity results not from one lesion but from persistent agents/antigens + defective resolution + reactivation + dysbiosis + autoimmunity + a defective circuit switch, amplified by positive-feedback loops among the biological abnormalities – so that correcting any single abnormality may not break the cycle.
Chapter ref: ch16: chronicity/amplifier synthesis
Prediction: If self-reinforcing vicious cycles sustain the illness, then (a) severity should correlate with the NUMBER of co-active abnormalities and bidirectional constraints, not any single marker; (b) therapies that break a single node should show partial but not complete remission; (c) residual unexplained variance should persist when any one abnormality is corrected. Falsified if correcting one specific abnormality reliably induces sustained remission in a substantial fraction of patients.
Treatment: Research-stage frame; argues for combination/multi-target strategies and for monitoring multiple abnormality axes. No specific clinical dosing recommendation.
Limitation: Integrative/synthesis claim (review), not a single testable primary finding; the closed-loop structure is inferred, not measured directly. Severity applicability unknown. (Origin: /integrate-topic komaroff-dantzer-symptom-persistence.)

Speculation p=0.52Peripheral Blood Methylome Distinguishes Long COVID from ME/CFS While Sharing a Common Epigenetic Core

Evidence: Peppercorn et al. 2025 (RRBS of PBMCs, n=5 ME/CFS / n=5 Long COVID / n=5 HC, age/sex-matched, University of Otago) — ME/CFS 214 DMFs vs HC (145 hyper / 69 hypo), Long COVID 429 DMFs (281 hyper / 148 hypo); 118 DMFs shared with Pearson R=0.88; 26 of 118 differ by more than 10% between the two conditions; 6 show opposite-direction methylation (Peppercorn et al. 2025). Single lab, small n, no independent replication (raw 0.52 discounted unchanged for ME/CFS population, weight 1.00).
Citations: (Peppercorn et al. 2025)
Mechanism: PBMC DNA methylation across ME/CFS and Long COVID share a common epigenetic core (Pearson R=0.88 on shared DMFs) yet retain condition-specific sites, of which six show opposite-direction changes; LC shows more abundant methylation changes, consistent with earlier disease stage (LC ~1 yr vs ME/CFS ~12 yr) or SARS-CoV-2-specific effects. PCA separates the three cohorts into distinct clusters.
Chapter ref: ch14d cross-disease: Peripheral Blood Methylome as a Long COVID vs ME/CFS Distinguishing Signature; ch19: Consolidation as Loss of Methylation; ch56: Per-Locus Dynamics: Vector Model for Bidirectional Methylation
Prediction: A stage-matched, larger (n≥50/group) methylation study with LC and ME/CFS at comparable time-from-onset should (i) reproduce the Pearson R=0.88 shared-makeup relationship, (ii) shrink the LC-vs-ME/CFS DMF amplitude gap when stage is matched, and (iii) determine whether the six opposite-direction DMFs replicate as condition-specific or collapse with stage matching. Falsified if stage-matched cohorts show no reproducible condition-specific DMFs.
Treatment: None yet — a diagnostic/differential-stratification hypothesis, not a treatment target. If the six opposite-direction DMFs replicate, they could support a blood-based test distinguishing LC from ME/CFS, but this is research-stage and unvalidated.
Limitation: Small n (5/5/5), single lab, no independent replication, cross-sectional (no directionality), PBMC proxy not tissue; stage mismatch (LC 1 yr vs ME/CFS 12 yr) confounds condition-specific vs time-from-onset attribution; opposite-direction DMFs not validated for diagnosis. Severity applicability unknown. (Origin: /integrate-topic peppercorn-methylation-landscapes.)

Speculation p=0.25The EP3R “Stuck Switch” — a Candidate (Unproven) Nervous-System Persistence Mechanism

Evidence: Preoptic EP3 receptor neurons act as a two-way switch routing between fever (hypermetabolic) and torpor-like (hypometabolic) states in rodents (Machado et al. 2025). A speculation that a persistent (post-washout) failure of that switch could maintain a low-energy state without ongoing neuroinflammation – offered as a partial reading of the Omdal null (Komaroff and Dantzer 2025). Restates persistence in circuit vocabulary; no EP3R latch or desensitization demonstrated in any species or in ME/CFS (zero direct human evidence).
Citations: (Machado et al. 2025) (Komaroff and Dantzer 2025)
Mechanism: Candidate lesion (EP3R desensitization, biased signaling, fever-arm failure) could leave the brain switch in an energy-conserving position; a simpler rival reading is that the sickness-behavior model simply does not extend to inflammation-negative patients, whose symptoms may have a different cause.
Chapter ref: ch18: The EP3R “Stuck Switch” Hypothesis — a Candidate, Not a Demonstrated Mechanism
Prediction: Discriminating test is a reversible latch: transient PGE2 that persists as torpor output after ligand washout (bistability) in rodents; in humans, a maintained low defended temperature set-point with acute disengageability. PBMC EP3R is excluded as a CNS proxy. Falsified if no persistent reversible latch is demonstrable under washout, or no maintained set-point with acute disengageability in ME/CFS.
Treatment: Research/hypothesis-generation only. No switch-resetting intervention exists or is in trials; no clinical recommendation.
Limitation: Rodent-only; zero direct human evidence; torpor-with-hypothermia phenotype not reproduced in ME/CFS; not severity-stratified. (Origin: /integrate-topic komaroff-dantzer-symptom-persistence – brainstorm re-run.)

Speculation p=0.20Area Postrema Autoantibody × GLP-1 Gate — an Untested Cross-Reactivity Hypothesis

Evidence: The area postrema is both a route for circulating GPCR autoantibody access to brainstem nuclei and a dense GLP-1 receptor region (Azcue et al. 2026) (Komaroff and Dantzer 2025). The interference step requires an explicit, unsupported premise that ME/CFS GPCR autoantibodies (literature targets include adrenergic/muscarinic receptors) cross-react with or sterically impede GLP-1 receptors – no such cross-family interaction has been shown. Co-location of two facts does not by itself entail an interaction.
Citations: (Azcue et al. 2026) (Komaroff and Dantzer 2025)
Mechanism: If (unsupported premise) GPCR autoantibodies interfered with GLP-1 receptor signaling at the area postrema, they could blunt GLP-1-dependent anti-inflammatory signaling and help sustain neuroinflammation. A simpler established mechanism (agonistic autoantibodies acting on their own receptors) already explains part of the autonomic symptom profile.
Chapter ref: ch18: Area Postrema as a Possible Gate — an Untested Autoantibody × GLP-1 Hypothesis
Prediction: Decisive test: purified ME/CFS patient IgG vs controls in competitive binding against labeled GLP-1 on area-postrema membranes. If no displacement, the competitive-interference claim is falsified. Clinical predictions (blunted GLP-1-induced nausea; stratified GLP-1-RA response) are confounded by vagal dysfunction/dysautonomia and cannot stand alone.
Treatment: Not a prescribing recommendation. No GLP-1-RA use in ME/CFS is trial-supported; GPCR-autoantibody testing is research-only; GLP-1 RAs risk reduced intake/weight loss and nausea-driven orthostatic worsening in comorbid POTS and severe ME/CFS.
Limitation: Cross-reactivity premise untested and mechanistically unmotivated; GPCR-autoantibody findings contested and single-source; not severity-stratified. (Origin: /integrate-topic komaroff-dantzer-symptom-persistence – brainstorm re-run.)

Hypothesis p=0.65Viral dUTPase drives the TFH/activin-A axis that generates the antibody-secreting plasma cells daratumumab depletes

Evidence: EBV/HHV-6A dUTPases enhance TFH-cell differentiation and extrafollicular activities in ME/CFS, with ME/CFS patients showing elevated activin A and IL-21 correlating with anti-viral-dUTPase antibodies; EBV dUTPase induced marginal-zone B and invariant NKT-FH expansion in mouse spleen (Cox et al. 2022). Raw 0.65 (ME/CFS cohort, peer-reviewed, partially replicated via later dUTPase-antibody findings), discounted unchanged at weight 1.00.
Citations: (Cox et al. 2022)
Mechanism: Persistent herpesvirus reactivation (via dUTPase, an early lytic protein) diverges the germinal-center response toward activin A/IL-21-driven extrafollicular antibody output, plausibly generating CD38+ long-lived plasma cells (LLPCs) that continue secreting pathogenic autoantibodies independent of ongoing B-cell cycling – the cell type rituximab (CD20+) spares but daratumumab (anti-CD38) deletes (Cox et al. 2022).
Chapter ref: ch34 sec-12 Daratumumab (Anti-CD38); ch19: The Plasma Cell Sanctuary; ch33 sec-02h origin-elimination
Prediction: If this mechanism holds, long-lived autoantibody-producing cells in ME/CFS should be CD38+ and CD20−, and their depletion (daratumumab) should produce a sustained drop in the offending autoantibody titers with a response latency matching antibody decay (8–9 mo), as observed in the pilot. Falsified if daratumumab responders show no fall in the candidature autoantibody, or if non-responders retain elevated titers with intact CD38+ plasma cells.
Treatment: Research-stage only. Narrows the humoral-autoimmunity target to the CD38+ long-lived plasma cell and supports plasma-cell-directed agents (daratumumab) over B-cell depletion in the autoantibody-positive subgroup; none of this is a prescribing recommendation.
Limitation: Direct dUTPase→LLPC causality not experimentally proven (mouse used EBV dUTPase only); TFH/activin-A axis not independently replicated; dUTPase antibodies could reflect reactivation rather than steady-state LLPC output; not severity-stratified. NK data (Ray 2026) constrain any planned depletion by warning that CD38+ NK co-deletion may blunt response in already-NK-poor patients (Ray et al. 2026). (Origin: /integrate-topic daratumumab update.)

Hypothesis p=0.26A circulating serum factor in ME/CFS and Long COVID reproduces a biphasic muscle metabolic phenotype in otherwise-healthy biofabricated tissue

Evidence: Healthy 3D biofabricated skeletal muscle exposed in vitro to ME/CFS and Long COVID patient sera shows up-regulated glycolysis, mitochondrial hyperfusion, elevated oxygen consumption early, then contractile weakness and toroidal mitochondrial fragmentation by 96–144 h (Mughal et al. 2025). The serum-transfer phenomenon has prior support across models (Fluge et al. 2016) (Schreiner et al. 2020) (Appelman et al. 2024); anti-mitochondrial antibodies are excluded as the mediator (Nilsson et al. 2020). Raw 0.65, discounted 0.26 by in-vitro population weight 0.40.
Citations: (Mughal et al. 2025) (Fluge et al. 2016) (Schreiner et al. 2020) (Appelman et al. 2024) (Nilsson et al. 2020)
Mechanism: A serum-borne mediator (candidate classes: cytokines, HHV-6 microRNA, exosomes, viral fragments) drives pyruvate dehydrogenase impairment and a compensatory glycolytic/hypermetabolic adaptation that decompensates into mitochondrial fragmentation and reduced contractile capacity – reproducing in isolated healthy muscle the glycolytic shift documented in patient biopsies, independent of deconditioning, neural outflow, or vascular factors.
Chapter ref: ch20 Family 17: A Circulating Serum Factor Reproduces the ME/CFS Muscle Metabolic Phenotype in Healthy Tissue; ch07 sec-21: Is Short-Exposure Muscle Metabolism Hypermetabolic or Hypometabolic in ME/CFS?
Prediction: Depleting or neutralizing the putative serum factor (immunoadsorption, specific cytokine/exosome blockade) should prevent or reverse the derangement – attenuated glycolysis, preserved mitochondrial integrity – in the 3D model, and measurably reduce post-exertional muscle fatigue if translatable. Falsified if patient sera no longer induce the biphasic response with the factor removed.
Treatment: Not a prescribing recommendation. Identifies the circulating mediator as a research target (immunoadsorption, cytokine blockade) that is still preclinical; no clinical mitigation is established.
Limitation: Anchor finding is single in-vitro study (unpopulated; not independently replicated); not severity-stratified; mediator identity unknown; in-vitro population weight 0.40 caps clinical relevance. (Origin: /integrate-topic biofabrication-mughal-3d-muscle-cfs-sera.)

Speculation p=0.28Biofabricated 3D skeletal muscle as a functional ex-vivo assay for serum-borne muscle pathology

Evidence: A validated 3D biofabrication platform has been used to expose healthy muscle to patient sera and produce a mechanistic metabolic readout (Mughal et al. 2025), built on platform validation in Duchenne MD and drug screening (Fernández-Garibay et al. 2022). Raw 0.70, discounted 0.28 by in-vitro population weight 0.40.
Citations: (Mughal et al. 2025) (Fernández-Garibay et al. 2022)
Mechanism: If the biphasic serum response is reproducible and patient-specific, the biofabricated tissue provides a medium-throughput functional endophenotype – a measurable readout of whether an individual’s serum impairs muscle metabolism – usable to screen candidate circulating mediators and modulators before animal or human trials.
Chapter ref: ch20: Biofabricated 3D Skeletal Muscle as a Functional Assay for Serum-Borne Muscle Pathogens
Prediction: A blinded cohort of ME/CFS, Long COVID, and healthy sera should yield a biphasic muscle response that is significantly more frequent/severe in patient versus control sera and correlates with reported PEM or fatigue severity.
Treatment: Research tool only; not a therapeutic proposal.
Limitation: Diagnostic utility, inter-lab reproducibility, and correlation with clinical severity are unproven; lacks neural/immune/vascular context; not severity-stratified. (Origin: /integrate-topic biofabrication-mughal-3d-muscle-cfs-sera.)

Speculation p=0.30The in-vitro serum response is a three-phase sequence (PDH compensation → cofactor exhaustion → mitochondrial collapse), not a static state

Evidence: Biofabricated 3D skeletal muscle exposed to patient serum shows up-regulated glycolysis and mitochondrial hyperfusion at 48 h, then toroidal fragmentation and contractile failure at 96–144 h (Mughal et al. 2025); patient sera also drive PDH-related myoblast metabolic shift (Fluge et al. 2016). The phase decomposition is an interpretation reconciling short-exposure hypermetabolic and long-exposure hypometabolic findings; raw 0.30, discounted from in-vitro weight.
Citations: (Mughal et al. 2025) (Fluge et al. 2016)
Mechanism: Serum-driven pyruvate-dehydrogenase inhibition forces compensatory glycolysis and substrate shift (Phase I); sustained high-flux glycolysis depletes cofactor and antioxidant pools (NAD⁺/NADH, thiamine pyrophosphate, glutathione) (Phase II); exhaustion tips into mitochondrial fragmentation and contractile failure (Phase III) – reconciling ostensibly contradictory hypermetabolic and hypometabolic bodies of evidence into one temporal cycle that maps onto the PEM time-course.
Chapter ref: ch07 sec-21: A Three-Phase Model: PDH Compensation, Cofactor Exhaustion, Mitochondrial Collapse
Prediction: Serial PDH activity, NAD⁺/NADH, and mitochondrial morphology measurements in the 3D model must show PDH decline first, then cofactor depletion, then fragmentation – any different ordering falsifies the model.
Treatment: Not a prescribing recommendation. Suggests phase-specific, mechanistically-motivated candidate metabolic support (thiamine/riboflavin/alpha-lipoic acid, tested in-vitro first); no clinical use established.
Limitation: Single un-replicated in-vitro study; phase sequence not directly measured as a continuous trajectory; not severity-stratified. (Origin: /integrate-topic biofabrication-mughal-3d-muscle-cfs-sera – brainstorm 1.1.)

Speculation p=0.22The circulating serum factor is likely a multi-component cocktail rather than a single molecule

Evidence: The biphasic response engages at least four distinct processes (PDH inhibition, calcium dysregulation, mitochondrial fission, contractile impairment), which no single species plausibly drives (Mughal et al. 2025); anti-mitochondrial antibodies are excluded as the sole mediator (Nilsson et al. 2020); serum transfers a multi-faceted antiviral-metabolic state (Schreiner et al. 2020). Discounted from in-vitro/indirect evidence.
Citations: (Mughal et al. 2025) (Nilsson et al. 2020) (Schreiner et al. 2020)
Mechanism: A concurrent set of mediators – a PDH-inhibitory cytokine (TNFα/IL-6), a mitochondrial-fission or cell-danger signal (e.g. HHV-6 microRNA), a calcium/ion-channel disruptor, and an inflammatory/exosomal danger signal – rather than one molecule, explains why removing any single ingredient may fail to rescue the muscle phenotype.
Chapter ref: ch20 Family 17: The Circulating Serum Factor Is Likely a Multi-Component Cocktail, Not a Single Molecule
Prediction: Serum fractionation should show that no single fraction (e.g. exosomes alone, a single cytokine) recapitulates the full biphasic phenotype; falsified if one isolated fraction reproduces the complete picture.
Treatment: Not a prescribing recommendation. Argues against single-cytokine-target strategies and toward broader serum-factor removal (immunoadsorption) as the research direction; no clinical use.
Limitation: Structurally motivated inference, not directly demonstrated; mediator identity unknown; not severity-stratified. (Origin: /integrate-topic biofabrication-mughal-3d-muscle-cfs-sera – brainstorm 1.3.)

Open Question p=n/aSerum fractionation of ME/CFS sera is the highest-priority experiment to identify the circulating mediator

Evidence: The unknown serum mediator must be narrowed from an anonymous class to a molecular species; fractionation by size, heat-lability, nuclease-sensitivity, and immunoglobulin depletion, tested on the 3D model, is the decisive experiment (Mughal et al. 2025) (Fluge et al. 2016) (Schreiner et al. 2020) (Nilsson et al. 2020).
Citations: (Mughal et al. 2025) (Fluge et al. 2016) (Schreiner et al. 2020) (Nilsson et al. 2020)
Mechanism: Fractionating serum and applying each fraction to biofabricated muscle with quantitative readouts (lactate efflux, PDK mRNA, mitochondrial morphology, contractile force) identifies which molecular class transmits the metabolic pathology; a parallel blinded ME/CFS vs LC vs healthy comparison tests whether the assay discriminates conditions.
Chapter ref: ch20: Serum Fractionation Is the Highest-Priority Next Experiment for Identifying the Circulating Mediator
Prediction: The active mediator class will be recoverable, and patient sera will induce a fraction-dependent biphasic response reproducibly; falsified if no fraction reproduces the phenotype in a validated assay.
Treatment: Research-direction formulation; not a treatment proposal.
Limitation: Requires replication of the anchoring in-vitro platform and individual (non-pooled) patient sera; not yet performed. (Origin: /integrate-topic biofabrication-mughal-3d-muscle-cfs-sera – brainstorm 2.1.)

Speculation p=0.20Toroidal mitochondrial fragmentation as a candidate disease-specific ultrastructural signature in ME/CFS muscle

Evidence: Biofabricated 3D muscle exposed to patient serum shows ring-shaped (toroidal) mitochondrial fragmentation at the decompensation phase (Mughal et al. 2025), a morphology distinct from normal fission and linked to Drp1 over-activation/Opa1 loss; whether it generalizes to patient biopsies is untested. Discounted from in-vitro evidence.
Citations: (Mughal et al. 2025) (Charlton et al. 2025)
Mechanism: A stress-specific mitochondrial morphology distinct from normal fission, plausibly reflecting Drp1 over-activation and Opa1 loss; if reproduced in patient-muscle EM and absent from the deconditioning bed-rest phenotype and inflammatory myopathy, it could serve as an objective, self-report-independent microscope-based marker of ME/CFS muscle pathology.
Chapter ref: ch20 Family 17: Toroidal Mitochondrial Fragmentation as a Candidate Disease-Specific Ultrastructural Signature
Prediction: Electron microscopy of ME/CFS patient muscle biopsies should show toroidal mitochondria at a higher rate than bed-rest-treated healthy muscle and age-matched controls; falsified if toroidal forms are equally common in bed-rest or healthy tissue.
Treatment: Not a prescribing recommendation. If toroidal morphology proves irreversible, it would reinforce energy pacing as tissue preservation rather than mere symptom control; no clinical intervention.
Limitation: Morphology seen in one in-vitro study; may be an artifact of the culture system; biopsy confirmation and specificity untested; not severity-stratified. (Origin: /integrate-topic biofabrication-mughal-3d-muscle-cfs-sera – brainstorm 1.2.)

Speculation p=0.40Hibernation Arousal Machinery as a Cross-Species Resource for the ME/CFS Low-Energy State

Evidence: Hibernating mammals exhibit a reversible, spontaneously-arousing torpor state driven by conserved signals: central adenosine A1-receptor activation induces torpor in a non-hibernating rat (Shimaoka et al. 2018); arachidonic-acid -> PPAR-alpha/TRPV-Ca2+ is an arousal lipid regulator (L. Wang et al. 2026); mTORC1 reactivation is a conserved metabolic switch (C.-W. Wu and Storey 2021); BAT UCP1 thermogenesis drives arousal (Hunstiger, Johannsen, and Oliver 2023); non-neuronal choroid-plexus sensors may initiate arousal (Markussen et al. 2024); and non-hibernating mammalian cells retain a latent “hibernation-like” adaptive-pausing program (Jobava et al. 2021). All model-system/cross-species (heavily discounted); no ME/CFS human data.
Citations: (Shimaoka et al. 2018) (L. Wang et al. 2026) (C.-W. Wu and Storey 2021) (Hunstiger, Johannsen, and Oliver 2023) (Markussen et al. 2024) (Jobava et al. 2021) (Duffy, Staples, and Tessier 2022)
Mechanism: The arousal/recovery machinery is a (reversible) energy-state-switch resource whose signals (mTORC1, ISR/adaptive-pausing, arachidonic-acid/PPAR-alpha, A1AR-as-entry/A2A-as-arousal-shift) overlap the paper’s existing ISR/mTORC1 content (ch07 Post-Exertional Malaise Timing Reflects Integrated Stress Response Kinetics and ISR assay content); it contributes a specific assay (polysome-profile) and a cross-species precedent that ISR/pausing is reversible, rather than a distinct novel mechanism.
Chapter ref: ch18: Hibernation Arousal Biology as a Candidate Resource for Metabolic-Reactivation Research; ch07 ISR cross-ref Post-Exertional Malaise Timing Reflects Integrated Stress Response Kinetics
Prediction: A discriminating test with a matched-sedentary control arm: patient-derived ME/CFS PBMCs/iPSC cells should show a reduced polysome:monosome ratio and stalled-initiation-codon mRNAs relative to both healthy AND matched-sedentary controls, partially reversible on ISR inhibition (ISRIB) or mTORC1 reactivation beyond the sedentary-control component. A normal polysome profile falsifies pausing engagement; a positive-only-vs-healthy (not sedentary) result is ambiguous. Research prediction only.
Treatment: None. Basic-science drug-discovery resource; no clinical recommendation. Interbout arousal increases oxidative damage (Duffy, Staples, and Tessier 2022) – a safety caveat gating any future therapeutic extrapolation.
Limitation: All model-system/cross-species (translation gap); no ME/CFS human data; torpor is largely a small-mammal adaptation (primate hibernation rare – dwarf lemur (Blanco et al. 2024)). Severity applicability unknown. (Origin: /integrate-topic hibernation-biology-torpor-arousal.)

Hypothesis p=0.75SARS-CoV-2 infection raises new-onset ME/CFS risk, persisting up to four years post-infection

Evidence: A large electronic health record cohort ($n = 147{,}377$; Montefiore) found elevated new-onset ME/CFS risk sustained to four years after SARS-CoV-2 infection, adjusted hazard ratio 1.46 (hospitalized) and 1.56 (non-hospitalized) versus 111{,}301 controls (Hadidchi et al. 2025). Directionally consistent with RECOVER ($n = 11{,}785$, approx. 2.8-fold incidence, IOM criteria) (Leonard A. Jason et al. 2025), the CDC INSPIRE cohort ($n = 4{,}376$) (Unger et al. 2024), and a CDC fatiguing-illness cohort ($n = 13{,}611$; outcome is post-COVID fatigue, not ME/CFS criteria) (Vu et al. 2024). Raw 0.75 (ME/CFS cohort, peer-reviewed, large n), discounted unchanged at weight 1.00.
Citations: (Hadidchi et al. 2025) (Leonard A. Jason et al. 2025) (Unger et al. 2024) (Vu et al. 2024)
Mechanism: An acute SARS-CoV-2 infection triggers a post-infectious process that, in a susceptible subset, resolves into chronic ME/CFS – consistent with the post-infectious trigger model established for Epstein-Barr virus and SARS-CoV-1 (Hickie et al. 2006) (Moldofsky and Patcai 2011). The four-year persistence argues against a transient pandemic-era effect and for a sustained post-infectious pathophysiology. None of the acute-phase biomarkers tested (ferritin, D-dimer, LDH, CRP) discriminated converters, separating acute inflammatory markers from post-acute predictors (Hadidchi et al. 2025).
Chapter ref: ch01 sec-04: Epidemiology, Epidemiology; ch14d: Speculative Cross-Disease Connections; ch06: Onset Patterns
Prediction: ME/CFS incidence after SARS-CoV-2 should remain above pre-pandemic baseline for several years post-infection in other large cohorts with comparable follow-up; the four-year hazard-ratio elevation should replicate. Falsified if cohorts with $\ge$ 4-year follow-up find the excess risk decays to baseline by year two to three, or if the finding reflects EHR/ascertainment artifact rather than true new-onset disease.
Treatment: None – epidemiological risk finding, not an intervention. Implies post-COVID monitoring: patients with persisting post-acute symptoms should be assessed for ME/CFS criteria and managed per standard ME/CFS guidance; no novel treatment is indicated.
Limitation: The four-year horizon is single-study (not yet directly replicated – comparators have 6-month to 2-year follow-up); EHR ICD-coded outcome underestimates true ME/CFS and cannot confirm diagnostic criteria; pre-COVID baseline ME/CFS status was not excluded; severity applicability unknown – cohort not severity-stratified. (Origin: /integrate-topic hadidchi2025-cfs-me-4yrs-post-covid.)

Hypothesis p=0.40Post-acute (not acute) iron dynamics as the temporal predictor of post-COVID ME/CFS conversion

Evidence: The Hadidchi null that acute-phase biomarkers (ferritin, D-dimer, LDH, CRP) do not predict post-COVID ME/CFS conversion, combined with the iron-redox temporal phase-shift model (Hadidchi et al. 2025) (Hanson et al. 2024) (Sonnweber et al. 2022) (Bahar Kavyani et al. 2024), constrains the converter-discriminating window to the post-acute transition (weeks 2–12 onward) rather than the acute phase.
Citations: (Hadidchi et al. 2025) (Hanson et al. 2024) (Sonnweber et al. 2022) (Bahar Kavyani et al. 2024)
Mechanism: Acute inflammatory hypoferremia (IL-6 -> hepcidin spike) is universal and non-discriminatory; converters diverge from recoverers in the post-acute transition as hepcidin falls and functional iron deficiency (elevated ferritin, low TSAT) emerges – so a converter-predicting blood test is expected at 3–6 months, not day 0–30.
Chapter ref: ch14d: postcovid postacute iron prediction
Prediction: A longitudinal study measuring ferritin, TSAT, hepcidin at 1, 3, 6, 12 months post-COVID must show 3-month (not 1-month) iron trajectories separating future ME/CFS converters (IOM-2015) from recoverers, e.g. AUC > 0.70. Falsified if all post-acute timepoints are non-predictive.
Treatment: None – research/diagnostic prediction, not an intervention. If validated, an approx. $20 ferritin+TSAT measurement at the 3-month post-COVID visit could flag patients for ME/CFS monitoring.
Limitation: No existing longitudinal post-COVID iron-panel study; severity applicability unknown (incidence cohorts not severity-stratified); single-study null. (Origin: /integrate-topic hadidchi2025-cfs-me-4yrs-post-covid – Phase-4 brainstorm idea 1.1.)

Open Question p=0.50Medical Education Reform — What Would Move the Needle?

Evidence: ch40 documents a medical-education deficit but no intervention studies; no study tests whether adding ME/CFS content to curricula changes diagnosis/referral/outcomes (Bateman et al. 2021). A mandatory-CME model (e.g., opioid/implicit-bias-mandate-style) is proposed but never trialed. (Certainty: descriptive evidence only; no intervention).
Citations: (Bateman et al. 2021)
Mechanism: The education deficit is self-perpetuating — physicians untrained in ME/CFS cannot recognize it or teach the next generation; reform requires evidence-tested interventions, not only aspirational recommendations.
Chapter ref: ch40: Medical Education Reform: What Would Move the Needle?
Prediction: A CME/curriculum intervention should measurably change diagnosis rate, referral pattern, or outcome (vs. no-intervention control); absence of change would indicate the barrier is structural, not educational.
Limitation: No prospective intervention data in ME/CFS; severity applicable across all levels. (ch40, prior cycle.)

Hypothesis p=0.55Diagnostic Delay as a Healthcare-System Metric (iatrogenic harm)

Evidence: Average ME/CFS diagnostic delay 5-10 years across surveys (Bateman et al. 2021); delay is iatrogenic harm (inappropriate GET/psychiatric misdiagnosis during the gap, employment/savings loss, repeated invalidation). Consistent across multiple surveys; no prospective delay-to-harm study.
Citations: (Bateman et al. 2021)
Mechanism: Diagnostic delay exposes patients to harmful recommendations and invalidation; reducing delay is a low-cost “treatment” (each month of delay avoided is a month of appropriate care).
Chapter ref: ch40: Diagnostic Delay as a Healthcare-System Metric
Prediction: A registry linking diagnostic delay (months) to later QoL/employment outcomes should show a monotonic relationship (delay -> harm).
Limitation: Cross-sectional survey evidence; no prospective study; severity applicability all, greatest for those progressing to severe. (ch40, prior cycle.)

Open Question p=N/ADo Specialist Clinics Improve Outcomes?

Evidence: Zero RCTs/controlled comparisons of specialist ME/CFS clinics (BHC, Stanford, OMI, Hadassah, Charite) vs. primary care on diagnostic accuracy, functional outcomes, or satisfaction. Recommendation for specialist care rests on expert consensus/patient preference, not demonstrated superiority.
Citations: (Bateman et al. 2021)
Mechanism: Whether specialty structure improves outcomes is unmeasured; clinic existence creates an implicit standard of care that most patients cannot access, without evidence it is superior.
Chapter ref: ch40: Do Specialist Clinics Improve Outcomes?; ch40 BHC care-delivery example
Prediction: A controlled comparison (or quasi-experiment, The Specialist Clinic Quasi-Experiment) of specialist vs. well-informed primary care; null would mean current unequal access is not justified by outcomes.
Limitation: Evidence gap identification, not a factual claim; severity most critical for severe/very-severe. (ch40, prior cycle.)

Speculation p=0.50Co-Production as a Healthcare Design Principle

Evidence: Qualitative co-production study (n=8) with ME/CFS patients identified preference for multidisciplinary teams, mHealth symptom tracking, PEM-aware pathways (Thornton et al. 2025). Small/unvalidated in ME/CFS; methodology sound generically.
Citations: (Thornton et al. 2025)
Mechanism: Designing services WITH patients (co-production) may better meet energy-limited, multidisciplinary, PEM-aware needs than standard clinic-centered design.
Chapter ref: ch40: Co-Production as a Healthcare Design Principle
Prediction: Co-produced ME/CFS services should show higher retention/satisfaction than non-co-designed services.
Limitation: n=8 qualitative; not ME/CFS-validated; severity most important for severe/very-severe. (ch40, prior cycle.)

Open Question p=N/AThe Universal Access Null Hypothesis — What If Reform Doesn’t Change Outcomes?

Evidence: If all barriers removed (education, delay, guidelines, specialist access, disability, invalidation), would outcomes improve? Partly refuted (reducing delay/GET-avoidance almost certainly prevents iatrogenic harm) but not for benefit (no evidence any care model improves long-term function).
Citations: (Bateman et al. 2021)
Mechanism: Distinguishes removing HARM (GET, invalidation, benefit denial — evidence-backed) from providing BENEFIT (specialist care, co-production, multidisciplinary — untested).
Chapter ref: ch40: The Universal Access Null Hypothesis
Prediction: Reform separating harm-removal from benefit-provision; benefit claims remain untested until controlled comparisons exist.
Limitation: Descriptive/qualitative health-services evidence; no care-model comparative studies. (ch40, prior cycle.)

Hypothesis p=0.45Diagnostic Desert — Geographic Access as a Self-Reinforcing Trap

Evidence: 10x variation in ME/CFS diagnosis across English ICBs (Samms and Ponting 2025); PEM makes travel an active harm (radius constraint shorter than any other chronic disease), producing a self-reinforcing desert (fewer diagnoses -> apparent low prevalence -> no deployment -> fewer access).
Citations: (Samms and Ponting 2025)
Mechanism: PEM-adjusted travel impedance (distance x PEM severity) predicts diagnosis probability better than raw distance, and is ME/CFS-specific (fibromyalgia, lacking PEM barrier, shows weaker clustering).
Chapter ref: ch40: Diagnostic Desert Hypothesis
Prediction: PEM-adjusted distance from nearest specialist inversely correlates with ICB diagnosis rate, stronger for ME/CFS than fibromyalgia; opening a clinic in a desert should produce a diagnostic surge.
Limitation: Geographic variation documented; the trap mechanism is novel/untested; severity most relevant for severe/very-severe. (ch40, prior cycle.)

Speculation p=0.35The Guideline Cascade Duration — Contested Diseases Have Longer Implementation Gaps

Evidence: Evidence-to-practice lag averages ~17 years; contested illnesses likely longer (pre-existing beliefs, no specialty champions, hard-to-audit negative recommendations). German G-BA statutory directive is a natural experiment.
Citations: (Bateman et al. 2021)
Mechanism: For contested diseases, guideline uptake is systematically delayed: belief revision, absence of specialty champions, and negative (GET-withdrawal) recommendations are harder to audit than positive ones.
Chapter ref: ch40: The Guideline Cascade Duration — Contested Diseases Have Longer Implementation Gaps
Prediction: German physicians show higher PEM-concern awareness than UK at matched time-from-publication (Germany: binding directive vs. UK advisory NICE 2021).
Limitation: Implementation-science support is general; contested-illness amplification novel; NICE-2021 cascade unobserved; all severity. (ch40, prior cycle.)

Speculation p=0.40Healthcare Invalidation x PEM Synergy — a Bootstrap Trap Preventing Care Re-Entry

Evidence: Invalidation (Bontempo 2025) drives healthcare avoidance; PEM prevents clinic participation (Bontempo, Bontempo, and Duberstein 2025). Interaction: too-traumatized-to-trust AND too-fatigued-to-shop = bootstrap trap, even when good care becomes available.
Citations: (Bontempo, Bontempo, and Duberstein 2025)
Mechanism: Past invalidation + PEM (provider-searching is physiologically costly) keeps the most-harmed patients outside the system; reform investments may preferentially benefit milder patients.
Chapter ref: ch40: Healthcare Invalidation × PEM Synergy — A Bootstrap Trap Preventing Care Re-Entry
Prediction: When a new specialist opens, the first 50 patients will have lower baseline invalidation scores and milder PEM than the regional ME/CFS population; refuted if avoidance does not interact with PEM to predict time-to-specialist-contact.
Limitation: Both mechanisms individually documented; synergy inferred not directly observed; severity most critical for long-duration severe patients. (ch40, prior cycle.)

Open Question p=0.75The NICE 2021 Natural Experiment — did UK practice change?

Evidence: NICE NG206 (Oct 2021) withdrew GET and recognized PEM; UK centralized data (CPRD ~20m patients) makes an interrupted-time-series answerable: pre-NICE vs post-NICE on diagnoses/GET-proxy-referrals/delay, with fibromyalgia+RA controls (Samms and Ponting 2025).
Citations: (Samms and Ponting 2025)
Mechanism: Guideline-attributable change detected by structural break in referral/exercise patterns for ME/CFS but not controls; if no break, implementation-gap concern confirmed.
Chapter ref: ch40: The NICE 2021 Natural Experiment
Prediction: Structural break in ME/CFS referral/diagnosis patterns post-NICE-2021 vs. controls; absence confirms the implementation gap.
Limitation: Feasibility high (standard method, data exist); the study has not yet been run. (ch40, prior cycle.)

Open Question p=0.55The Specialist Clinic Quasi-Experiment — distance as instrument

Evidence: Geographic proximity to specialist clinic as instrumental variable (PEM-adjusted distance); two-stage least squares estimates clinic-use effect on delay/function/PE-related ED visits, with MS comparator.
Mechanism: If specialist clinics improve outcomes, distance->use->better function; if null (Do Specialist Clinics Improve Outcomes?), apparent benefit reflects selection (wealthier/milder/health-literate reach them).
Chapter ref: ch40: The Specialist Clinic Quasi-Experiment
Prediction: Two-stage: PEM-adjusted distance predicts clinic use; clinic use predicts diagnostic delay, functional status, and PEM-ED visits; controls for selection by severity.
Limitation: Feasibility reasonable (UK data exist; US richer on claims, poorer on function); un-run. (ch40, prior cycle.)

Open Question p=0.50The Medical Education Pilot Trial — does teaching doctors change what they do?

Evidence: Cluster-RCT (n=20-30 practices, 1:1) of a 2-hour ME/CFS module (criteria, PEM, guidelines, EHR tool) vs. usual care; primary outcome new ME/CFS diagnoses per 10k patients over 18 months; powered to detect a doubling.
Mechanism: If education raises knowledge but not diagnosis rate, the barrier is structural (time, referral-pathway absence), not educational — upstream-failure model would need revision.
Chapter ref: ch40: The Medical Education Pilot Trial
Prediction: Education arm shows higher ME/CFS diagnosis rate; absence implies structural (not educational) barrier.
Limitation: 18-month follow-up may be too short (delay averages 5+ years); feasible but un-run. (ch40, prior cycle.)

Open Question p=0.55The PEM-Proof Care Delivery Trial — visits designed around what ME/CFS does to patients

Evidence: RCT (n=200 newly diagnosed, two arms, identical clinical content) comparing PEM-avoiding delivery (telehealth, async messaging, actigraphy, coordinator, energy-conservation pre-visit) vs. standard in-person clinic; primary SF-36 physical function at 12 months, secondary PEM frequency.
Mechanism: If PEM-avoiding delivery is superior on functional outcomes, PEM-aware delivery is a clinical-effectiveness lever, not just a preference; severe/housebound hypothesized to benefit most.
Chapter ref: ch40: The PEM-Proof Care Delivery Trial
Prediction: PEM-avoiding arm shows better SF-36 physical function / fewer PEM episodes at 12 months than standard care.
Limitation: Blinding to delivery channel impossible (actigraphy as objective check); feasible but un-run. (ch40, prior cycle.)

Hypothesis p=0.60PEM Is a Multi-Symptom Cascade Extending Beyond Simple Fatigue

Evidence: Meta-analytic odds ratio ~10.4 for PEM in ME/CFS vs controls (Brown and Jason 2020); factor analysis in n=2,308 loads PEM as a distinct primary factor separable from cognitive/sleep domains (Conroy, Islam, and Jason 2023); exploratory factor analysis shows the fatigue component of PEM itself has two sub-components (generalized and muscle-specific) (McManimen, Sunnquist, and Jason 2019); PEM-specific instruments (DSQ-PEM) retain discriminant validity against fatigue scales (Kuczyk et al. 2025). Replicated across factor-analytic, meta-analytic, and psychometric lines.
Citations: (Brown and Jason 2020), (Conroy, Islam, and Jason 2023), (McManimen, Sunnquist, and Jason 2019), (Kuczyk et al. 2025)
Mechanism: PEM is a multi-effector post-exertional cascade; fatigue is one component readout (itself multi-faceted) among several; this supports that PEM extends beyond simple fatigue, but does not by itself establish that PEM can occur with zero fatigue.
Chapter ref: ch03 sec-01-pem: PEM Is a Multi-Symptom Cascade That Extends Beyond Simple Fatigue
Prediction: A within-subject crash time-series will determine whether crashes dominated by cognitive/autonomic/pain symptoms can occur with fatigue absent (two independent criteria: free-text fatigue-absence, and zero fatigue under direct multi-synonym probing).
Limitation: Construct-distinction evidence is moderately strong; the stronger claim “PEM can occur with zero fatigue” remains a candidate hypothesis without direct documentation. Severity coverage not stratified; ambulatory cohorts. (ch03, this cycle.)

Speculation p=0.60Diagnostic Criteria Hierarchy: PEM-Required vs PEM-Optional Definitions

Evidence: Systematic review of 25 case definitions: Fukuda (1994) requires fatigue, makes PEM optional; CCC (2003), ICC (2011), IOM (2015) make PEM compulsory (Lim and Son 2020) (Institute of Medicine 2015). PEM-required criteria identify patients differing on intervention tolerance (Kielland, Liu, and Jason 2023) and stratify severity independent of fatigue (May et al. 2020).
Citations: (Lim and Son 2020), (Institute of Medicine 2015), (Kielland, Liu, and Jason 2023)
Mechanism: Using PEM-optional (Fukuda) criteria dilutes the diagnosis with chronic-fatigue-of-other-etiology patients, weakening the cohort for PEM-relevant trials and epidemiology.
Chapter ref: ch03 sec-01-pem: Diagnostic Criteria Differentiate PEM-Requiring from PEM-Optional Definitions
Prediction: Fukuda-positive/IOM-negative patients should show at least a 0.3-point smaller SF-36 physical-function improvement or at least a 10-percentage-point higher non-recovery rate vs CCC/IOM-positive patients over 12 months; indistinguishable trajectories refute PEM’s independent prognostic weight.
Limitation: Hierarchy documented; the trajectory/response prediction is indirect (mixed-criteria cohorts, no direct within-subject trial). Severity not stratified; ambulatory. (ch03, this cycle.)

Open Question p=N/ASelf-Reported vs Objective PEM: Why the Gap?

Evidence: In Long COVID, 67% self-report PEM but only 5.9% (2/34) show objectively provoked PEM after standardized CPET (Stussman et al. 2025); PEM-item wording materially changes classification (Leonard A. Jason et al. 2015).
Citations: (Stussman et al. 2025), (Leonard A. Jason et al. 2015)
Mechanism: Open question: gap could reflect protocol failure to provoke PEM, non-physical triggers, conflation of exercise fatigue with PEM, or need for 2-day CPET — four candidate explanations with precedent.
Chapter ref: ch03 sec-01-pem: How Well Does Self-Reported PEM Align with Objectively Provoked PEM?
Prediction: A study using both self-report and 2-day objective provocation with multi-trigger protocols will resolve which explanation(s) account for the self-report/objective dissociation.
Limitation: Small Long COVID cohort (n=34) able to attend CPET — biased toward ambulatory patients; not stratified by severity. (ch03, this cycle.)

Speculation p=0.40PEM-Without-Fatigue: Temporal Cases (crash window / onset / baseline)

Evidence: No study directly tests PEM-without-fatigue. Indirect support: four-symptom PEM prediction set includes three non-fatigue domains (Davenport et al. 2023); PEM stratifies severity independent of baseline fatigue (May et al. 2020); crash-predominant phenotype recognised (ch18).
Citations: (Davenport et al. 2023), (May et al. 2020)
Mechanism: PEM is effort-triggered multi-system; a crash may be dominated by cognitive/autonomic/pain/flulike symptoms (fatigue subdominant or below reporting threshold), at onset, or a patient may have near-normal baseline fatigue yet be PEM-positive (crash-predominant).
Chapter ref: ch03 sec-01-pem: Is Post-Exertional Malaise Possible Without Fatigue?
Prediction: Two independent criteria: (a) true biological fatigue-absence is falsified if no objectively confirmed crash is ever described in purely non-fatigue terms under free-text elicitation (no fatigue prompt); (b) the artifact reading is falsified if a measurable fraction (>10%) of crashes are described in purely non-fatigue terms under free-text and still report zero fatigue under direct multi-synonym probing.
Limitation: All scenarios candidate; no direct within-title documentation; severity not stratified, severe/very-severe reporting constrained. (ch03, this cycle.)

Speculation p=0.40PEM-Without-Fatigue: Candidate Mechanisms M1–M5

Evidence: Five indirect mechanisms: (M1) non-fatigue dominant expressive channels (Davenport et al. 2023) (Conroy, Islam, and Jason 2023); (M2) two-factor PEM substructure (McManimen, Sunnquist, and Jason 2019); (M3) trigger-type dependence; (M4) labeling/measurement frame (Leonard A. Jason et al. 2015); (M5) self-report vs objective dissociation (Stussman et al. 2025). M4 is the most parsimonious (no novel pathway; directly supported by wording-sensitivity evidence; cert 0.45).
Citations: (Davenport et al. 2023), (Conroy, Islam, and Jason 2023), (McManimen, Sunnquist, and Jason 2019), (Leonard A. Jason et al. 2015), (Stussman et al. 2025)
Mechanism: If PEM-without-fatigue occurs, any of five pathways (channel dominance, two-factor PEM, trigger type, labeling, measurement gap) could explain a non-fatigue-dominant crash; none isolated or directly tested. The labeling/measurement-artifact account (M4, with M5) is the default until disproven.
Chapter ref: ch03 sec-01-pem: Mechanisms by Which a Crash Could Express Without Prominent Fatigue
Prediction: Falsifiable, two independent criteria: (a) true biological fatigue-absence falsified if no crash is ever fatigue-free under free-text elicitation (no fatigue prompt); (b) artifact reading falsified if a measurable fraction of crashes are fatigue-free under free-text AND still report zero fatigue under direct multi-synonym probing. Additional: (c) trigger-type differences in fatigue intensity; (d) M2 low-muscle-fatigue-arm sparing.
Limitation: All mechanisms inferred (indirect/analogical); none directly tested; stringent honesty constraint — must not assert as established fact. Severity not stratified. (ch03, this cycle.)

Open Question p=N/AIs “PEM Without Fatigue” Real Biology or Always a Measurement Artifact?

Evidence: Strong null interpretation: reported fatigue-absence may always be measurement/labeling artifact — fatigue is imprecise and culturally loaded (Leonard A. Jason et al. 2015); IOM requires fatigue alongside PEM (Institute of Medicine 2015); no validated PEM instrument scores PEM-positive with explicit zero fatigue.
Citations: (Leonard A. Jason et al. 2015), (Institute of Medicine 2015)
Mechanism: If null holds, the temporal cases and mechanisms above describe experience/reporting variants (channel dominance, vocabulary, trigger type) of fatigue-looking crashes, not biological fatigue-absence. Deciding biology-vs-artifact determines whether low-fatigue crashes are treated as real PEM or an elicitation gap.
Chapter ref: ch03 sec-01-pem: Is “PEM Without Fatigue” Ever a Real Phenomenon, or Always a Measurement Artifact?
Prediction: A within-subject study pairing free-text elicitation (no fatigue prompt) with a structured multi-system PEM instrument discriminates: if patients describing non-fatigue crashes still rate fatigue when directly probed, artifact dominates; if a measurable fraction report no fatigue even under direct multi-synonym probing, artifact reading is incomplete.
Limitation: Open question — no decisive data; presented as the balancing null, not an assertion. Severity not stratified. (ch03, this cycle.)

Hypothesis p=0.60Fatigue Is Embedded Within Coherent Multi-System Symptom Clusters (Brain / Gut-Immune / Autonomic)

Evidence: Factor analysis in n=748 adults with ME/CFS identified three symptom clusters — Brain, Gut-Immune, Autonomic — each with strong model fit (EFA/CFA/SEM) (Habermann-Horstmeier and Horstmeier 2025); fatigue distributed across domains rather than forming a separate factor.
Citations: (Habermann-Horstmeier and Horstmeier 2025)
Mechanism: Fatigue is a cross-cutting symptom whose precipitating driver may differ by cluster, rather than a unitary construct; treating fatigue as a single target may miss cluster-specific mechanisms.
Chapter ref: ch03 sec-00-fatigue: Fatigue Is Embedded Within Coherent Multi-System Symptom Clusters
Prediction: In a pre-registered trial stratifying ME/CFS patients by dominant symptom cluster and assigning cluster-targeted intervention, a significant cluster × treatment interaction on a validated fatigue instrument must emerge (p < 0.05 corrected; interaction η²p ≥ 0.01). Absence of interaction or only a main effect refutes cluster-specific fatigue mechanism.
Limitation: Cross-sectional; self-report; single-sample factor solution not yet independently replicated; does not establish causal mechanism. Severity not stratified. (ch03, this cycle.)

Hypothesis p=0.65Severity-Based Fatigue Subgroups Exist and Depend on Case Definition

Evidence: K-means clustering of the Australian registry (n=2,873 patients vs n=797 controls) identified four severity subgroups with significantly impaired HRQoL; ICC-defined patients had worst outcomes; cluster structure depended on case definition (Eaton-Fitch and Marshall-Gradisnik 2026).
Citations: (Eaton-Fitch and Marshall-Gradisnik 2026)
Mechanism: Fatigue severity is not a single number; the observed subgroup structure changes with the diagnostic criteria applied, so severity classification is partly an artifact of case definition.
Chapter ref: ch03 sec-00-fatigue: Severity-Based Fatigue Subgroups Exist and Depend on Case Definition
Prediction: Replication of k-means in independent cohort (n ≥ 500, same case definition) must recover ≥3 of 4 original subgroups (silhouette ≥ 0.25), with significant between-cluster differences (p < 0.05 corrected) on external measure — e.g. 7-day actigraphy step count or MFI-20 subscales. Refuted if all pairwise contrasts p > 0.05 after Holm–Bonferroni or if different case definition dissolves the 4-cluster solution.
Limitation: Self-selected registry volunteers; cross-sectional; k-means clusters descriptive, may not capture true latent subtypes; single registry not yet replicated. Severity: ambulatory registry; severe/very-severe under-represented. (ch03, this cycle.)

Open Question p=N/ADo Subjective Fatigue and Objective Fatigability Dissociate in ME/CFS?

Evidence: Subjective fatigue and objective fatigability may not correlate closely: actigraphy shows objectively reduced activity (Liu et al. 2025) and neuroimaging shows impaired central motor drive (Bedard et al. 2026), while subjective scales capture experienced exhaustion; no large study has correlated both within the same ME/CFS cohort.
Citations: (Liu et al. 2025), (Bedard et al. 2026)
Mechanism: Open question: whether patients reporting severe fatigue but normal performance (or vice versa) are a meaningful subtype or measurement dissociation is unresolved for fatigue specifically, by contrast with related autonomic findings.
Chapter ref: ch03 sec-00-fatigue: Do Subjective Fatigue and Objective Fatigability Dissociate?
Prediction: A study pairing a subjective fatigue instrument with objective fatigability (actigraphy + performance test) in the same cohort will establish whether the two orders dissociate and what any dissociation predicts clinically.
Limitation: No dedicated fatigue discordance study exists; related evidence from other autonomic measures not directly transferable. Severity not stratified. (ch03, this cycle.)

Speculation p=0.42Acute CNS-Parenchymal Inflammation Predicts Long-Term Neurodegeneration — A Cross-Disease Template for ME/CFS

Evidence: A large US electronic-health-record cohort (TriNetX, ~129 M patients, 72 organizations) found encephalitis predicts long-term dementia with composite risk ratios of 2.11 (>60 y) and 5.16 (40–60 y) over ten years; strongest for non-infectious/post-infectious inflammatory (autoimmune) etiologies (RR 3.93), non-significant for bacterial (RR 1.35, 0.97–1.87) (Aditi et al. 2026). An independent UK primary-care cohort reproduced elevated post-encephalitis cognitive/dementia sequelae (Granerod et al. 2017). CNS-inflammation → neurodegeneration mechanism is established in Alzheimer’s disease (microglial/astroglial activation (Heneka et al. 2025); causal NLRP3 roles in tau (Ising et al. 2019) and amyloid (Heneka et al. 2013)); ME/CFS grouped with chronic neuroimmune-dysfunction disorders (Cohen et al. 2024). Cross-disease inference: same acute-CNS-inflammation → long-term-neurodegeneration axis is the template by which sustained ME/CFS neuroinflammation (TSPO-PET (Nakatomi et al. 2014); exosome-driven microglial IL-1$\beta$ (Tsilioni, Natelson, and Theoharides 2022)) could, if it persists, contribute to progressive cognitive decline.
Citations: (Aditi et al. 2026) (Granerod et al. 2017) (Heneka et al. 2025) (Ising et al. 2019) (Heneka et al. 2013) (Cohen et al. 2024) (Javonillo et al. 2026) (Nakatomi et al. 2014) (Tsilioni, Natelson, and Theoharides 2022)
Mechanism: Acute, direct CNS parenchymal inflammation (encephalitis) — especially autoimmune/post-infectious-inflammatory — initiates a self-sustaining neuroinflammatory process (microglial/astroglial activation, NLRP3) that measurably precedes and predicts later neurodegeneration. By analogy, sustained ME/CFS neuroinflammation could, if it persists, be a progressive pathology driver rather than a reversible symptom correlate; inflammation quality (autoimmune/post-infectious) matters more than mere presence (bacterial encephalitis not significant).
Chapter ref: ch14d-cross-disease: encephalitis dementia precedent; ch19 causal hierarchy: chronicity criterion longitudinal temporal upgrade; ch08 subsec-05 neuroinflammation: Hundreds of Blood Biomarkers Distinguish ME/CFS, Independent of Inactivity; ch18 sec-14 long-term consequences: Chronic Glymphatic Impairment as a Risk Factor for Accelerated Neurodegeneration in ME/CFS
Prediction: If sustained ME/CFS neuroinflammation drives neurodegeneration through the encephalitis/Alzheimer axis, then longitudinal ME/CFS cohorts (n $>=$ 200, ≥ 5-yr follow-up) will show (i) elevated baseline plasma NfL/GFAP or CSF neuroinflammation markers predicting worsening objective cognitive performance over time, and (ii) a dose–response between TSPO-PET signal (or equivalent glial marker) and rate of cognitive decline. Falsified if ME/CFS patients show stable cognition over ≥ 5 years despite elevated neuroinflammation markers, or if no neuroinflammation marker predicts any cognitive trajectory (indicating non-degenerative, reversible neuroinflammation).
Treatment: No clinical treatment recommendation (cross-disease, indirect). If confirmed, would shift rationale toward earlier anti-neuroinflammatory intervention and long-term cognitive monitoring of ME/CFS patients — not currently actionable, no ME/CFS dementia data.
Limitation: Entirely analogical — no ME/CFS dementia cohort exists; the ME/CFS neuroinflammation premise itself is contested (single TSPO-PET study null (Raijmakers et al. 2021), Neuroinflammation Measurement Challenges). Etiology specificity (bacterial null) and animal preprint cautioning that acute viral neuroinflammation does not uniformly accelerate amyloid (Javonillo et al. 2026) temper over-generalization. Severity applicability unknown (general-population cohort, not ME/CFS, not severity-stratified). (Origin: /integrate-topic encephalitis-dementia-risk.)

Speculation p=0.25Anellovirus Burden as an Immune-State Signature Rather Than a Viral Cause in ME/CFS

Evidence: Briese et al. multicenter virome study found no consistent group-specific viral nucleic acid differences in ME/CFS except a lower prevalence of anelloviruses in cases (30.5% vs 54.1%, $p$ < 0.001) (Briese et al. 2023); Maguire et al. (IMPACC, n=1154) found elevated Anelloviridae transcript reads in the long-COVID physical-disability PRO group (Maguire et al. 2026), and noted prior anellovirus links to chronic fatigue syndrome and multiple sclerosis. Neither study measured anellovirus burden and immune markers in the same ME/CFS patients; immune-state-marker reading is an inference, not a finding.
Citations: (Briese et al. 2023), (Maguire et al. 2026)
Mechanism: Anellovirus (TTV/TTMV) burden may reflect immune-competence/dysregulation state rather than productive viral infection. Directional form: innate-hyperactivation-dominant subgroups → low TTV; adaptive-exhaustion-dominant → high TTV (see Constitutive Immune Activation Without Secretory Output). The apparent direction difference across cohorts may be a method artifact (Briese binary prevalence vs Maguire transcript abundance).
Chapter ref: ch08 sec-06-other-implicated-viruses: Anellovirus Burden as an Immune-State Signature Rather Than a Viral Cause in ME/CFS (non-directional form) and Constitutive Immune Activation Without Secretory Output (directional form); ch14d-cross-disease long-COVID overlap
Prediction: Using the directional map (innate-hyperactivation→low TTV; adaptive-exhaustion→high TTV), a harmonized TTV assay in one cohort will show innate-hyperactivation-dominant subgroups with lower TTV and adaptive-exhaustion-dominant subgroups with higher TTV than controls, and TTV tracking an immune marker rather than symptom severity alone. Falsified if TTV is a stable, immune-independent, disease-defining feature across all subgroups, or if harmonization eliminates the direction difference (both non-significant).
Limitation: Briese full text abstract-level (in-document numbers from the sibling spec used); Maguire is a hospitalized COVID-19 cohort (translation gap, population-discounted 0.85; hospitalization/steroid confound uneliminated); cross-sectional; competing explanations include method incommensurability, redundant-bystander, technical bias, and cohort-composition effects. Severity not stratified. Certainty lowered to 0.25 per adversarial review (was 0.40). (ch08, this cycle.)

Open Question p=N/ADoes Viral-Gene-Product Surveillance Have Any Diagnostic or Mechanistic Role in ME/CFS?

Evidence: Multicenter PCR + high-throughput sequencing surveillance of blood, feces, and saliva found no consistent group-specific viral differences in ME/CFS except lower anelloviruses, leading the authors to recommend focusing future investigations on adaptive immune responses rather than viral-gene-product surveillance (Briese et al. 2023).
Citations: (Briese et al. 2023)
Mechanism: Open question: whether viral-gene-product surveillance adds diagnostic or mechanistic value in ME/CFS, or whether the productive-replication arm of the viral-persistence model is unsupported and should yield to adaptive-immune investigation.
Chapter ref: ch08 sec-06-other-implicated-viruses: No Productive Viral Infection Detected by Nucleic-Acid Surveillance of Non-Tissue Compartments in ME/CFS
Prediction: A study correlating anellovirus burden and adaptive-immune markers in the same ME/CFS cohort will determine whether the null surveillance result reflects absence of productive infection (supporting adaptive-immune focus) or a surveillance technical limitation.
Limitation: Balancing null presented as a research-direction question, not an assertion; single null surveillance study; full cohort-stratification details not retrieved. Severity not stratified. (ch08, this cycle.)

Hypothesis p=0.52The Luteal Phase May Confer Relative Orthostatic Protection in POTS

Evidence: Ten women with POTS tolerated upright posture longer with less symptomatic orthostatic decompensation in the mid-luteal phase (higher presyncope rate in early follicular) than in the early follicular phase, independent of medication (Fu et al. 2010). A same-group follow-up found no cycle-phase effect on presyncope incidence, baroreflex sensitivity, or muscle sympathetic nerve activity (Stickford et al. 2015) — an unresolved contradiction on the orthostatic-tolerance outcome.
Citations: (Fu et al. 2010) (Stickford et al. 2015)
Mechanism: Luteal-phase hormonal milieu (progesterone vasodilation/volume retention, estradiol NO-mediated vasodilation) may improve peripheral vascular/volume response to orthostasis in a condition defined by maladaptive vasodilation and venous pooling — but the effect is unconfirmed (single small positive vs single small same-group null on the same outcome).
Chapter ref: ch21 sec-01 menstrual cyclicity: The Luteal Phase May Confer Relative Orthostatic Protection in POTS, Is the Luteal-Phase Orthostatic Effect Real? — An Unresolved Contradiction
Prediction: A prospective cycle-phase study in women with ME/CFS + comorbid POTS (n ≥ 20, LH-surge-confirmed phase, head-up tilt/active stand + symptom scoring) should reproduce a luteal-phase improvement in orthostatic tolerance and symptom burden. Falsified if luteal-phase tolerance is not better than early-follicular in the same women — which is what the same-group Stickford study found.
Treatment: Cycle phase is a confounder to control in orthostatic treatment trials; phase-aware planning of orthostatic symptom burden. No new drug. The treatment implication is conditional on resolving the unconfirmed effect.
Limitation: Unresolved contradiction: Fu (n=10) positive vs Stickford (n=10, same lab) null on presyncope/orthostatic tolerance; not independently replicated; POTS population, not a ME/CFS cohort (population weight 0.80); not severity-stratified.

Hypothesis p=0.40Postpartum Immune Reconstitution as an ME/CFS Trigger or Relapse Driver

Evidence: Pregnancy induces a tolerogenic, Th2-shifted immune state (elevated Tregs, reduced NK cytotoxicity) that collapses rapidly postpartum as estrogen and progesterone fall; postpartum relapse at 3–6 months is a documented clinical pattern (Slack et al. 2023); pregnancy reported as ME/CFS trigger in a minority of cases (Thomas et al. 2022). Immune-reconstitution mechanism extrapolated from HIV-IRIS precedent, not measured directly in ME/CFS.
Citations: (Slack et al. 2023) (Thomas et al. 2022) (Schacterle and Komaroff 2004)
Mechanism: Postpartum collapse of pregnancy-induced immunotolerance + rapid steroid/allopregnanolone withdrawal precipitates immune reconstitution against persistent antigens and unmasks autonomic/sleep instability in the 3–6 month window.
Chapter ref: ch21 sec-02 pregnancy & postpartum: Postpartum Immune Reconstitution as an ME/CFS Trigger or Relapse Driver
Prediction: Women developing ME/CFS within 12 months postpartum should show steeper Treg decline between 3rd trimester and 3 months postpartum and evidence of EBV/HHV-6 reactivation in the postpartum window vs healthy postpartum controls. Falsified if immune-reconstitution markers do not differ between postpartum-onset ME/CFS and healthy postpartum women.
Treatment: Postpartum window becomes a monitoring + early-intervention target in high-risk women; no current treatment recommendation.
Limitation: Relapse timing documented but mechanism extrapolated (HIV-IRIS analogy), not directly measured in ME/CFS; not severity-stratified.

Hypothesis p=0.26Estradiol and Progesterone Directly Modulate Mast Cell Activation

Evidence: In-vitro and animal work establishes estradiol primes/sensitises mast cells toward activation and degranulation while progesterone modulates (often suppresses) them (Zaitsu et al. 2007) (Muñoz-Cruz et al. 2015) (Jensen et al. 2010); environmental estrogens modulate mast cells (Narita et al. 2007); ovariectomised-mouse model confirms ovarian-hormone-withdrawal effects on mast cells (Jensen et al. 2010).
Citations: (Zaitsu et al. 2007) (Muñoz-Cruz et al. 2015) (Jensen et al. 2010) (Narita et al. 2007)
Mechanism: Estradiol primes mast cell activation; progesterone modulates/suppresses it; ovarian-hormone state (cycle phase, pregnancy, menopause, HRT) therefore modulates mast-cell-dependent symptoms — the mechanistic bridge connecting female predominance of ME/CFS to its MCAS comorbidity.
Chapter ref: ch21 sec-04 HRT: Estradiol and Progesterone Directly Modulate Mast Cell Activation
Prediction: In women with ME/CFS + MCAS symptoms, serum tryptase/histamine should vary across the menstrual cycle and change with menopause or HRT in a direction consistent with model-system findings. Falsified if mast cell mediators in ME/CFS patients do not track hormonal state.
Treatment: Hormonal state is a candidate modifiable lever on mast-cell-dependent symptoms; direction of effect is individual (double-edged). No blanket recommendation.
Limitation: Model-system evidence only (in-vitro/animal, population weight 0.40–0.50) — translation gap to patients not confirmed in ME/CFS; not severity-stratified.

Hypothesis p=0.58Endometriosis Is Associated with a ~2.8-Fold Higher Risk of ME/CFS

Evidence: Systematic review + meta-analysis (13 studies, n from 84 to 134,805): endometriosis associated with OR 2.79 (95% CI 2.00–3.89) for ME/CFS; pooled OR 2.52 for the ME/CFS–endometriosis association; association heterogeneity I² = 0.0% (Compton et al. 2025). Consistent with earlier population-based finding (36% vs 17% endometriosis in cases vs controls (Boneva, Lin, and Unger 2011)).
Citations: (Compton et al. 2025) (Boneva, Lin, and Unger 2011)
Mechanism: Shared mast-cell/neuroinflammatory axis: endometriosis lesions produce IL-1β, TNF-α, NGF; both conditions feature mast cell hyperactivation, peripheral nerve sensitisation, estrogen-driven inflammation; bidirectional causation plausible (endometriosis inflammation seeds central sensitisation; ME/CFS immune dysregulation permits ectopic implant survival).
Chapter ref: ch21 sec-05 endometriosis & PCOS: Endometriosis Is Associated with a ~2.8-Fold Higher Risk of ME/CFS, Shared Mast Cell and Neuroinflammatory Axis Underlies the Endometriosis–ME/CFS Association
Prediction: In a prospective cohort, incidence of ME/CFS in surgically-confirmed endometriosis should exceed that in matched controls, and ME/CFS severity should correlate with endometriosis disease activity. Falsified if association reflects only ascertainment.
Treatment: Screening for endometriosis in ME/CFS women with pelvic symptoms and vice versa; treating one condition may be relevant to the other. No claim that treating endometriosis treats ME/CFS.
Limitation: Cross-sectional designs predominate; 54% self-reported endometriosis; US-centric; prevalence heterogeneity extreme (I² > 98%). Not severity-stratified.

Open Question p=N/ADoes PCOS Co-occur with ME/CFS? — No Direct Evidence Found

Evidence: Targeted search found no direct, adequately powered PCOS–ME/CFS co-occurrence study; the only hit (n=37, no control, null fatigue correlation, low-tier journal) fails inclusion criteria. PCOS association remains unestablished.
Mechanism: Open question: PCOS is an estrogen/androgen-dominant endocrine-metabolic condition in premenopausal women, so a mechanistic rationale for overlap exists, but no evidence supports an association.
Chapter ref: ch21 sec-05 endometriosis & PCOS: Does PCOS Co-occur with ME/CFS? — No Direct Evidence Found
Prediction: A proper prevalence study of PCOS in ME/CFS (and vice versa) is required before any association claim.
Treatment: No association to act on; manage any coexisting PCOS and ME/CFS as distinct conditions.
Limitation: Absence of evidence, not evidence of absence; treated as genuinely open.

Speculation p=0.25Cyclic Luteal→Menstrual Allopregnanolone Withdrawal as a Monthly PEM Amplifier

Evidence: Allopregnanolone (progesterone metabolite, GABA-A positive allosteric modulator) rises across the luteal phase and crashes at the luteal→menstrual transition. The postpartum version of this withdrawal is documented as a vulnerability window (Slack et al. 2023); the monthly version is unexamined. No ME/CFS study has measured allopregnanolone across the cycle or linked it to PEM timing.
Citations: (Slack et al. 2023)
Mechanism: Each cycle’s premenstrual allopregnanolone drop unmask the same GABAergic-autonomic vulnerability the postpartum drop produces in a single large event, amplifying PEM and autonomic instability at the luteal→menstrual boundary.
Chapter ref: ch21 sec-01 menstrual cyclicity: Cyclic Luteal→Menstrual Allopregnanolone Withdrawal as a Monthly PEM Amplifier
Prediction: PEM episode frequency and severity are significantly higher in the 3 days after luteal allopregnanolone peaks than at other phases, reduced by luteal micronized progesterone. Falsified if PEM does not cluster at the withdrawal boundary or progesterone does not blunt it.
Treatment: Luteal-phase micronized progesterone as a repeatable, non-pregnancy probe of the GABAergic-autonomic axis; interaction data not individually checked — manual review.
Limitation: Extrapolation from postpartum analogue; no ME/CFS cycle allopregnanolone data; not severity-stratified. (Origin: brainstorm.)

Speculation p=0.20Menopause as an Iron-Accumulation / Ferroptosis Transition in ME/CFS

Evidence: Reproductive axis is usually framed as iron-deficiency (heavy menses, pregnancy). Cessation of menstrual blood loss at menopause halts monthly iron excretion; chronic iron overload drives Fenton-chemistry oxidative stress and ferroptosis linked to mitochondrial dysfunction. No ME/CFS menopause-iron study exists.
Mechanism: Menopausal iron accumulation → ferroptosis → further mitochondrial/energy failure explains a non-hormonal, non-mast-cell reason for menopause-transition worsening in a subgroup; predicts iron reduction (phlebotomy) rather than supplementation may help.
Chapter ref: ch21 sec-03 menopause transition: Menopause as an Iron-Accumulation / Ferroptosis Transition — the Reverse of Deficiency
Prediction: Post-menopausal ME/CFS women with prior menorrhagia show elevated ferritin/transferrin saturation and ferroptosis markers (4-HNE, MDA) vs controls, correlating with fatigue severity. Falsified if iron stores and ferroptosis markers are not elevated or do not track severity.
Treatment: Iron reduction (phlebotomy, iron-restricted diet) — speculative; contraindicated in iron-deficient patients.
Limitation: Novel, mechanistically coherent but entirely unexamined in ME/CFS; menopause-transition evidence base itself indirect. (Origin: brainstorm.)

Prediction p=0.40Mast-Cell-Stabilizer Trials Should Be Stratified by Hormonal Phase and E2:P4 Ratio

Evidence: Estrogen-mast-cell axis established in model systems (Zaitsu et al. 2007) (Muñoz-Cruz et al. 2015) (Jensen et al. 2010); mast-cell-stabilizer trials in ME/CFS are analysed without any hormonal covariate.
Citations: (Zaitsu et al. 2007) (Muñoz-Cruz et al. 2015) (Jensen et al. 2010)
Mechanism: E2:P4 ratio (not absolute levels) predicts mast-cell reactivity — high E2 with low P4 = unopposed estradiol priming; high P4 = suppression. Stabilizer efficacy may concentrate in high-E2/low-P4 states.
Chapter ref: ch21 sec-04 HRT: Mast-Cell-Stabilizer Trials Should Be Stratified by Hormonal Phase and E2:P4 Ratio
Prediction: ≥30% greater stabilizer benefit in high-E2/low-P4 phase than high-P4 phase or post-menopause. Falsified if stabilizer efficacy is uniform across hormonal states.
Treatment: Research direction only (re-analysis/trial design); no treatment recommendation.
Limitation: Ratio-specific claim untested; research design. (Origin: brainstorm.)

Prediction p=0.45The Postpartum 3–6 Month Window Is an Ideal Prospective Onset-Cohort Target

Evidence: Postpartum window is a defined, time-bounded event with an identifiable trigger state (collapse of pregnancy hormonal/immune milieu); postpartum relapse timing 3–6 months documented (Slack et al. 2023) (Schacterle and Komaroff 2004).
Citations: (Slack et al. 2023) (Schacterle and Komaroff 2004)
Mechanism: Recruiting at-risk primiparous women before/during pregnancy and following through the 3–6 month window with biobanking captures onset prospectively — a direct test of the immune-reconstitution hypothesis.
Chapter ref: ch21 sec-02 postpartum: The Postpartum 3–6 Month Window Is an Ideal Prospective Onset-Cohort Target
Prediction: ~2% of ~150 at-risk primiparous women develop new/relapsed ME/CFS in the 3–6 month window, with steeper Treg decline and higher EBV/HHV-6 reactivation vs postpartum-healthy controls.
Treatment: Enables early biomarkers and early intervention; research design.
Limitation: Onset signal real but immune mechanism unproven; recruitment feasibility. (Origin: brainstorm.)

Prediction p=0.40A Longitudinal AMH Slope Panel Predicts Early Menopause Before the Event

Evidence: AMH is stable across the menstrual cycle and reflects remaining follicular pool; early menopause over-represented in ME/CFS (Boneva et al. 2015); four candidate mechanisms for accelerated ovarian aging documented Accelerated Ovarian Aging: An Inflammatory or Mitochondrial Driver.
Citations: (Boneva et al. 2015)
Mechanism: Serial AMH + FSH/estradiol use the rate of AMH decline as marker of accelerated follicular attrition, flagging early menopause years before the event.
Chapter ref: ch21 sec-03 early menopause: A Longitudinal AMH Slope Panel Predicts Early Menopause Before the Event
Prediction: AMH decline slope >1.5× steeper in ME/CFS women aged 25–40 vs controls over 24 months; steep-slope subgroup reaches menopause earlier.
Treatment: Early bone/cardiovascular protection and HRT planning; biomarker.
Limitation: No longitudinal AMH data exist in ME/CFS. (Origin: brainstorm.)

Prediction p=0.35Pregnancy Response as a Natural Subtype-to-Treatment Diagnostic Probe

Evidence: Tripartite pregnancy split documented (Schacterle and Komaroff 2004) (Slack et al. 2023); candidate subtype axes (immune/volume/metabolic) proposed Which Pathophysiological Subtypes Improve Versus Worsen in Pregnancy?.
Citations: (Schacterle and Komaroff 2004) (Slack et al. 2023)
Mechanism: A woman’s pregnancy response assigns her to a treatment-relevant subtype: improved (immune/volume dominant), worsened (metabolic dominant), unchanged (uncertain) — convertible to a stratification input for trials and care.
Chapter ref: ch21 sec-02 pregnancy tripartite: Pregnancy Response as a Natural Subtype-to-Treatment Diagnostic Probe
Prediction: Baseline measures (autoantibodies, tilt-test, CPET) predict pregnancy trajectory with concordance >0.6, and reported direction predicts response to the corresponding treatment class.
Treatment: Stratification input; no standalone treatment claim.
Limitation: Tripartite observation established but subtype-probe use novel/untested. (Origin: brainstorm.)

Open Question p=0.40Crash-Phase Near-Syncopal “Shutdown” Quality: Distinct Phenomenon or Energy-Collapse Metaphor?

Evidence: Patients sometimes describe severe crashes in near-syncopal terms (sinking, approaching loss of consciousness without losing consciousness). Orthostatic syncope/pre-syncope is common in ME/CFS on upright tilt (Bou-Holaigah et al. 1995) (Stewart et al. 1998) and correlates with worse PEM (L. A. Jason, McGarrigle, and Vermeulen 2024), but no study names a distinct near-syncopal quality intrinsic to the post-exertional crash. Cerebral hypoperfusion under orthostatic/exertional stress is common (Novak et al. 2026) but contested (Razumovsky et al. 2003); a submaximal-exercise provocation reports reduced global CBF with post-exertional worsening (Rayhan and Baraniuk 2021).
Citations: (Bou-Holaigah et al. 1995) (Stewart et al. 1998) (L. A. Jason, McGarrigle, and Vermeulen 2024) (Novak et al. 2026) (Razumovsky et al. 2003) (Rayhan and Baraniuk 2021)
Mechanism: If real, a crash-phase near-syncopal quality would reflect exertional/orthostatic cerebral hypoperfusion distinct from upright-posture-only orthostatic syncope; the substrate (reduced cerebral blood flow) is plausible but mechanistically contested.
Chapter ref: ch03 sec-01-pem physiological basis: Do Some PEM Crashes Carry a Near-Syncopal “Shutdown” Quality Distinct From Upright Orthostatic Intolerance?
Prediction: A two-day CPET in patients reporting near-syncopal crashes should produce orthostatic-BP or cerebral-perfusion changes during/shortly after exertion (not only on upright tilt), and the near-syncopal description should co-occur with objective orthostatic findings. Falsified if no orthostatic/perfusion change is found in either post-exertional or upright settings.
Treatment: Orthostatic testing of patients who describe near-syncopal crashes; no new treatment claim.
Limitation: Feature under test has no direct published support (0 PubMed hits for crash-phase near-syncope terms); severity applicability unknown. (Origin: integrate-topic crash-phase-near-syncope-pem, PARTIAL decision.)

ID / Label	Details	Phase / Cert
hyp virtual-hypoxia-brain-lactate	Elevated resting brain lactate with a blunted rise under hypoxia supports intrinsic mitochondrial/bioenergetic inefficiency (“virtual hypoxia”): patients show a ~27% higher baseline thalamic Lac/tCr (0.171 vs 0.135; $\beta$=0.035, $p$=0.021) and fail to raise it under two hypoxic challenges where controls do (H1 $p$=0.028, H2 $p$=0.039 vs patients H1 $p$=0.38, H2 $p$=0.46) (Bader et al. 2026). Consistent with Trapp’s virtual-hypoxia proposal (Trapp and Stys 2009) and bioenergetic-inefficiency accounts (Tomas et al. 2017). Replication: not yet — single preprint. Limitations: proof-of-concept, modest sample, cross-sectional, hypoxic challenge ≠ exertion. Falsifiability: resting lactate stays elevated or response stays blunted in a second independent cohort, and normalises with an intervention that restores mitochondrial ATP production. Consequence: gives a concrete brain-imaging readout that ME/CFS fatigue is linked to a measurable failure to ramp up energy production on demand. (ch07 lactate accumulation: Virtual Hypoxia: Elevated Resting Brain Lactate with Blunted Metabolic Reactivity; origin: integrate-topic experimental-hypoxia-virtual-hypoxia-brainstem.)	Phase 3 / 0.40
hyp brainstem-volume-open-question	Brainstem volume direction is unresolved: Vienna reports reduced brainstem/pons volume ($\beta$=-0.10% eTIV, $p$=0.013, FDR 0.039) (Bader et al. 2026), Griffith reports larger brainstem/pons (pons $p$=0.003, whole brainstem $p$=0.005) (Thapaliya et al. 2023). Thapaliya2023/Barnden2018/Thapaliya2022 are the same Griffith lab cluster — not independent replications (Thapaliya et al. 2023) (Barnden et al. 2018) (Thapaliya et al. 2022). Net independent clusters = 2, opposite directions. Replication: neither direction replicated by an independent lab. Falsifiability: multi-site harmonised segmentation gives a consistent direction across independent labs. Consequence: the true direction would localise a structural site of pathology and help explain brainstem-related symptoms (autonomic dysfunction, dyspnoea, sleep disturbance). (ch09 sec-01: Brainstem Volume Direction Contradicts Across Cohorts; origin: integrate-topic experimental-hypoxia-virtual-hypoxia-brainstem.)	Phase 3 / N/A
spec cbf-reactivity-variability	Gross cerebrovascular reactivity to a controlled hypoxic stressor is preserved on average (whole-brain CBF +4.8±13.0% controls vs +3.7±11.7% patients, no group-mean difference), but patient-to-control variance ratios are elevated at the first challenge (H1: 2.27–6.94, significant in 3/4 ROIs after FDR), absent at H2 (Bader et al. 2026) (Biswal, Kunwar, and Natelson 2011) (He et al. 2013). Replication: not yet — exploratory variance analysis, single preprint. Limitations: variance-based, exploratory; hypoxic challenge ≠ exertion. Falsifiability: a second cohort reproduces elevated patient CBF-response variance at an initial challenge and correlates it with severity. Consequence: hints the difficulty may be unstable, person-to-person and moment-to-moment CBF adaptation rather than a fixed inability to change blood flow — unproven as a biomarker. (ch09 sec-05: Preserved Gross Cerebrovascular Reactivity but Greater Inter-Individual Variability; origin: integrate-topic experimental-hypoxia-virtual-hypoxia-brainstem.)	Phase 3 / 0.35
spec ms-virtual-hypoxia-bridge	The “virtual hypoxia” concept from multiple sclerosis — chronically failing tissue despite normal arterial oxygen due to impaired mitochondrial ATP + increased demand (Trapp and Stys 2009) (Mahad, Trapp, and Lassmann 2015) — is applied to ME/CFS as a mechanistic bridge, not identity, on the strength of the Vienna finding of elevated resting brain lactate and blunted metabolic reactivity despite normal arterial oxygenation (Bader et al. 2026). ME/CFS lacks MS demyelination; the shared element is bioenergetic inefficiency under normal oxygen. Replication: not independently replicated in ME/CFS; single-site preprint. Limitations: transfers bioenergetic-diagnostics logic only, not MS-specific interventions; no direct demonstration ME/CFS neurons fail under normal oxygen. Falsifiability: MS-like bioenergetic imaging signatures are abnormal in an ME/CFS virtual-hypoxia subgroup in the same direction as MS while NAA remains normal — refuted if ME/CFS shows no such signature despite elevated lactate. Consequence: lets ME/CFS research reuse bioenergetic imaging tools and diagnostic logic developed for MS. (ch16: Multiple Sclerosis “Virtual Hypoxia” as a Mechanistic Template — Not an Identity; origin: brainstorm.)	Phase 5 / 0.45
spec long-covid-virtual-hypoxia-trajectory	A shared virtual-hypoxia mechanism (elevated brain lactate, reduced metabolic flexibility) may underlie both ME/CFS and long COVID as a post-infectious metabolic signature, with trajectory distinguishing them: normalising in early long COVID recovery vs fixed in ME/CFS (Bader et al. 2026). Replication: not yet. Limitations: hypothesis-generating; the Vienna study did not measure long COVID; trajectory difference is inferred. Falsifiability: the bioenergetic marker (brain lactate / metabolic reactivity) normalises with recovery in early long COVID but stays fixed in ME/CFS — refuted if the marker is equally fixed in both. Consequence: a shared post-infectious metabolic mechanism would unify ME/CFS and long COVID research and allow cross-trial learning. (ch16: Shared “Virtual Hypoxia” Mechanism in Long COVID and ME/CFS — Different Trajectory; origin: brainstorm.)	Phase 5 / 0.40
spec thalamic-lactate-stratification	Elevated resting thalamic lactate (Lac/tCr) is a candidate stratification biomarker for trials of tissue-oxygenation or mitochondrial interventions (e.g. HBOT) in ME/CFS (Bader et al. 2026) (Hadanny et al. 2024). NOT a validated diagnostic; hypothesis-generating. Replication: not yet. Limitations: single preprint; requires prospective validation; peripheral-vs-brain lactate proxy unproven. Falsifiability: fails if it does not reach discriminating power (e.g. AUC ≥0.70) and test–retest reproducibility, and does not predict differential treatment response in a prospective trial. Consequence: if validated, gives trial designers a mechanism-anchored imaging readout to select the “virtual-hypoxia” subgroup most likely to respond. (ch36: Thalamic Lac/tCr as a Candidate Stratification Biomarker for Energy-Metabolism Trials; origin: brainstorm.)	Phase 5 / 0.40

ID / Label	Details	Phase / Cert
oq pots-cardiac-emergency-threshold	Open question: no ME/CFS-specific study defines when a POTS-related collapse becomes a cardiac emergency, and no ME/CFS data quantify sudden-cardiac risk in POTS; the cardiac-vs-neurally-mediated syncope distinction is transferred from general cardiology. Falsifiability: if cardiac syncope were specifically prevalent in ME/CFS, a cohort with ambulatory ECG monitoring or cardiac-syncope outcome would detect a higher-than-expected arrhythmic-event rate — untested. Consequence: the safe default (apply general-cardiology cardiac-syncope criteria) rests on transferred evidence; this is a genuine research priority, not resolved. (ch24 sec-12: Is There an ME/CFS-Specific Cardiac-Emergency Threshold in POTS?; origin: integrate-topic adult-red-flags-safety-netting-protocol.)	Phase 3 / N/A
oq syncope-recovery-time-discriminator	Open question: because ME/CFS has chronic orthostatic instability, the usual prodrome-based cardiac-vs-NMH syncope distinction is unreliable; recovery time and recovery quality after collapse is a candidate ME/CFS-appropriate discriminator (neurally-mediated recovers quickly supine with full orientation; cardiac/sustained-arrhythmia has slower, incomplete, or lingering recovery). Falsifiability: among ME/CFS patients with recurrent collapse, recovery-to-baseline within 5 min of supine positioning with full orientation and no chest pain/palpitations has near-zero true-cardiac rate; recovery >15 min, persistent confusion, chest pain, or palpitations has significantly higher identified cardiac/sustained-arrhythmia rate on urgent evaluation — untested. Consequence: if validated, gives a concrete rule for when a faint warrants urgent assessment. (ch24 sec-12: Can Recovery Time After Collapse Discriminate Cardiac From Neurally-Mediated Syncope in ME/CFS?; origin: brainstorm.)	Phase 5 / N/A
oq research-priorities-safety-netting	Research-priority statement: four ME/CFS-specific studies would move the safety protocol from transferred to measured risk — (1) ambulatory cardiac monitoring cohort for syncope, (2) severe-ME mortality/cachexia registry, (3) prospective incidence cohort for refeeding/VTE/pressure-ulcer sepsis in severe bedbound ME/CFS, (4) ED-recognition intervention study. Consequence: identifies the highest-impact research that would quantify medical-emergency risk specifically in severe ME/CFS. (ch24 sec-12: Research Priorities: Quantifying Medical-Emergency Risk in Severe ME/CFS; origin: brainstorm.)	Phase 5 / N/A

ID / Label	Details	Phase / Cert
spec long-covid-reversibility	Speculation: long COVID immune dysregulation (PD-1/TIM-3 exhaustion, elevated nucleocapsid IgG, neutralizing capacity) may be partly reversible within ~24 months, in contrast to the durable, epigenetically locked exhaustion of ME/CFS. Falsifiability: recovering post-infectious patients normalize PD-1/TIM-3 and reconstitute naive T/B within 24 months, while ME/CFS-progressors retain exhaustion markers with no reconstitution — tested by longitudinal immune profiling; falsified if recovering patients show no normalization or ME/CFS-progressors fully reconstitute. Consequence: an early abnormal immune profile in post-infectious illness is not necessarily permanent exhaustion; argues for early-intervention trials within a potentially reversible window. (ch08 sec-02: Long COVID Immune Dysregulation as a Time-Limited Precursor State; evidence Phetsouphanh 2024 cert 0.60; origin: literature synthesis.)	Phase 3 / 0.40
oq cortisol-postinfectious-contested	Open question: Klein et al. 2023 (Nature) reported lower morning cortisol in long COVID, convergent with ME/CFS HPA blunting; Fleischer et al. 2024 found no peripheral IL-1β/IL-6/TNFα or cortisol difference in PASC at a single timepoint. The discrepancy (morning multi-site vs single-timepoint peripheral) is unresolved; peripheral cytokines/cortisol are timepoint-sensitive and not stable stand-alone biomarkers. Falsifiability: dynamic (repeated/ACTH-stimulated) or severity-stratified cortisol measures would resolve whether hypocortisolism is consistent in the post-infectious phenotype. Consequence: clinicians/researchers should not rely on a single cortisol or cytokine measurement to confirm or exclude post-infectious immune/HPA dysregulation. (ch08 sec-02: Cortisol in Post-Infectious Illness: A Contested Peripheral Biomarker; evidence Klein 2023, Fleischer 2024; origin: literature synthesis.)	Phase 3 / N/A
lim no-immunotherapy-mecfs-basis	Limitation: no ME/CFS evidence base exists for borrowing oncology immunotherapy (checkpoint blockade anti-PD-1/anti-CTLA-4, CAR-T) to reverse T-cell exhaustion. Unselected IVIG/rituximab/TPE failed (RituxME phase III, post-COVID TPE phase II). Checkpoint blockade carries substantial immune-related-adverse-event/autoimmune risk in a population already predisposed. Consequence: patients/clinicians should not expect oncology immunotherapy for ME/CFS; plausible use is restricted to biomarker-defined, carefully selected subgroups as a research question, not a recommendation. (ch08 sec-12: No Evidence Base for Borrowing Oncology Immunotherapy in ME/CFS; evidence Kaplan 2026; origin: literature synthesis.)	Phase 3 / N/A
lim lc-convergence-cohort-overlap	Limitation: the ME/CFS–long-COVID convergence must not be read as independent corroboration — Petrov 2025 (convergent lymphocytes/cytokines) and Petrov 2026 (divergent monocyte/DC) are drawn from the same Plovdiv research group with shared authorship and overlapping recruitment (sample sizes n=190 vs n=207, precise overlap not fully documented); Phetsouphanh 2024 is a longitudinal extension of the same ADAPT biobank as Phetsouphanh 2022. Convergence + reversibility are analyses of overlapping patient populations, not independent replications. Consequence: the convergence and reversibility signals are weaker than their headline certainties imply; independent-cohort replication must precede any firm cross-disease claim. (ch08 sec-02: Cohort Overlap Constrains the Convergence Claim; origin: brainstorm.)	Phase 5 / 0.70
lim lc-reversibility-mild-bias	Limitation: long-COVID reversibility and EBV-null findings come from mild cohorts (Phetsouphanh mild-moderate, Hoeggerl mild/asymptomatic, Lorenz retrospective PCS); the severe or ME/CFS-phenotype subgroup — where persistence, epigenetic locking, and reactivation matter most — is under-sampled. Consequence: reversibility in mild cohorts should not be extrapolated to severe or ME/CFS-phenotype patients, where persistence is the documented pattern. (ch08 sec-02: Mild-Disease Sampling Bias in the Long-COVID Reversibility Evidence; origin: brainstorm.)	Phase 5 / 0.65
lim checkpoint-blockade-gate	Limitation/protective gate: cancer exhaustion-stage biology supplies a concrete selection criterion if checkpoint blockade is ever considered — anti-PD-1 rescues progenitor/transcriptionally-exhausted (chromatin-plastic) T cells but fails on terminally, epigenetically-fixed ones (established in the oncology exhaustion-lineage/checkpoint-response literature). Established ME/CFS exhaustion is epigenetically locked; early long-COVID exhaustion is transcriptionally reversible (resolves by 24 months (Phetsouphanh et al. 2024)). Gate: checkpoint blockade has rationale only in the transcriptionally-exhausted, PD-1-high, non-epigenetically-locked subset — present in early long COVID, absent in established ME/CFS. Consequence: if ME/CFS T cells show the terminally-exhausted epigenetic signature, anti-PD-1 lacks mechanistic rationale and would likely fail with autoimmune risk — a testable rule to prevent futile/harmful unselected immunotherapy. (ch08 sec-12: Checkpoint Blockade: A Protective Selection Gate Before Any Consideration; origin: brainstorm.)	Phase 5 / 0.35
syn lc-mecfs-convergence-reversible	Synthesis: long-COVID immune dysregulation is convergent with ME/CFS (same T-cell exhaustion, exhausted B cells, exaggerated EBV/VZV antibody responses (Klein et al. 2023); no significant lymphocyte/CD8/NK/cytokine difference (Petrov et al. 2025)) but partly reversible — resolving by ~24 months in mild cohorts, in contrast to the durable, epigenetically-locked exhaustion of established ME/CFS. Constrained by cohort-overlap (same Plovdiv group; Cohort Overlap Constrains the Convergence Claim) and mild-cohort sampling bias (Mild-Disease Sampling Bias in the Long-COVID Reversibility Evidence). Most defensible claim: the shared convergent pattern’s persistence — not its presence — distinguishes ME/CFS. Consequence: the key discriminator is whether immune dysregulation persists and is epigenetically locked, pointing to longitudinal designs and independent-cohort replication, and cautioning against treating reversible long-COVID changes as permanent exhaustion. (ch08 sec-02: Long COVID as a Convergent but Partly Reversible Immune State; origin: integrate-topic immune-checkpoint-tolerance-immunotherapy.)	Phase 10a / N/A

ID / Label	Details	Phase / Cert
hyp episwitch-3d-chromatin-biomarker	Hypothesis: 3D chromosome-conformation architecture in blood differs between severe ME/CFS and healthy controls, forming a blood-based diagnostic signal orthogonal to DNA methylation and miRNA markers (Hunter et al. 2025). Reported 92% sensitivity / 98% specificity / 96% accuracy in a single retrospective vendor-affiliated study (Oxford BioDynamics; n=47 severe ME/CFS vs 61 controls). Falsifiability: an independent cohort (n ≥ 100 ME/CFS vs matched controls) failing to reproduce sensitivity/specificity within ±5 percentage points, or EpiSwitch failing to distinguish ME/CFS from fibromyalgia/depression beyond chance, refutes specificity to ME/CFS. Consequence: if independently replicated, a blood-based objective diagnostic for ME/CFS becomes plausible — but today it is an unvalidated research finding; the reported specificity is against healthy controls only and cross-condition discrimination (fibromyalgia, depression, long-COVID fatigue) is untested. (ch36 sec: 3D Chromatin Architecture Is an Independent ME/CFS Biomarker Layer; evidence Hunter 2025 cert 0.50; severity severe/very-severe; origin: literature integration.)	Phase 3 / 0.50
hyp 3d-chromatin-IL2-jakstat-axis	Hypothesis: the IL-2/JAK-STAT pathway enrichment reported in the EpiSwitch ME/CFS panel is biologically mechanistically grounded — 3D chromatin topology is coupled to IL-2 and JAK-STAT signalling (TRIM28 organizes chromatin to control IL-2 in T cells (Wei et al. 2025); IL-2 restructures the 3D genome of CD4+ T cells (Ward et al. 2025); CTCF-coordinated 3D enhancer architecture shapes immune gene expression and CTCF depletion rewires the CD4+ T-cell response to JAK inhibitors by reprogramming the STAT5 enhancer network (E.-C. Lee et al. 2025)). This bridges the 3D-genomic biomarker finding to the documented T-cell and cytokine dysregulation in ME/CFS. Falsifiability: in an independent cohort, Hi-C or Capture-C in ME/CFS CD4+ T cells shows the IL-2-responsive loop contacts at the STAT5 enhancer loci (Lee 2025) shifted in the same direction as IL-2 stimulation, versus unstimulated healthy T cells. Refuted if these loop contacts are statistically indistinguishable (P ≥ 0.05) from healthy resting T cells after controlling for activation markers (CD69/CD25). Consequence: if the IL-2/3D-chromatin link holds, it strengthens the case for IL-2 as a therapeutic target and links an epigenetic biomarker to a testable immune mechanism; the current evidence is non-ME/CFS-specific (human/mouse T cells) and the translation to ME/CFS is unvalidated. (ch36 sec: The IL-2/JAK-STAT Axis Is Mechanistically Coupled to 3D Chromatin Architecture; evidence Wei/Ward/Lee 2025, cert 0.45; origin: literature integration.)	Phase 3 / 0.45
hyp trim28-unifying-node	Hypothesis: impaired TRIM28 (KAP1) chromatin maintenance unifies the 3D-genomic (EpiSwitch), HERV-expression, and IL-2 findings — loss of TRIM28-mediated silencing/loop-maintenance simultaneously derepresses HERVs (Giménez-Orenga, HERV activation coincides with TRIM28/SETDB1 sites (Giménez-Orenga et al. 2025)) and destabilises the 3D architecture constraining IL-2/JAK-STAT loci (Wei: TRIM28→IL-2 (Wei et al. 2025); Hunter: IL-2/JAK-STAT hub (Hunter et al. 2025)). Falsifiability: ME/CFS immune cells with normal TRIM28 occupancy and SETDB1-dependent H3K9me3 at the implicated loop-anchor/HERV loci refute the unifying-node hypothesis. Consequence: two “competing” epigenetic fingerprints may trace to one upstream chromatin-maintenance defect, a natural focus for mechanistic study and eventual drug targeting. (ch36 sec: TRIM28 as a Unifying Node Across 3D-Genomic, HERV, and IL-2 Findings; evidence Wei 2025 + Giménez-Orenga 2025, cert 0.30; origin: brainstorm.)	Phase 5 / 0.30
hyp frozen-chromatin-state	Hypothesis: the ME/CFS EpiSwitch signature reflects a loop conformation frozen in the activated position — the chromatin-architectural residue of an immune-activation program triggered but never resolved — rather than active IL-2 signalling. IL-2 restructures the CD4+ 3D genome dynamically (Ward (Ward et al. 2025)), so a static snapshot may capture a “trapped” state; this resolves the paradox of normal-to-low circulating cytokines despite immune-dysfunction phenotypes. Falsifiability: ME/CFS CD4+ T-cell Hi-C at IL-2-pathway loci indistinguishable from healthy cells after normalising for activation status, or loops relaxing to baseline within hours of rest, refute the frozen-chromatin hypothesis. Consequence: if immune cells are stuck in the “on” position at the DNA-folding level, it explains persistence after the trigger clears and points to therapies that reset folding rather than only adjusting signals. (ch36 sec: A “Frozen” Chromatin State as Trapped Immune-Activation Memory; evidence Ward 2025, cert 0.30; origin: brainstorm.)	Phase 5 / 0.30
lim episwitch-caveats	Critical caveats limiting the EpiSwitch diagnostic claim: (1) generic-illness confound — severe/housebound ME/CFS differs from healthy controls on deconditioning, stress, polypharmacy, sleep; the signature may reflect being severely ill, not ME/CFS-specific pathology; (2) overfitting risk — 200 markers fitted in n=47 with only internal validation is a textbook discovery-cohort overfitting hazard; (3) vendor COI — every EpiSwitch clinical paper is Oxford BioDynamics-authored, with a proprietary closed platform and no independent replication; (4) severity selection — housebound-only cohort, generalisability to mild/moderate unshown. Consequence: the 92%/98% figures should be treated as unconfirmed discovery-cohort numbers until a neutral, severity-representative external replication; the test is research-stage, not a clinical diagnostic. (ch36 sec: 3D Chromatin Architecture Is an Independent ME/CFS Biomarker Layer; origin: brainstorm critical categories.)	Phase 5 / n/a
syn episwitch-epigenetic-convergence	Synthesis: several independent epigenetic measurement layers — 3D chromosome-conformation (EpiSwitch), the IL-2/JAK-STAT pathway it reports, endogenous-retrovirus expression, and conventional DNA-methylation and miRNA markers — converge on a common theme of immune-regulatory dysregulation. The IL-2/JAK-STAT axis is the shared hub, and a single chromatin-maintenance mechanism (TRIM28/KAP1) plausibly underlies both the 3D-genomic and HERV signatures. This convergence strengthens a mechanistic hypothesis about shared immune dysregulation but not a validated clinical diagnostic — the EpiSwitch specificity is against healthy controls only and cross-condition testing (fibromyalgia, depression, long-COVID) is untested. Consequence: multiple independent epigenetic fingerprints appear to point at one underlying immune-regulatory defect, which is encouraging for understanding the disease but does not yet justify using any of them as a clinical test. (ch36 sec: Convergent Epigenetic Layers Point Toward a Shared Immune-Regulatory Defect; origin: Phase 10a synthesis.)	Phase 10a / n/a

ID / Label	Details	Phase / Cert
spec irisin-signaling-resistance	Hypothesis: circulating thrombospondin-1 (TSP-1) antagonises irisin signaling through the HSP90_$\alpha$/αvβ5 integrin axis, producing “irisin signaling resistance” that contributes to the impaired metabolic adaptation and PEM of ME/CFS. A 2026 cross-sectional cohort (92 ME/CFS, CCC) found lower baseline plasma irisin and a blunted irisin response to a 90-min mechanical stress challenge (p=0.034); functional cellular-dielectric-spectroscopy assays showed TSP-1 inhibits irisin signaling concentration-dependently and that irisin requires αvβ5 and extracellular HSP90_$\alpha$, while TSP-1 remains a dominant antagonist (Souma et al. 2026) (Boström et al. 2012) (Kim et al. 2018) A et al. (2023; Rogers et al. 2014) (Roberts, Kaur, and Isenberg 2017). Falsifiability: patient-derived PBMC or muscle cells from ME/CFS patients with elevated TSP-1 showing normal irisin-stimulated signalling, or TSP-1 reduction restoring no metabolic phenotype, refute the mechanism. Consequence: if confirmed it reframes PEM as a failure of a specific exercise-induced signalling pathway, offering a TSP-1/irisin biomarker and testable targets (TSP-1 reduction, NO restoration, HSP90_$\alpha$ stabilization) — all hypothesis-stage with no human dosing/safety data. (ch07 sec-15: Irisin Signaling Resistance via TSP-1 as a Mechanism of Impaired Metabolic Adaptation in PEM; evidence Souma 2026 cert 0.45 discounted (raw 0.55, single cohort); severity mild+moderate-severe; translation gap in vitro→human; origin: literature integration.)	Phase 3 / 0.45
oq irisin-tsp1-severity-paradox	Open question: baseline irisin independently predicts fatigue severity (β=0.67, p=0.021) and moderate-to-severe patients show elevated both irisin and TSP-1 — a paradox (lower group-level irisin yet higher in the most severe). Competing models: (a) compensatory-but-ineffective response overridden by TSP-1, vs (b) a distinct severity-associated regulatory programme, possibly sex-specific (irisin-PEM correlation held in males R=0.53, p=0.01, not females) (Souma et al. 2026). Falsifiability: a longitudinal study across PEM episodes discriminates: compensation predicts irisin+TSP-1 rise together before recovery; distinct-biology predicts a stable severity set-point not tracking acute PEM. Consequence: resolving this determines whether TSP-1-suppressing or irisin-restoring therapies could help or chase a compensatory signal — currently unknown, requires longitudinal biomarker study. (ch07 sec-15: The Irisin–TSP-1 Severity Paradox: Compensation or Distinct Biology?; evidence Souma 2026; cert 0.30; severity mild+moderate-severe; cohort overlap Moreau-group biobank; origin: literature integration.)	Phase 3 / 0.30
spec tsp1-vascular-metabolic-convergence	Hypothesis: TSP-1 is a vascular↔︎metabolic convergence node — the same molecule already documented as an endothelial-activation marker in ME/CFS (Heng 2025 panel; broader secretome vasculature dysregulation in Hoel 2026 proteomics) may also be the dominant antagonist of irisin signaling at the HSP90_$\alpha$/αvβ5 axis, thereby simultaneously driving vascular dysfunction and impaired metabolic adaptation via CD47-mediated NO suppression and irisin-axis antagonism (Heng et al. 2025) (Hoel et al. 2026) (Souma et al. 2026) (Rogers et al. 2014) (Roberts, Kaur, and Isenberg 2017). Falsifiability: plasma TSP-1 will correlate with BOTH endothelial markers AND the blunted exertional irisin response in one cohort, with the top TSP-1 quartile showing the worst perfusion AND metabolic adaptation; falsified if TSP-1 elevation segregates with vascular but not metabolic dysfunction. Consequence: if one molecule underlies both poor circulation and post-exertional crash, it becomes a far more attractive single drug target; currently a unifying hypothesis resting on two separate single-source observations. (ch07 sec-15: TSP-1 as a Vascular–Metabolic Convergence Node; evidence Heng/Hoel/Souma, cert 0.40; severity mild+moderate-severe; translation gap in vitro→human; origin: brainstorm.)	Phase 5 / 0.40

ID / Label	Details	Phase / Cert
spec theanine-caffeine-attention-differential	Speculation: in a double-blind placebo-controlled three-way crossover trial in 21 adolescents with ADHD, a high-dose L-theanine-caffeine combination and methylphenidate both reduced selective-attention false alarms (P=0.038, P=0.035) and increased P3b amplitude while decreasing P3b latency (P $< 0.05$), but ONLY methylphenidate improved behavioral reaction time (43.89 ms, P=0.018) (Nawarathna et al. 2026). The pattern is NOT a clean selection-vs-speed dissociation: P3b latency is itself a processing-speed index, and the non-dopaminergic combination improved it, so the divergence is specifically between two speed measures (neural P3b latency improved in both; behavioral RT improved only with methylphenidate). Route-separability is further undercut by convergent FPN-DMN effects of both caffeine and methylphenidate (Becker et al. 2022) and a non-dopaminergic theanine choice-RT effect in healthy adults (Gerolymos et al. 2026); the finding rests on a single small trial from one research group (n=21, acute single-dose, ADHD cohort, no ME/CFS data, not independently replicated) (Kahathuduwa et al. 2020). Related speculation: the same caffeine-adenosine axis underlies the proposed A2A-density caffeine paradox in ME/CFS Elevated A2A Receptor Density Underlies ME/CFS Caffeine Paradox. Falsifiability: an adequately-powered ADHD crossover (n≈60+) showing theanine-caffeine also shortens behavioral RT would confirm the RT null was underpowering; if it replicates RT-null with improved P3b latency, it supports a motor/premotor vs perceptual speed dissociation; three nulls bound the claim — L-theanine null for fatigue (Gerolymos et al. 2026), caffeine no ME/CFS association (Palacios et al. 2023), caffeine monotherapy null (Al Shahab et al. 2025) — so the adenosine route’s causal role in ME/CFS is currently unsupported and probably null. Consequence: cross-disease mechanism context only — NOT an ME/CFS treatment recommendation; caffeine carries withdrawal-fatigue/tolerance harm (Carbone et al. 2025) and the entry only informs the PFC catecholamine-inverted-U model (ch07 sec-28: Catecholamine vs Non-Dopaminergic Mechanisms: Attention Selection vs Processing Speed; raw cert 0.55, ADHD disease-model → discounted 0.41; severity unknown; origin: literature integration).	Phase 3 / 0.41
oq slow-but-accurate-mecfs-signature	Open question: which cognitive pattern does ME/CFS show on a selective-attention task — “slow-but-accurate” (preserved error rate, selectively slowed reaction time, if the non-dopaminergic selection route is spared while the dopaminergic speed route fails) OR “slow-and-inaccurate” (increased false alarms from ATP-expensive inhibitory networks failing first, per the PFC-energy framework) (Nawarathna et al. 2026). The two readings point opposite ways and both are testable; the question is unresolved. Falsifiability: an objective selective-attention task in ME/CFS (vs matched healthy and depressed controls) showing proportionally impaired errors+reaction time, or normal reaction time, falsifies the slow-but-accurate reading; preserved accuracy with selective speed loss supports it; an accuracy deficit supports the impulse-inhibition-first reading — the three outcomes are mutually exclusive and testable. Consequence: whichever pattern replicates, it provides an objective cognitive-behavioral readout of PFC energy/catecholamine state cheaper than imaging/EEG, and sharpens the ME/CFS brain-fog vs uniformly-slowed primary-depression distinction — both candidate phenotypes currently predictions from one ADHD trial, not established findings (ch07 sec-28: Does ME/CFS Show Preserved Accuracy With Selective Speed Loss, or a General Accuracy Deficit?; cert 0.20; cross-disease extrapolation; severity unknown; origin: brainstorm).	Phase 5 / 0.20

ID / Label	Details	Phase / Cert
oq neurogenic-vs-muscular-cramp	Open question: whether spontaneous, exertion-independent cramps in ME/CFS are fully explained by the muscular (sarcolemmal Na⁺/K⁺-ATPase depolarization) mechanism — the prior-favored account, being the only published ME/CFS-specific explanation and consistent with documented muscle sodium overload and subsarcolemmal mitochondrial pathology ((Wirth and Steinacker 2025) (Petter et al. 2022) (Bizjak et al. 2024)) — or whether a small neurogenic (motor-nerve-terminal hyperexcitability; HCN channel, spinal reflex — (Czesnik et al. 2015) (Maughan and Shirreffs 2019)) contribution exists in addition. The neurogenic mechanism is the general-population default for cramps but has no direct ME/CFS-specific support. Falsifiability: EMG/nerve-conduction showing ectopic discharges or raised HCN inward rectification would establish a neurogenic route; normal nerve function with sarcolemmal abnormality would support the muscular mechanism being complete; no ME/CFS study has yet performed this discrimination. Consequence: the muscular mechanism should be treated as the working default and no current treatment change is indicated; whether a neurogenic contribution exists is an unanswered, testable question. (ch04 sec-03: Neurogenic vs Muscular Origin of Spontaneous Cramps; evidence Czesnik 2015 0.70/Wirth 2025 0.35; severity unknown; origin: literature integration.)	Phase 3 / n/a
spec motor-nerve-hyperexcitability-cramp	Hypothesis: ME/CFS spontaneous cramps partly reflect motor-nerve-terminal hyperexcitability (ion-channel driven: HCN) rather than only the energy-deficit model; small-fiber neuropathy present in ME/CFS could excite intramuscular nerves. Falsifiability: threshold-tracking axonal excitability showing elevated HCN-driven inward rectification in cramp ME/CFS patients vs cramp-free controls; falsified if axonal excitability is normal or purely sarcolemmal. Consequence: if replicated, cramps could become a treatable nerve-excitability problem — but the mechanism has no direct ME/CFS-specific support and should not change practice. (ch04 sec-03: Motor-Nerve Hyperexcitability as a Contributor to ME/CFS Spontaneous Cramps; evidence Czesnik 2015 cert 0.70, transferability-discounted to 0.30; severity unknown; origin: brainstorm.)	Phase 3 / 0.30
spec single-pump-failure-cramp-unification	Hypothesis: the Na⁺/K⁺-ATPase maintains resting membrane potential in both muscle fibres and motor-nerve terminals, so the muscular and neurogenic cramp mechanisms may be ONE pump failure expressed in two compartments, dissolving the dichotomy. Falsifiability: paired sarcolemmal + motor-axonal excitability in the same limb showing correlated abnormalities; falsified if one is normal while the other is abnormal. Consequence: if true, clinicians need not choose between two rival explanations — a single energy/ion defect causes both. (ch04 sec-03: Single Pump Failure as a Unifying Explanation for Both Cramp Mechanisms; cert 0.15; severity unknown; origin: brainstorm.)	Phase 5 / 0.15

ID / Label	Details	Phase / Cert
spec metabolic-circadian-entrainment	Speculation: the metabolic hormone leptin can influence the speed of circadian re-entrainment to an external schedule, complementing light and melatonin as circadian levers. Molecular substrate: DMH LepR neurons project to the SCN and shift clock phase ((Tang et al. 2023) (Faber et al. 2021)); the clock reciprocally gates leptin signalling ((Osorio-Mendoza et al. 2025)). An encapsulated-cell therapy delivering constitutively-produced (non-phasic) leptin accelerated re-entrainment to phase advances and delays in mice and cynomolgus macaques without impairing sleep ((Fleury et al. 2026)). Falsifiability: selective ablation of DMH LepR neurons or SCN LepR innervation abolishes the entrainment-accelerating effect of systemic leptin elevation in an animal model; in humans, a timed metabolic challenge against a light pulse measurably alters phase-shift magnitude. Consequence: if the coupling holds in humans, it expands the toolbox for re-stabilising ME/CFS sleep-wake timing beyond light and melatonin — but it is a single unreplicated preclinical lead, the lever is non-phasic, and it is untested in the ME/CFS circadian system. (ch10 sec-06: Metabolic-Circadian Entrainment Coupling: Leptin as a Modulator of Phase Re-alignment; evidence animal-model, raw cert 0.55–0.75 discounted to 0.28–0.38, set at 0.30; translation gap animal→human; severity unknown; origin: literature integration.)	Phase 3 / 0.30
oq leptin-therapeutic-direction	Open question: whether raising leptin could ever aid ME/CFS circadian disruption, or whether that direction is wrong. ME/CFS-specific data caution against it: circulating leptin is elevated in ME/CFS ((Domingo et al. 2024)) or unremarkable ((Cleare, O’Keane, and Miell 2001)), light rather than metabolic signalling is the dominant circadian lever ((Cambras et al. 2026)), and even direct circadian interventions (melatonin, phototherapy) produced no CFS symptom benefit ((Williams et al. 2002)). Consequence: treat the metabolic-circadian coupling as a research/diagnostic direction, not a treatment target — the existing data point toward light and scheduling, and away from elevating an already-elevated or normal hormone. (ch10 sec-06: Could Raising Leptin Ever Help ME/CFS Circadian Disruption—or Would It Be the Wrong Direction?; severity unknown; origin: literature integration.)	Phase 3 / n/a
oq leptin-timing-amplitude	Open question: whether ME/CFS leptin is altered in circadian timing/amplitude rather than amount — a reconciliation of the Cleare ((Cleare, O’Keane, and Miell 2001)) and Domingo ((Domingo et al. 2024)) readings, which point numerically the same way (higher in CFS) and are single-timepoint snapshots of a circadian hormone. A 24-hour serial profile (phase-referenced to DLMO) would reveal phase-shift/flattening even where spot means are indistinguishable. Falsifiability: serial profiling shows a normal rhythm within a pre-specified effect-size margin (amplitude ratio ≥1.5-fold or phase offset ≥2 h) — falsifies timing hypothesis; confirms flattening/phase-shift beyond the threshold — supports it. Consequence: if confirmed, the relevant ME/CFS variable may be when-not-how-much, giving a feasible measurement protocol — but it is a research hypothesis with no current clinical application. (ch10 sec-06: Is ME/CFS Leptin Altered in Timing Rather Than Amount—the Cleare-vs-Domingo Reconciliation?; severity unknown; origin: brainstorm.)	Phase 5 / 0.15

ID / Label	Details	Phase / Cert
oq t1w-t2w-myelin-substrate	Open question: whether the elevated T1w/T2w myelin-signal seen in long COVID and recovered-COVID brains reflects remyelination, neuroinflammatory gliosis, or iron/water content changes. A multimodal MRI study (n=47: 19 long COVID, 12 COVID-recovered, 16 never-infected) found altered T1w/T2w signal across all three group comparisons (long COVID > controls in precentral/middle temporal gyrus; recovered > long COVID in pons/midbrain/cerebellar tonsil/SLF; recovered > controls in precentral/posterior cingulate), correlating with physical (r=0.56) and cognitive (r=-0.64) function (Thapaliya et al. 2025); the authors read it as possible remyelination but concede it “may also indicate inflammation or gliosis.” Falsifiability: a study combining T1w/T2w with myelin-water-fraction or quantitative-susceptibility mapping in the same cohort resolves whether the signal tracks myelin, gliosis, or iron. Consequence: whether the scan reflects healing (remyelination) or ongoing damage (inflammation/gliosis) changes what the finding means clinically — but the substrate is currently unresolved. (ch09 sec-01: Elevated T1w/T2w Myelin Signal: Remyelination, Gliosis, or Iron?; evidence Thapaliya 2025, cert n/a; severity unknown; origin: literature integration.)	Phase 3 / n/a
spec multimodal-mri-biomarker	Hypothesis: a multimodal MRI panel (T1w/T2w myelin-signal + DTI microstructure + MRS neurochemistry) is a candidate research-stage biomarker for post-infectious brain involvement, discriminating long COVID / recovered COVID / never-infected and correlating with physical and cognitive function (Thapaliya et al. 2025), supported by independent-lab microstructural findings in ME/CFS and post-COVID (cingulum FA at 85% diagnostic accuracy (K. Wu et al. 2026); diffusion-NII edema/infiltration in ME/CFS (Yu2026diffusion?)-neuroinflammation; post-COVID DWI review (Jahanshahi et al. 2026)). Falsifiability: multi-site harmonised replication failing to reproduce a stable multimodal signature, or the signal tracking non-specific factors (age, deconditioning, mood) as strongly as post-infectious status, falsifies the claim. Consequence: if validated, it gives an objective non-invasive way to detect and track brain involvement — but it is a research tool, not a clinical test today. (ch36 sec: Multimodal MRI Panel (T1w/T2w + DTI + MRS) as a Candidate Post-Infectious Biomarker; evidence Thapaliya 2025 0.47 discounted→0.40 + Wu 0.70 + Yu 0.65; severity unknown; origin: literature integration.)	Phase 3 / 0.40
spec postinfectious-bidirectional-microstructure	Hypothesis: two cross-disease observations from post-infectious neuroimaging cohere — (1) a shared brainstem–cerebellar–thalamic–cingulate limbic-cortical vulnerability circuit (recurring regions: pons, midbrain, cerebellar tonsil, SLF, cingulum (Thapaliya et al. 2025) (Thapaliya et al. 2021) (K. Wu et al. 2026)), and (2) a bidirectional diffusion-microstructure signature (elevated FA/restricted diffusion = remyelination/repair; reduced FA/elevated diffusivity = demyelination/edema/injury) that reframes the “inconsistent findings” complaint as a predictable damage-to-repair continuum (Maksoud et al. 2020) (Yu2026diffusion?)-neuroinflammation (Lu et al. 2020). Falsifiability: circuit-specificity fails if alteration is no stronger in this circuit than control tracts; bidirectional synthesis fails if diffusion direction is random with respect to recovery state. Consequence: focuses imaging on a shared circuit and on measuring the damage-vs-repair balance rather than arguing over direction — a research-direction change, not clinical. (ch14d: Shared Brainstem-Cerebellar-Limbic Vulnerability and the Bidirectional Microstructure Signature in Post-Infectious Fatigue; cert 0.28; severity unknown; origin: brainstorm.)	Phase 5 / 0.28

ID / Label	Details	Phase / Cert
oq ldn-fm-pain-meta-divergence	Open question: whether low-dose naltrexone improves pain in fibromyalgia, given divergent meta-analyses — a 2025 meta-analysis found no between-group superiority vs placebo ((Ologunowa et al. 2025)) while a 2024 meta-analysis reported significant pain reduction (MD −0.86) and higher pressure pain threshold ((Vatvani et al. 2024)); the discrepancy reflects differing trial sets and methods, the positive analysis carries an erratum, and the certainty difference (0.56 vs 0.52 discounted) is within measurement uncertainty so neither is weighted. Secondary-outcome 30%-responder analysis of the FINAL trial was null on all six non-pain outcomes (Nielsen, Vaegter, and Due Bruun 2026), leaning toward the null meta-analysis, but the pain-specific question remains open. Falsifiability: a pre-registered pooled responder analysis of LDN in fibromyalgia demonstrating a significant ≥30% pain-responder advantage over placebo would resolve the conflict toward the positive meta-analysis; conversely, a pooled responder analysis finding no ≥30% advantage (or equivalence) would resolve it toward the null meta-analysis. Consequence: clinicians cannot rely on a consistent evidence verdict for LDN in fibromyalgia pain, so expectations should be modest and uncertain. (ch31: Does Low-Dose Naltrexone Improve Pain in Fibromyalgia? Divergent Meta-Analyses; severity unknown; origin: literature integration.)	Phase 3 / n/a
spec ldn-tlr4-occupancy-gap	Speculation: the null fibromyalgia LDN responder results may be mechanistically expected because clinical-dose LDN never reaches meaningful TLR4 occupancy. (+)-naltrexone is a weak TLR4 antagonist; the optimized derivative CIAC101 required ~6200× potency gain to reach nanomolar TLR4 antagonism ((Gao et al. 2025)). Clinical LDN is racemic at 4.5–6 mg, so the TLR4-blocking species may need concentrations orders of magnitude above achieved levels — a dose-to-target translation failure, meaning the TLR4 rationale was never actually tested at clinical dose. Consistent with the alternative OGFr/enkephalin-rebound mechanism ((Zagon and McLaughlin 2018)) that may require longer duration or a fatigue-specific subtype (Nielsen, Vaegter, and Due Bruun 2026). Falsifiability: a dose-occupancy study showing clinical-dose LDN achieves below 10% TLR4 occupancy (no downstream NF-κB suppression) in patient PBMCs supports the below-threshold reading; measurable TLR4 antagonism at these doses falsifies it. Consequence: the FM null does not disprove the TLR4/microglial rationale — it may mean the dose never reached the target, shifting research from “does the mechanism work” to “was it ever tested at an engaging dose.” (ch31: Low-Dose Naltrexone: The TLR4 Mechanism May Never Be Engaged at Clinical Dose; cert 0.30; severity unknown; origin: brainstorm.)	Phase 5 / 0.30

ID / Label	Details	Phase / Cert
cf gastroparesis-delayed-emptying-mecfs	Clinical finding: delayed gastric emptying is a documented, measurable feature of chronic fatigue syndrome — a controlled radionuclide study found delayed liquid emptying in 23/32 (72%) and delayed solid emptying in 12/32 (38%) with the delay significantly correlated with symptom severity (p $<$ 0.001) (Burnet and Chatterton 2004). Direct ME/CFS evidence (raw certainty 0.60, no population discount); not yet replicated in a modern-IOM/ICC-criteria cohort. Falsifiability: a modern-criteria ME/CFS cohort showing no difference in scintigraphic gastric emptying versus matched controls would weaken this finding; replication of the delay would confirm it. Consequence: stomach emptying delay is a real, testable problem in ME/CFS, so it can be assessed with a standard gastric-emptying test rather than dismissed as a vague symptom. (ch04: Delayed Gastric Emptying Is Documented in a ME/CFS Cohort, Correlating With Symptom Severity; cert 0.60; severity not stratified; origin: literature integration.)	Phase 3 / 0.60
oq gastroparesis-enteric-icc-loss-mecfs	Open question: whether ME/CFS gastroparesis shares the structural enteric-neuron and interstitial-cell-of-Cajal (pacemaker-cell) loss documented in diabetic and idiopathic gastroparesis. Human antral tissue shows ICC and enteric-nerve loss in diabetic/idiopathic gastroparesis (Grover et al. 2011), and an animal model confirms cell/nerve loss accompanies slowed emptying (X.-Y. Wang et al. 2009); no ME/CFS gastric histology exists, so the ME/CFS form could be functional vagal failure, autoimmune ganglionic blockade, or structural degeneration. Falsifiability: normal ICC and enteric-nerve density in ME/CFS gastric specimens with documented gastroparesis would falsify the structural-shared-pathology reading; evidence of cell/nerve loss would support it. Consequence: if ME/CFS gastroparesis involves structural pacemaker-cell loss, prokinetics that stimulate surviving nerves would have limits and treatment would need to target cell-loss prevention or replacement. (ch04: Does ME/CFS Gastroparesis Share the Enteric-Nerve and Pacemaker-Cell Loss Seen in Diabetic and Idiopathic Gastroparesis?; cert 0.40; severity unknown; origin: literature integration.)	Phase 3 / 0.40
spec gastroparesis-autoimmune-ganglionic-blockade	Speculation: a subset of ME/CFS gastroparesis could reflect autoimmune ganglionic (α3 nicotinic acetylcholine-receptor) blockade — modeled on a post-SARS-CoV-2 autoimmune GI dysmotility case that responded to immunotherapy (Montalvo et al. 2022) — a potentially reversible mechanism distinct from structural nerve loss. Speculative for ME/CFS: no ME/CFS cohort has been screened for ganglionic AChR antibodies; the autoimmune GI dysmotility literature in ME/CFS is a single post-viral case. Falsifiability: measuring ganglionic AChR antibodies in ME/CFS patients with documented gastroparesis — a meaningful antibody-positive subset whose emptying improves with immunotherapy would support the claim; titers that do not track emptying delay or immunotherapy response would falsify it. Consequence: a reversible autoimmune subset of ME/CFS gastroparesis would have a real immunotherapy treatment path, testable with an existing blood antibody panel. (ch04: Autoimmune Ganglionic Acetylcholine-Receptor Blockade Could Be a Reversible Cause of Some ME/CFS Gastroparesis; cert 0.30; severity unknown; origin: brainstorm.)	Phase 5 / 0.30
lim gastroparesis-evidence-anchor-and-alternatives	Limitation: the direct ME/CFS gastroparesis evidence rests on a single 2004 cohort (n=32) predating modern diagnostic criteria (Burnet and Chatterton 2004) with one n=1 null (Corrado et al. 1998) and no modern-IOM/ICC replication; non-specific alternatives (medication side-effects, functional dyspepsia/visceral hypersensitivity (Debourdeau et al. 2024), deconditioning, reporting bias) could produce the same pattern without a distinct ME/CFS lesion, and cross-disease histology (Grover et al. 2011) (X.-Y. Wang et al. 2009) is population-discounted. Consequence: clinicians should exclude the common non-specific causes (drug effects, dyspepsia) with objective testing before attributing symptoms to a ME/CFS-specific emptying defect. (ch04: Gastroparesis Evidence in ME/CFS Is Anchored on One Old, Unreplicated Cohort — and Non-Specific Alternative Explanations Exist; severity across all; origin: literature integration.)	Phase 5 / n/a

ID / Label	Details	Phase / Cert
oq adult-onset-adhd-mix-status	Open question: whether the “adult-onset ADHD is a distinct syndrome” reading (from the Dunedin birth cohort (Moffitt et al. 2015)) still holds. Evidence to date favors a mix, but the question remains open: repeated comprehensive assessments of an MTA comparison cohort (n=239, ages 10 to 25) excluded roughly 95% of those who screened positive on careful assessment, with the remainder adolescent-onset or explained by substance use or comorbidity (Sibley et al. 2018); a dedicated review concluded most late-onset cases develop between ages 12–16, rarely without childhood precursors, while cautioning the data cannot yet clarify whether early and late onset share underlying neural mechanisms (Asherson and Agnew-Blais 2019); and retrospective recall of childhood ADHD symptoms is unreliable (accuracy about 55%) (Breda et al. 2020). The strongest reading is that much apparent adult onset is adolescent-onset or missed childhood ADHD, so the acquired-catecholamine interpretation applies, if at all, to a narrow residual subset — but the evidence base is a small US comparison cohort plus a self-referential research cluster, not settled consensus, so the question is open. Falsifiability: a prospective cohort with repeated childhood assessments that confirmed a substantial de novo (no childhood precursors, no substance use) adult-onset ADHD group would partially revive the distinct-syndrome reading; current MTA-derived evidence weighs against it but does not settle it. Consequence: for the ADHD–ME/CFS framing, ADHD is best treated as a largely childhood/adolescent-onset predisposing trait; the shared-metabolic-reserve hypothesis applies most strongly to childhood/adolescent-onset ADHD. (ch14d Architectural Uncertainty: Architecture A Cannot Be Ruled Out; cert 0.47 — discounted from Sibley2018 0.65, Asherson2019 0.62, Breda2020 0.58 each ×0.75 cross-disease weight; severity unknown; origin: literature integration.)	Phase 2 / 0.47
hyp adhd-nrf2-pathway-measured	Hypothesis (updated claim): NRF2 pathway activity in ADHD has now been measured once — a 2026 cross-sectional study of 60 adults with ADHD versus 60 controls found serum NRF2 and HO-1 protein significantly reduced in ADHD and negatively correlated with symptom severity (all p $<$ 0.001; ROC AUC 0.756 for NRF2, 0.797 for HO-1) (Gürbüzer, Ozkaya, and Mercantepe 2026). This replaces the earlier “no study has measured NRF2 in ADHD” claim and is consistent with — but does not prove — the dopamine-NRF2-NLRP3 axis: it measured circulating serum protein, not NRF2 nuclear translocation or NQO1 target-gene expression, and covers adult ADHD only in a single unreplicated study. Falsifiability: an ADHD PBMC study showing no difference in NRF2 nuclear translocation or NQO1 expression between ADHD and controls would weaken the axis claim; replication of reduced NRF2 in a second independent ADHD cohort would strengthen it. Consequence: a measurable (if preliminary) NRF2 deficit in ADHD adds plausibility to the dopamine-NRF2-NLRP3 axis, and suggests serum NRF2/HO-1 as a candidate exploratory biomarker — but because the measurement was serum protein, not NRF2 nuclear translocation or NQO1 expression, it does not yet establish which NRF2-dependent endpoint an intervention should target. (ch14d sec:x1-adhd-nrf2-nlrp3: ADHD Dopamine-NRF2-NLRP3 Axis as Shared Pathophysiology with ME/CFS; cert 0.41; adult-only, severity unknown; origin: literature integration.)	Phase 3 / 0.41

ID / Label	Details	Phase / Cert
oq lc-adhd-acquired-causal	Open question: whether SARS-CoV-2 infection acquires new-onset AD(H)D or merely reveals preexisting neurodivergence. A translational viewpoint proposes a bidirectional Long Covid–AD(H)D link via convergent neuroimmune dysfunction (frontal-striatal-hippocampal circuits, catecholamine neuroimmune dysregulation, tryptophan-kynurenine overactivation, mitochondrial bioenergetic defects) and an acquired, infection-triggered neuroimmune-mediated dopaminergic/noradrenergic dysfunction (Spanoghe et al. 2026). The causal claim is unresolved: post-COVID ADHD symptom onset is reported and stimulant prescribing rose post-COVID (Koonce and Martin 2024) (Gimbach et al. 2024), with AD(H)D as a risk factor for Long Covid (Merzon et al. 2022); but a 20-year national cohort found no independent COVID effect on AD(H)D diagnosis/treatment rates (Shkalim Zemer et al. 2024), and the prescribing rise is consistent with catch-up diagnosis (Gimbach et al. 2024). Because the certainty gap between the strongest null (0.70 raw) and the positive epidemiology is ≤0.15, both sides are presented without weighting. Falsifiability: a prospective post-infectious cohort with validated AD(H)D scales plus an executive/immune-biomarker profile at enrollment and longitudinally would distinguish de novo onset from unmasking of preexisting traits; reliance on retrospective diagnosis or prescription records cannot settle it. Consequence: determines whether post-viral attention difficulties are interpreted as newly acquired brain dysfunction requiring investigation or as unmasked preexisting neurodivergence — changing clinical interpretation and management while not altering the need to address the symptoms. (ch14d Shared Neuroimmune Substrate Linking Long Covid, AD(H)D, and ME/CFS Executive Dysfunction; cert 0.40; severity unknown; origin: literature integration.)	Phase 2 / 0.40
hyp lc-adhd-neuroimmune-shared-substrate	Hypothesis: a shared neuroimmune substrate links Long Covid, AD(H)D, and ME/CFS executive dysfunction — specifically kynurenine-pathway overactivation disrupting dopamine/noradrenaline transmission and intersecting mitochondrial bioenergetics (Spanoghe et al. 2026). Direct human evidence: kynurenine-pathway activation correlates with post-acute COVID cognitive impairment (Cysique et al. 2023); kynurenic acid lowers striatal dopamine at nanomolar concentrations in animals (Rassoulpour et al. 2005); kynurenine intersects mitochondrial function (Tanaka et al. 2022) and mitochondrial complex suppression accompanies COVID cognitive decline (Xu et al. 2025); dopamine is immunomodulatory (Sarkar et al. 2010) (Feng and Lu 2021). Precision-immunopsychiatry (immune/neurocognitive endophenotype stratification) and off-label AD(H)D-targeted pharmacotherapy in Long Covid are proposed, with autonomic dysregulation and PEM as limiting factors (Krishnan et al. 2022) (Fesharaki-Zadeh, Lowe, and Arnsten 2023) (Spanoghe et al. 2026). Falsifiability: in ME/CFS patients with executive dysfunction, plasma KYN/TRP ratio will correlate positively with objective executive deficit and negatively with a dopaminergic-function proxy, persisting after controlling for fatigue severity; falsified if KYN/TRP does not track executive dysfunction independent of overall fatigue. Consequence: provides a mechanism-specific target (kynurenine-to-dopamine signaling) and a caution that AD(H)D-type medication for cognitive symptoms is observational only, not a validated ME/CFS treatment. (ch14d Shared Neuroimmune Substrate Linking Long Covid, AD(H)D, and ME/CFS Executive Dysfunction; cert 0.35; severity unknown; origin: literature integration.)	Phase 2 / 0.35
hyp mito-kynurenine-nad-sink	Hypothesis: the kynurenine and mitochondrial arms of the LC-AD(H)D framework converge on a single prefrontal bioenergetic bottleneck — chronic kynurenine-pathway activation draws down the NAD⁺ pool that mitochondria require, so the energetically expensive prefrontal cortex shows the first ATP deficit, producing the shared executive/inattentive phenotype. Kynurenine-pathway overactivation diverts tryptophan toward the kynurenine-NAD⁺ catabolic arm (Cysique et al. 2023); mitochondrial complex suppression accompanies COVID cognitive decline (Xu et al. 2025); the kynurenine pathway intersects mitochondrial function (Tanaka et al. 2022). Unifies mechanisms (3) and (4) of the Spanoghe framework into one molecular mechanism (Spanoghe et al. 2026). Falsifiability: in ME/CFS patients with executive dysfunction, prefrontal ATP/phosphocreatine (MRS) will correlate inversely with kynurenine-pathway load and executive-deficit severity, independent of general fatigue; falsified if prefrontal bioenergetic markers do not track kynurenine-pathway load after controlling for fatigue. Consequence: gives a single druggable target (kynurenine-to-NAD⁺ balance) behind the separate kynurenine and mitochondrial hypotheses, and suggests shifting the pathway away from the NAD⁺-consuming arm might preserve prefrontal energetics. (ch14d Mitochondrial-Kynurenine NAD⁺ Sink: A Unifying Executive-Dysfunction Mechanism; cert 0.40; severity unknown; origin: brainstorm idea 1.4.)	Phase 2 / 0.40

ID / Label	Details	Phase / Cert
oq depression-neurogenesis-stall-mechanism	Open question: whether adult human hippocampal neurogenesis stalls in major depressive disorder. A single-cell + spatial + proteomic atlas of ~500,000 hippocampal nuclei reported a stalled neurogenic lineage in MDD (more quiescent neural stem cells, fewer neuroblasts, reduced DCX/BDNF, elevated interferon and stress signaling) and argued for molecular reclassification of depression (Peng et al. 2026). The premise that adult human hippocampal neurogenesis persists at a measureable level is directly contested: one group reports persistence into the ninth decade (Boldrini et al. 2018) (Boldrini et al. 2019), building on the foundational BrdU demonstration (Eriksson et al. 1998); the opposing group concludes very few, if any, new neurons are born in the adult human hippocampus (Sorrells et al. 2018) (Sorrells et al. 2021). The certainty gap between the strongest positive (0.80) and strongest null (0.68) is ~0.12, within the ±0.10 band — both sides are presented without weighting. Falsifiability: a pre-registered multi-method (single-nucleus RNA + multiple antibody markers) post-mortem study in independent cohorts that either reproduces the MDD neurogenesis stall or demonstrates undetectable neurogenesis at any adult age would settle the controversy; agreement between methods is required to exclude fixation/antibody artifacts. Consequence: determines whether stalled hippocampal neurogenesis can serve as a molecular feature of primary depression at all — if the underlying process is not reproducibly measureable in adults, it cannot be used to distinguish depression from ME/CFS or to guide any intervention. (ch04 Is Molecular Depression Distinct From Reactive Depression in ME/CFS?; ch16 Molecular Reclassification of Depression and the Depression-ME/CFS Boundary; cert 0.40 — controversy unresolved, both sides discounted; severity unknown; origin: literature integration.)	Phase 2 / 0.40
spec postinfectious-neurogenesis-suppression-mecfs	Speculation: a post-infectious or HPA-axis process could suppress adult hippocampal neurogenesis in ME/CFS, paralleling the depression-axis finding. Mechanism bridges are indirect: (a) HPA-axis dysfunction is documented in CFS (Papadopoulos and Cleare 2012) and adult hippocampal neurogenesis buffers stress/HPA negative feedback in animal models (Snyder et al. 2011); (b) mild SARS-CoV-2 infection suppresses hippocampal neurogenesis and oligodendrogenesis via microglial reactivity and elevated CCL11, linked to cognitive symptoms in long COVID (Fernández-Castañeda et al. 2022). There are zero direct studies of adult hippocampal neurogenesis in ME/CFS — the extrapolation is unsupported by direct data and additionally contingent on the unresolved adult-human-neurogenesis controversy (Sorrells et al. 2018) (Sorrells et al. 2021). Falsifiability: direct measurement of dentate-gyrus neurogenic markers (DCX, nestin, Ki67) in ME/CFS post-mortem or surgical hippocampal tissue showing density comparable to controls would falsify suppression; a replicated reduction below matched controls would support it — but no such ME/CFS tissue study exists. Consequence: if replicated, a neurogenesis deficit could link the post-infectious onset of ME/CFS to a measurable hippocampal consequence and eventually offer a target — but current evidence is too thin for any clinical or diagnostic use. (ch16 Molecular Reclassification of Depression and the Depression-ME/CFS Boundary; cert 0.30 — indirect links only, zero direct ME/CFS data; severity unknown; origin: literature integration.)	Phase 3 / 0.30

ID / Label	Details	Phase / Cert
spec angelman-ube3a-cross-disease	Speculation: Angelman syndrome (UBE3A/E6AP E3 ubiquitin-ligase loss) may model ME/CFS-relevant bioenergetic and GABAergic vulnerability. Ube3a loss impairs mitochondrial oxidative phosphorylation and lowers neuronal ATP in a mouse model (Su et al. 2011); in silico work links UBE3A-dependent mitochondrial transcripts to energy metabolism (Panov et al. 2020); AS models show elevated reactive-oxygen species (Simchi et al. 2023) and reduced tonic GABAergic (GABA-A) inhibition (Watanabe et al. 2026), alongside fragmented sleep (Qu et al. 2024) — each domain independently proposed in ME/CFS (Le et al. 2025) (Shankar et al. 2025) (L. Davis et al. 2025) (Wirth and Scheibenbogen 2026) (Liu et al. 2025). No direct AS–ME/CFS co-occurrence or mechanistic link exists (0 PubMed hits), so this is hypothesis-generating, not established shared pathophysiology, and two structural disanalogies limit extrapolation: AS is congenital/monogenic/neurodevelopmental while ME/CFS is adult-onset/polygenic, and UBE3A dosage sensitivity (loss and duplication both yield overlapping outcomes) limits specificity (Kurmashev 2026). Falsifiability: if the analogy holds, ME/CFS should show impaired mitochondrial oxidative phosphorylation/ATP and reduced tonic GABA-A inhibition consistent with the AS-like phenotype regardless of acquired-vs-genetic origin; UBE3A-pathway variant enrichment is an optional corroborating (not falsifying) test, since an acquired deficit would show pathway pathology without genetic enrichment. Where such carriers are identified, iPSC-derived neurons should recapitulate the reduced tonic inhibition and lower ATP seen in AS models, though an iPSC null is non-decisive given technical recapitulation limits. Consequence: a research hypothesis only — no current clinical or diagnostic application; if it holds, it points toward UBE3A/ubiquitin-pathway and GABAergic tonic-inhibition circuits as a shared vulnerability underlying energy and brain-fog symptoms, giving a concrete biochemical test. (ch14d Angelman Syndrome (UBE3A) as a Cross-Disease Model for ME/CFS Mitochondrial and GABAergic Vulnerability; cert 0.20 — cross-disease analogy, animal/in-silico/overview evidence discounted for non-ME/CFS population and developmental stage; severity unknown; origin: literature integration.)	Phase 5 / 0.20

ID / Label	Details	Phase / Cert
spec guanfacine-nac-bridge	Speculation: low-dose guanfacine (PFC-selective α2A-adrenoceptor agonism) plus N-acetylcysteine (Nrf2 antioxidant) as an inter-cluster bridge spanning the ch15 catecholamine cluster and Nrf2 cluster — a deliberate fixed combination, distinct from either single agent. Reported as open-label intervention for cognitive deficits in Long COVID (Fesharaki-Zadeh, Lowe, and Arnsten 2023) and TBI (Khasnavis et al. 2024) (Fesharaki-Zadeh et al. 2025). Mechanistic rationale is parallel non-overlapping targets (PFC α2A signaling + glutathione/Nrf2 redox support (Cherneva et al. 2025)); no direct α2A→Nrf2 molecular cross-talk is established (0 PubMed hits). Zero ME/CFS data; open-label case series only. Falsifiability: in ME/CFS with documented oxidative stress and PFC-dependent cognitive deficits, guanfacine+NAC improves n-back/Stroop more than either alone at 8 weeks; falsified if no added benefit over monotherapy, or if augmentation is oxidative-burden-independent, or if orthostatic intolerance exceeds guanfacine monotherapy (Okamoto et al. 2024). Consequence: hypothesis-generating — if confirmed, gives a tolerability-favorable combination targeting both the prefrontal noradrenergic deficit and oxidative stress implicated in ME/CFS brain fog; not a current treatment. (ch15 Speculation (clinical-finding:guanfacine-nac-postinfectious?); cert 0.30; severity unknown; origin: literature integration + user-directed.)	Phase 2 / 0.30

ID / Label	Details	Phase / Cert
spec saffron-serotonergic-kynurenine-modulator	Speculation: saffron bioactives (crocin, safranal, crocetin) inhibit SERT at the fluoxetine binding site (human ex vivo (Wauquier et al. 2022); animal (Mohammadi et al. 2023)) and inhibit MAO-A/B (in vitro (De Monte et al. 2014)), reduce serum kynurenine and raise melatonin (rodent (De la Fuente Muñoz et al. 2023)), downregulate neurotoxic kynurenine components (murine (Monchaux de Oliveira et al. 2026)), and shift gut-microbial tryptophan toward tryptamine and indole-acetic acid (ex vivo (Horvath et al. 2026)). Zero primary-ME/CFS trials; a null RCT on fatigue in healthy subclinical-depression adults (Amadieu et al. 2025); fatigue RCTs are only comorbid-secondary (COPD (Dastan et al. 2025); sarcoidosis (Moghimi Dehkordi et al. 2026)) or cross-disease (Parkinson’s (Hajhashemy, Bagherniya, and Sadeghi 2026)). Combined SERT + MAO inhibition carries serotonin-syndrome risk with SSRIs/SNRIs/MAOIs (Căuș, Lupoae, and Chițescu 2026), directly relevant to the SSRI-paradox (hyper-serotonergic) model in which serotonergic agents may worsen ME/CFS. High-dose saffron has uterine-stimulation risk in pregnancy (Alshdefat et al. 2026). Falsifiability: if the hyper-serotonergic model holds, saffron worsens fatigue in ME/CFS (reverse of its reported comorbid-fatigue benefit) and should be avoided with serotonergic antidepressants; falsified if saffron improves ME/CFS fatigue in a primary-ME/CFS RCT despite SERT inhibition. Consequence: do not recommend saffron for ME/CFS fatigue or mood; treat it as an unproven, potentially-worsening serotonergic agent that also touches the kynurenine and gut-tryptophan axes. (ch18 Saffron as an Unproven Serotonergic-Kynurenine Modulator; cert 0.20; severity unknown; origin: literature integration — external-contact proposal.)	Phase 2 / 0.20

ID / Label	Details	Phase / Cert
hyp ahr-gut-microbiome-axis	Hypothesis: the aryl-hydrocarbon receptor (AhR), a ligand-activated transcription factor sensing gut-microbial tryptophan and indole metabolites (indole-3-acetic acid, indole-3-propionic acid, indole-3-aldehyde, tryptamine) and kynurenine-pathway metabolites, is an altered gut-microbiome–immune axis in ME/CFS. AhR activation drives IL-22-producing ILC3 and gamma-delta T cells and reinforces the intestinal barrier while restraining Th17 inflammation (Rothhammer and Quintana 2019) (Thirugnanam et al. 2026). Direct ME/CFS evidence found altered stool AhR-agonist activity that was elevated specifically in the neurocognitive-symptom subgroup rather than uniformly (Esteban et al. 2026), with supporting comorbid IBS+CFS urinary tryptophan-metabolite data (Chojnacki et al. 2025). The mechanism extends (not replaces) the already-integrated kynurenine pathway, since kynurenine metabolites are themselves AhR ligands (Torrelli-Diljohn, Kulkarni, and Vitturi 2026). Falsifiability: ME/CFS patients with neurocognitive symptoms should show elevated stool/plasma AhR-agonist activity and altered indole metabolites vs cognitively-unaffected ME/CFS and healthy controls, correlating with cognitive performance and barrier markers; falsified if the association does not track the neurocognitive subgroup or fails to correlate with barrier/immune readouts. Consequence: if confirmed, gut-microbial tryptophan metabolism and AhR signaling become a shared upstream mechanism linking intestinal and cognitive features of ME/CFS, pointing toward dietary/microbial restoration of a neuroprotective (transient) AhR ligand balance — no intervention established for ME/CFS today. (ch12 AhR-Gut-Microbiome Axis: Tryptophan-Derived Ligands Modulate Intestinal Barrier and Immune Tone Direct Evidence: Altered Gut-Microbial AhR Agonists Track Neurocognitive Symptoms in ME/CFS AhR Evidence Is Subgroup-Specific and Lacks Immune-Readout Confirmation; cert 0.40; severity unknown — anchor not stratified; origin: literature integration — external-contact proposal, pre-identified gap.)	Phase 2 / 0.40

ID / Label	Details	Phase / Cert
hyp fibromyalgia-cns-shared-genetic-vulnerability	Hypothesis: fibromyalgia shows brain/neural-enriched genetic architecture, and its co-occurrence with ME/CFS may reflect a partially shared central genetic vulnerability. The largest fibromyalgia GWAS (Kerrebijn 2026, Nature Medicine, 2.56M individuals, 54,629 cases) identified 26 risk loci (strongest: coding variant in HTT, plus GPR52, DCC, DRD2/NCAM1, MDGA2, CELF4) and found heritability exclusively enriched in brain tissues and neural cell types, with no immune/glial enrichment — consistent with, not proof of, a central-nervous-system (nociplastic) role (Kerrebijn et al. 2026). This parallels the brain-enriched architecture independently established for ME/CFS by DecodeME (DecodeME Consortium, Ponting, et al. 2025) and the Maccallini meta-GWAS (Maccallini 2026). Confirmed shared risk regions are OLFM4 and RABGAP1L (DCC in the earlier overlap); GPR52/HTT are fibromyalgia-risk genes whose presence in ME/CFS is untested. Falsifiability: a cross-trait GWAS/PRS analysis between fibromyalgia and ME/CFS will show significant genetic correlation and shared brain-enriched heritability; fibromyalgia PRS will be elevated in ME/CFS patients with comorbid fibromyalgia; whether HTT/GPR52 appear in ME/CFS GWAS is a testable prerequisite; falsified if the two conditions show near-zero genetic correlation or divergent enrichment patterns. Consequence: if confirmed, a shared central genetic vulnerability would make central-sensitization mechanisms a research priority to test across both conditions — but the direct genetic correlation remains to be measured, so no clinical change follows from the genetics alone. (ch14 Kerrebijn 2026 Fibromyalgia GWAS: 26 Risk Loci and Brain-Enriched Heritability Fibromyalgia as CNS Disorder with Shared Genetic Vulnerability with ME/CFS; cert 0.55; severity unknown — GWAS not stratified by severity; origin: literature integration.)	Phase 2 / 0.55
hyp shared-transdiagnostic-cns-genetic-factor	Hypothesis: fibromyalgia shares substantial genetic variance with chronic pain and psychiatric/somatic traits, and ME/CFS shows overlapping genetic correlations (the transdiagnostic CNS-factor interpretation is one candidate formalization, not established). Fibromyalgia showed rg > 0.7 with low back pain, PTSD, and IBS, and pervasive positive genetic correlation with depression, somatoform/dissociative disorders, and migraine (Kerrebijn et al. 2026); GenomicSEM analyses report a shared nociplastic-pain heritable factor (Johnston, Signer, and Huckins 2025) and a shared latent genetic liability across fibromyalgia-psychiatric traits (Lin et al. 2026). ME/CFS already shows high genetic correlation with IBS (rg 0.75) and depression (rg 0.60) (DecodeME Consortium, Ponting, et al. 2025). Falsifiability: a transdiagnostic genomic-SEM factor across these conditions will show significant heritability and shared neural cell-type enrichment, and nociplastic-pain PRS will predict severity across ME/CFS, fibromyalgia, and IBS cohorts; falsified if the shared factor explains negligible variance, if enrichment is condition-specific, or if correlations are attributable to population structure. Consequence: high pairwise genetic correlation across fibromyalgia, ME/CFS, IBS, and chronic pain is a real finding that argues for shared genetic underpinnings, but a single central-sensitization mechanism is unproven and transdiagnostic treatment strategies remain a hypothesis to test. (ch14 High Fibromyalgia Genetic Correlation With Chronic Pain and Psychiatric Traits; cert 0.42; severity unknown; origin: literature integration.)	Phase 2 / 0.42
hyp shared-central-genetic-architecture-fibro-mecfs	Hypothesis: the ME/CFS-fibromyalgia comorbidity may be underlain by a shared central (brain/neural) genetic architecture. Both conditions independently show brain/neural-cell-type heritability enrichment (fibromyalgia: (Kerrebijn et al. 2026); ME/CFS: (DecodeME Consortium, Ponting, et al. 2025) (Maccallini 2026)), consistent with — but not proof of — a shared central vulnerability; the co-occurrence figure is inflated by overlapping diagnostic criteria (Wolfe 2016) and the decisive direct fibromyalgia × ME/CFS genetic correlation is untested. This is a cross-reference to the detailed ch14 analysis, not an independent claim. Falsifiability: a direct cross-trait genetic-correlation analysis of fibromyalgia and ME/CFS will be significantly positive, and fibromyalgia PRS will be elevated in ME/CFS patients with comorbid fibromyalgia; falsified if the two conditions show near-zero genetic correlation despite clinical overlap. Consequence: if confirmed, a shared central genetic basis would make central-sensitization mechanisms a research priority to test across both conditions — but genetic architecture does not by itself determine effective treatment, so this is a research direction, not a current management change. (ch04 Shared Central Genetic Architecture May Underlie the ME/CFS-Fibromyalgia Comorbidity Three-Line Genetic Convergence on Neuronal Biology; cert 0.52; severity unknown; origin: literature integration.)	Phase 2 / 0.52
hyp fibromyalgia-autoimmune-reconciliation	Hypothesis: the no-MHC GWAS finding and the passive-IgG autoantibody evidence in fibromyalgia are not contradictory because germline genetic architecture and acquired antibodies are independent layers. The Kerrebijn 2026 GWAS found no MHC signal and no immune/glial heritability enrichment (genetic evidence against a primarily autoimmune/HLA-linked architecture) (Kerrebijn et al. 2026), yet passive-transfer evidence shows fibromyalgia/long-COVID IgG reproduces symptoms in mice (acquired humoral autoimmunity) (Goebel et al. 2021). An absence of HLA-linked germline risk does not rule out acquired pathogenic antibodies; whether a fibromyalgia antibody subset maps onto the non-HLA-linked central-sensitization architecture is a framing device, not an independently tested hypothesis. Falsifiability: fibromyalgia patients responding to immunomodulation will cluster in an autoantibody-positive subset without enrichment for the 26 GWAS loci; falsified if the GWAS loci and the autoantibody subset fully overlap (arguing for a unified HLA-linked mechanism). Consequence: fibromyalgia need not be forced into an “is/isn’t autoimmune” binary — the no-MHC finding and the passive-IgG evidence can both be true because germline genetics and acquired antibodies are separate layers. (ch14 Fibromyalgia Autoimmunity Is Not Contradicted by the Absence of an HLA Signal; cert 0.30; severity unknown; origin: literature integration + brainstorm.)	Phase 2 / 0.30

ID / Label	Details	Phase / Cert
oq lc-trajectory-chronicity	Open question: post-infectious syndromes (Long COVID) can become self-sustaining rather than resolving — 85% of those symptomatic at 2 months remained symptomatic at 1 year, and cognitive-impairment prevalence increased from 16% (2 mo) to 26% (12 mo), with neurological symptoms often delayed in onset and parosmia showing ~3-month onset (H. E. Davis et al. 2023). The increasing cognitive trajectory argues that at least a subset of Long COVID converges on an ME/CFS-like chronic state (ME/CFS is generally considered lifelong). This temporal evidence is integrated into ch14d as a counterfactual-validity argument for post-infectious chronicity. Consequence: if post-infectious syndromes commonly become self-sustaining or worsen over the first year, this argues for early mechanism-targeted intervention before chronicity locks in — relevant to both Long COVID and post-infectious ME/CFS onset. (ch14d Long COVID Trajectory: Temporal Evidence for Post-Infectious Chronicity; cert 0.60; severity unknown; origin: literature integration.)	Phase 3 / 0.60
oq lc-vaccine-heterogeneity	Open question: vaccination has heterogeneous effects on established Long COVID symptoms — 16.7% relief, 21.4% worsening, remainder unchanged (Tsuchida et al. 2022) (H. E. Davis et al. 2023), even though vaccination reduces the risk of new Long COVID (~15-41% partial protection). The heterogeneous response indicates Long COVID (and by extension ME/CFS) is not a single uniform process; the same intervention can improve or worsen depending on underlying mechanism. Consequence: a treatment that helps some post-infectious patients and harms others signals mechanistic heterogeneity, arguing for individualised titration and mechanism-based stratification rather than uniform protocols. (ch14d Vaccination and Established Long COVID: Heterogeneous Symptom Response; cert 0.45; severity unknown; origin: literature integration.)	Phase 3 / 0.45
oq insufficient-early-antibody-chronicity	Open question: a low/absent acute SARS-CoV-2 antibody response predicts Long COVID at 6-7 months in both hospitalized and non-hospitalized patients (García-Abellán et al. 2021) (Augustin et al. 2021) (H. E. Davis et al. 2023), suggesting an insufficient adaptive response (not only an overactive one) can gate post-infectious chronicity. Causal direction unestablished — low antibody could be a marker of viral persistence, a severity confound, or genuine immunocompromise. Consequence: if a weak early antibody response helps predict who develops a chronic post-infectious illness, it could support early immune-supportive intervention in the acute-to-subacute window, relevant to both Long COVID and post-infectious ME/CFS. (ch08 Does Insufficient Early Antibody Response Gate Post-Infectious Chronicity?; cert 0.55; severity unknown; origin: literature integration.)	Phase 3 / 0.55
lim seroreversion-control-bias	Limitation: a substantial proportion of SARS-CoV-2-infected patients never seroconvert or serorevert within months (more commonly in women, children, mild infections) (Van Elslande et al. 2021) (H. E. Davis et al. 2023), so serology-based control classification misassigns seroreverted symptomatic patients into control groups, biasing comparisons toward null and under-ascertaining post-infectious illness. The same testing-bias risk applies to ME/CFS research whenever serology defines infection exposure. Consequence: researchers should not rely on serology alone to assign infection-exposure status; symptom-based and clinically-diagnosed cohorts strengthen validity — a methodological correction transferable to post-infectious ME/CFS study design. (ch08 Seroreversion Creates Control-Group Bias in Post-Infectious Research; cert 0.55; severity unknown; origin: literature integration.)	Phase 3 / 0.55
lim lc-extrapolation-limits	Limitation: extrapolating Long COVID findings to ME/CFS carries limits that temper the confidence of the overlap argument — (1) the Davis 2023 review is a narrative (not systematic) synthesis with some preprint/small-cohort findings (H. E. Davis et al. 2023); (2) Long COVID is mostly studied in the first 1-2 years (acute-to-chronic extrapolation) while ME/CFS is lifelong, and many Long COVID symptoms resolve while ME/CFS persists; (3) the ~50% criteria overlap may partly reflect self-referential symptom criteria rather than shared biology, and the 2-day CPET divergence argues against full mechanistic equivalence; (4) several Long COVID findings derive from overlapping cohorts, inflating apparent certainty. Consequence: Long COVID evidence is a strong suggestive bridge and hypothesis source for ME/CFS, not proof of mechanistic identity — direct head-to-head mechanistic and longitudinal studies are still required. (ch14d Long COVID-ME/CFS Extrapolation: Limits of the Counterfactual; cert 0.55; severity unknown; origin: brainstorm critical category.)	Phase 5 / 0.55

ID / Label	Details	Phase / Cert
hyp central-motor-drive-cascade	Hypothesis: the earlier fatigability in ME/CFS reflects a failure to up-regulate central motor drive under sustained effort — a ≥4-step neurophysiological cascade (cortical motor output → corticospinal drive → spinal motoneuron recruitment → neuromuscular transmission → muscle-fiber recruitment → afferent feedback) rather than peripheral muscle exhaustion (Bedard et al. 2026). Multimodal neuroimaging (grip force + EMG + EEG + fMRI + corticomuscular coherence) in n=15 ME/CFS vs n=19 controls showed equal maximum voluntary force but earlier fatigue onset, with healthy controls steadily increasing muscle (Dimitrov index) and brain (EEG power, BOLD) activity until fatigue then declining slowly, whereas ME/CFS showed minimal fluctuation — an absent up-regulation of motor-cortical and subcortical output. This is an association, not established causation (the authors explicitly disclaim a causal link; only TMS or a drug-intervention study could establish direction). The differential-diagnostic value lies in which central-acting interception drug restores motor-drive up-regulation: dopaminergic/effort-node probes (modafinil/armodafinil (Minzenberg and Carter 2008), methylphenidate, amphetamines, bromocriptine/rotigotine) and glutamatergic (amantadine) agents, each targeting a distinct cascade node (see Section Systemic inflammation is downstream of a more upstream cause). Falsifiability: if central motor drive is the bottleneck, ME/CFS patients whose motor-drive up-regulation is restored by a central-acting agent should show later fatigue onset and a normalized Dimitrov-index/EEG/BOLD trajectory on the same grip-force protocol, while peripheral ergogenic aids should not; falsified if a peripheral intervention alone restores performance, or if no central-acting agent alters the motor-drive trajectory. Consequence: reframing ME/CFS fatigability as a brain-level failure to drive muscle — rather than a purely peripheral muscle problem — directs research and treatment toward the central nervous system (dopaminergic/effort circuits) and gives a testable drug-response framework, though no drug is recommended on this evidence alone. (ch03 Central Neural Origin of Fatigability; ch34 Systemic inflammation is downstream of a more upstream cause; cert 0.45 — the 0.60 association discounted for its associational (non-causal) design and single small sample; severity unknown — NIH intramural cohort not stratified; origin: literature integration — gap-fill of prior fatigue-cycle ch30-tier NONE.)	Phase 3 / 0.45

1 Contents

References

A, Mu, Thomas E. Wales, Haixia Zhou, Sorin-Valeriu Draga-Coletă, Christoph Gorgulla, Katherine A. Blackmore, Melanie J. Mittenbühler, et al. 2023. “Irisin Acts Through Its Integrin Receptor in a Two-Step Process Involving Extracellular Hsp90α.” Molecular Cell 83 (11): 1903–1920.e12. https://doi.org/10.1016/j.molcel.2023.05.008.

Aditi, Thomas Blackwell, Xiang Fang, Surendra Sharma, Matthew Mendoza, Alan Landay, Georgiy Golovko, and Parimal Samir. 2026. “Long-Term Risk of Dementia Following Encephalitis: A Large-Scale Retrospective Cohort Study of Electronic Health Records.” Journal of Neurology 273 (9): 511. https://doi.org/10.1007/s00415-026-14017-3.

Al Shahab, Shatha, Rawan Al Balushi, Amna Qambar, Ruqayah Abdulla, Maryam Qader, Shooq Abdulla, and Haitham Jahrami. 2025. “Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review.” Nutrients 17 (9): 1482. https://doi.org/10.3390/nu17091482.

Alfonsa, Hannah, Robert J. Burman, Peter J. N. Brodersen, Sarah E. Newey, Kashif Mahfooz, Tomoko Yamagata, Marios C. Panayi, David M. Bannerman, Vladyslav V. Vyazovskiy, and Colin J. Akerman. 2023. “Intracellular Chloride Regulation Mediates Local Sleep Pressure in the Cortex.” Nature Neuroscience 26 (1): 64–78. https://doi.org/10.1038/s41593-022-01214-2.

Alshdefat, Ahmad, Ahmad Ayed, Ismael Aqtam, Omowunmi Ibitoye, Sherry Vincent, and Abdulaziz A Furqani. 2026. “Saffron and Pregnancy: Cultural Practices, Beliefs, and Safety Evidence: An Integrative Review.” Journal of Evidence-Based Integrative Medicine 31: 2515690X261455162. https://doi.org/10.1177/2515690X261455162.

Alten, Rieke, Amy Grahn, Robert J Holt, Patricia Rice, and Frank Buttgereit. 2015. “Delayed-Release Prednisone Improves Fatigue and Health-Related Quality of Life: Findings from the CAPRA-2 Double-Blind Randomised Study in Rheumatoid Arthritis.” RMD Open 1 (1): e000134. https://doi.org/10.1136/rmdopen-2015-000134.

Amadieu, Camille, Quentin Leyrolle, Marta Farneti, et al. 2025. “Effect of Saffron Extract Supplementation on Mood in Healthy Adults with Subclinical Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Trial.” American Journal of Clinical Nutrition 122 (6): 1625–35. https://doi.org/10.1016/j.ajcnut.2025.09.050.

Andrillon, Thomas, and Delphine Oudiette. 2023. “What Is Sleep Exactly? Global and Local Modulations of Sleep Oscillations All Around the Clock.” Neuroscience & Biobehavioral Reviews 155: 105465. https://doi.org/10.1016/j.neubiorev.2023.105465.

Appelman, Brent, Braeden T. Charlton, Richie P. Goulding, Tom J. Kerkhoff, Ellen A. Breedveld, Wendy Noort, Carla Offringa, et al. 2024. “Muscle Abnormalities Worsen After Post-Exertional Malaise in Long COVID.” Nature Communications 15: 17. https://doi.org/10.1038/s41467-023-44432-3.

Asherson, Philip, and Jessica Agnew-Blais. 2019. “Annual Research Review: Does Late-Onset Attention-Deficit/Hyperactivity Disorder Exist?” Journal of Child Psychology and Psychiatry 60 (4): 333–52. https://doi.org/10.1111/jcpp.13020.

Augustin, M. et al. 2021. “Post-COVID Syndrome in Non-Hospitalised Patients with COVID-19: A Longitudinal Prospective Cohort Study.” The Lancet Regional Health - Europe 6: 100122. https://doi.org/10.1016/j.lanepe.2021.100122.

Azcue, N, A Prada, R Del Pino, M Acera, T Fernandez-Valle, N Ayo-Mentxakatorre, T Perez-Concha, et al. 2026. “Involvement of Autoantibodies Against G Protein-Coupled Receptors in Post-COVID Condition and Chronic Fatigue Syndrome.” Scientific Reports 16 (1): 20609. https://doi.org/10.1038/s41598-026-49131-9.

Bader, Viola, Katharina Estermann, Eva Niess, Tobias Zrzavy, Florian Fischmeister, Teresa Haider, Birgit Ludwig, et al. 2026. “Experimental Hypoxia to Probe Neuro-Metabolic and Vascular Dysregulation in ME/CFS: A Multimodal Proof-of-Concept MRI Study.” medRxiv. https://doi.org/10.64898/2026.08.10.26359935.

Baraniuk, J N, N Eaton-Fitch, and S Marshall-Gradisnik. 2024. “Meta-Analysis of Natural Killer Cell Cytotoxicity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Frontiers in Immunology 15: 1440643. https://doi.org/10.3389/fimmu.2024.1440643.

Barnden, Leighton R., Zack Y. Shan, Donald R. Staines, Sonya Marshall-Gradisnik, Kevin Finegan, Timothy Ireland, and Sandeep Bhuta. 2018. “Hyperintense Sensorimotor T1 Spin Echo MRI Is Associated with Brainstem Abnormality in Chronic Fatigue Syndrome.” NeuroImage: Clinical 20: 102–9. https://doi.org/10.1016/j.nicl.2018.07.011.

Bateman, Lucinda, Alison C. Bested, Hector F. Bonilla, Bela V. Chheda, Lily Chu, Jennifer M. Curtin, Tania T. Dempsey, et al. 2021. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management.” Mayo Clinic Proceedings 96 (11): 2861–78. https://doi.org/10.1016/j.mayocp.2021.07.004.

Becker, Maxi, Dimitris Repantis, Martin Dresler, and Simone Kühn. 2022. “Cognitive Enhancement: Effects of Methylphenidate, Modafinil, and Caffeine on Latent Memory and Resting State Functional Connectivity in Healthy Adults.” Human Brain Mapping 43 (14): 4225–38. https://doi.org/10.1002/hbm.25949.

Bedard, Patrick, Kristine M. Knutson, Patrick M. McGurrin, Felipe Vial, Traian Popa, Silvina G. Horovitz, Mark Hallett, Avindra Nath, and Brian Walitt. 2026. “Central Origin of Fatigability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Revealed by Multimodal Neuroimaging.” NeuroImage: Clinical 51: 104041. https://doi.org/10.1016/j.nicl.2026.104041.

Biswal, Bharat, Priyanka Kunwar, and Benjamin H. Natelson. 2011. “Cerebral Blood Flow Is Reduced in Chronic Fatigue Syndrome as Assessed by Arterial Spin Labeling.” Journal of the Neurological Sciences 301 (1-2): 9–11. https://doi.org/10.1016/j.jns.2010.11.018.

Bizjak, Daniel Alexander, Birgit Ohmayer, Jasmine Leonike Buhl, Elisabeth Marion Schneider, Paul Walther, Enrico Calzia, Achim Jerg, Lynn Matits, and Jürgen Michael Steinacker. 2024. “Functional and Morphological Differences of Muscle Mitochondria in Chronic Fatigue Syndrome and Post-COVID Syndrome.” International Journal of Molecular Sciences 25 (3): 1675. https://doi.org/10.3390/ijms25031675.

Blanco, Marina B, Lydia K Greene, Kayla H Welser, Erin E Ehmke, Anne D Yoder, and Peter H Klopfer. 2024. “Primate Hibernation: The Past, Present, and Promise of Captive Dwarf Lemurs.” Annals of the New York Academy of Sciences 1540 (1): 178–90. https://doi.org/10.1111/nyas.15206.

Blockmans, Daniel, Philippe Persoons, Boudewijn Van Houdenhove, and Herman Bobbaers. 2006. “Does Methylphenidate Reduce the Symptoms of Chronic Fatigue Syndrome?” American Journal of Medicine 119 (2): 167.e23–30. https://doi.org/10.1016/j.amjmed.2005.07.047.

Boldrini, Maura, Camille A. Fulmore, Alexandria N. Tartt, Laika R. Simeon, Iva Pavlova, Verica Poposka, Gorazd B. Rosoklija, et al. 2018. “Human Hippocampal Neurogenesis Persists Throughout Aging.” Cell Stem Cell 22 (4): 589–99. https://doi.org/10.1016/j.stem.2018.03.015.

Boldrini, Maura, Camille A. Fulmore, Alexandria N. Tartt, Laika R. Simeon, Iva Pavlova, Verica Poposka, Gorazd B. Rosoklija, et al. 2019. “Resilience Is Associated with Larger Dentate Gyrus, While Suicide Decedents with Major Depressive Disorder Have Fewer Granule Neurons.” Biological Psychiatry 85 (10): 850–62. https://doi.org/10.1016/j.biopsych.2018.12.022.

Boneva, Roumiana S, Jin-Mann Lin, and Elizabeth R Unger. 2011. “Gynecological History in Chronic Fatigue Syndrome: A Population-Based Case-Control Study.” Journal of Women’s Health 20 (1): 21–28. https://doi.org/10.1089/jwh.2009.1900.

Boneva, Roumiana S, Jin-Mann Lin, Florian Wieser, Urs M Nater, Beate Ditzen, Rebecca N Taylor, and Elizabeth R Unger. 2015. “Early Menopause and Other Gynecologic Risk Indicators for Chronic Fatigue Syndrome in Women.” Menopause 22 (8): 826–34. https://doi.org/10.1097/GME.0000000000000411.

Bontempo, Alyssa C., Jennifer M. Bontempo, and Paul R. Duberstein. 2025. “Ignored, Dismissed, and Minimized: Understanding the Harmful Consequences of Invalidation in Health Care—a Systematic Meta-Synthesis of Qualitative Research.” Psychological Bulletin 151 (4): 399–427. https://doi.org/10.1037/bul0000473.

Bosch, E L, Iris E C Sommer, and Daan J Touw. 2025. “The Influence of Female Sex and Estrogens on Drug Pharmacokinetics: What Is the Evidence?” Expert Opinion on Drug Metabolism & Toxicology 21 (6): 637–47. https://doi.org/10.1080/17425255.2025.2481891.

Boström, Pontus, Jun Wu, Mark P. Jedrychowski, Anisha Korde, Li Ye, James C. Lo, Kyle A. Rasbach, et al. 2012. “A PGC1-α-Dependent Myokine That Drives Brown-Fat-Like Development of White Fat and Thermogenesis.” Nature 481 (7382): 463–68. https://doi.org/10.1038/nature10777.

Bou-Holaigah, I., P. C. Rowe, J. Kan, and H. Calkins. 1995. “The Relationship Between Neurally Mediated Hypotension and the Chronic Fatigue Syndrome.” JAMA 274 (12): 961–67. https://doi.org/10.1001/jama.1995.03530120053041.

Breda, V, Luis Augusto Rohde, Ana M B Menezes, Luciana Anselmi, Arthur Caye, Diego L Rovaris, Eugenia S Vitola, Claiton H D Bau, and Eugenio H Grevet. 2020. “Revisiting ADHD Age-of-Onset in Adults: To What Extent Should We Rely on the Recall of Childhood Symptoms?” Psychological Medicine 50 (5): 857–66. https://doi.org/10.1017/S003329171900076X.

Briese, Thomas, Rafal Tokarz, Lucinda Bateman, Xiaoyu Che, Cheng Guo, Komal Jain, Vishal Kapoor, et al. 2023. “A Multicenter Virome Analysis of Blood, Feces, and Saliva in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Medical Virology 95 (8): e28993. https://doi.org/10.1002/jmv.28993.

Brigo, Natascha, Wolfram Mayr, Maja Taenzer, Judith Löffler-Ragg, Andrea Schroll, Sabine Engl, Burkhard Schütz, et al. 2025. “Concentrations of Uremic Bacterial Metabolites in Patients with Post-COVID-19 Syndrome.” Frontiers in Cellular and Infection Microbiology 15: 1582972. https://doi.org/10.3389/fcimb.2025.1582972.

Brown, Abigail, and Leonard A. Jason. 2020. “Meta-Analysis Investigating Post-Exertional Malaise Between Patients and Controls.” Journal of Health Psychology 25 (13–14): 2053–71. https://doi.org/10.1177/1359105318784161.

Burnet, Richard B., and Brian E. Chatterton. 2004. “Gastric Emptying Is Slow in Chronic Fatigue Syndrome.” BMC Gastroenterology 4: 32. https://doi.org/10.1186/1471-230X-4-32.

Cambras, Trinitat, Joan Carles Domingo, Ramon Sanmartin-Sentanes, Jose Alegre-Martin, and Jesus Castro-Marrero. 2026. “Association Between Light Exposure Patterns and Multidimensional Health Outcomes in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Findings from an Observational Cross-Sectional Cohort Study.” Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08556-6.

Carbone, Manuel Glauco, Giovanni Pagni, Claudia Tagliarini, Icro Maremmani, and Angelo Giovanni Icro Maremmani. 2025. “Caffeine in Aging Brains: Cognitive Enhancement, Neurodegeneration, and Emerging Concerns about Addiction.” International Journal of Environmental Research and Public Health 22 (8): 1171. https://doi.org/10.3390/ijerph22081171.

Căuș, Marius Nicolae, Mihaela Lupoae, and Carmen Lidia Chițescu. 2026. “Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data.” Pharmaceuticals (Basel) 19 (3): 399. https://doi.org/10.3390/ph19030399.

Charlton, Braeden T., Richie P. Goulding, Richard T. Jaspers, Brent Appelman, Michèle van Vugt, and Rob C. I. Wüst. 2025. “Skeletal Muscle Adaptations and Post-Exertional Malaise in Long COVID.” Trends in Endocrinology & Metabolism 36 (7): 614–22. https://doi.org/10.1016/j.tem.2024.11.008.

Charlton, Braeden T., Anouk Slaghekke, Brent Appelman, Moritz Eggelbusch, Jelle Y. Huijts, Wendy Noort, Paul W. Hendrickse, et al. 2026. “Skeletal Muscle Properties in Long COVID and ME/CFS Differ from Those Induced by Bed Rest.” Nature Communications. https://doi.org/10.1038/s41467-026-75725-y.

Cherneva, Dilyana I., Gabriela Kehayova, Simona Dimitrova, and Stela Dragomanova. 2025. “The Central Nervous System Modulatory Activities of N-Acetylcysteine: A Synthesis of Two Decades of Research.” Current Issues in Molecular Biology 47 (9): 710. https://doi.org/10.3390/cimb47090710.

Chojnacki, Marcin, Aleksandra Blonska, Aleksandra Kaczka, Jan Chojnacki, Ewa Walecka-Kapica, Natalia Romanowska, Karolina Przybylowska-Sygut, and Tomasz Poplawski. 2025. “Assessment of the Gut Microbiome in Patients with Coexisting Irritable Bowel Syndrome and Chronic Fatigue Syndrome.” Nutrients 17 (13): 2232. https://doi.org/10.3390/nu17132232.

Cleare, Anthony J., Veronica O’Keane, and John Miell. 2001. “Plasma Leptin in Chronic Fatigue Syndrome and a Placebo-Controlled Study of the Effects of Hydrocortisone.” Clinical Endocrinology 55 (1): 113–19. https://doi.org/10.1046/j.1365-2265.2001.01341.x.

Cohen, Jack, Aparna Mathew, Katerina D. Dourvetakis, Estefania Sanchez-Guerrero, Rajendra P. Pangeni, Narasimman Gurusamy, Kristina K. Aenlle, et al. 2024. “Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders.” Cells 13 (6): 511. https://doi.org/10.3390/cells13060511.

Compton, Sabrina, Rodolf Alkabalan, Judd Cadet, Azin Mastali, and Prakash V A K Ramdass. 2025. “Endometriosis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review and Meta-Analysis.” Diagnostics 15 (18): 2332. https://doi.org/10.3390/diagnostics15182332.

Conroy, Kristina E., Mohammed F. Islam, and Leonard A. Jason. 2023. “Evaluating Case Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Toward an Empirical Case Definition.” Disability and Rehabilitation 45 (5): 840–47. https://doi.org/10.1080/09638288.2022.2043462.

Corrado, G., G. Riezzo, P. Rea, C. Pacchiarotti, M. Cavaliere, and E. Cardi. 1998. “Normal Gastric Emptying Time and Myoelectrical Activity in an Adolescent with Chronic Fatigue Syndrome.” Italian Journal of Gastroenterology and Hepatology 30 (4): 444–45.

Cox, Brandon S, Khaled Alharshawi, Irene Mena-Palomo, William P Lafuse, and Maria Eugenia Ariza. 2022. “EBV/HHV-6A dUTPases Contribute to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Pathophysiology by Enhancing TFH Cell Differentiation and Extrafollicular Activities.” JCI Insight 7 (11): e158193. https://doi.org/10.1172/jci.insight.158193.

Cutolo, Maurizio. 2019. “Circadian Rhythms and Rheumatoid Arthritis.” Joint Bone Spine 86 (3): 327–33. https://doi.org/10.1016/j.jbspin.2018.09.003.

Cysique, Lucette A., David Jakabek, Stephanie G. Bracken, Yana Allen-Davidian, Benjamin Heng, Simone Chow, Mona Dehhaghi, et al. 2023. “The Kynurenine Pathway Relates to Post-Acute COVID-19 Objective Cognitive Impairment and PASC.” Annals of Clinical and Translational Neurology 10 (8): 1338–52. https://doi.org/10.1002/acn3.51825.

Czesnik, Dirk, James Howells, Francesco Negro, Hajo Wagenknecht, David Burke, and Hugh Bostock. 2015. “Increased HCN Channel Driven Inward Rectification in Benign Cramp Fasciculation Syndrome.” Brain 138 (Pt 11): 3168–79. https://doi.org/10.1093/brain/awv250.

Dastan, Farzaneh, Jamshid Salamzadeh, Jalal Heshmatnia, and Reza Mahmoudian. 2025. “Evaluating the Effects of Crocus sativus l. Herbal Product on Chronic Fatigue Syndrome in Patients with Chronic Obstructive Pulmonary Disease.” Iranian Journal of Pharmaceutical Research 24 (1): e165333. https://doi.org/10.5812/ijpr-165333.

Davenport, Todd E., Lily Chu, Staci R. Stevens, Jared Stevens, Christopher R. Snell, and J. Mark Van Ness. 2023. “Two Symptoms Can Accurately Identify Post-Exertional Malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Work 74 (4): 1199–1213. https://doi.org/10.3233/WOR-220554.

Davis, Hannah E., Lisa McCorkell, Julia Moore Vogel, and Eric J. Topol. 2023. “Long COVID: Major Findings, Mechanisms and Recommendations.” Nature Reviews Microbiology 21 (3): 133–46. https://doi.org/10.1038/s41579-022-00846-2.

Davis, Leah, Megan Higgs, Alice Snaith, Tiffany A. Lodge, Jessica Strong, José Antonio Espejo-Oltra, Slawomir Kujawski, et al. 2025. “Dysregulation of Lipid Metabolism, Energy Production, and Oxidative Stress in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Gulf War Syndrome and Fibromyalgia.” Frontiers in Neuroscience 19: 1498981. https://doi.org/10.3389/fnins.2025.1498981.

Dayal, Monika, Maulin S. Shah, Niloofar Radfar, Smit Patel, and Roshny Thomas. 2025. “Multimodal Management of Supine Hypertension with Orthostatic Hypotension in an Elderly Male Patient with Parkinson’s Disease.” Cureus 17 (4): e82394. https://doi.org/10.7759/cureus.82394.

De la Fuente Muñoz, Marina, Marta Román-Carmena, Sara Amor, Ángel L García-Villalón, Ana E Espinel, Daniel González-Hedström, and Miriam Granado García. 2023. “Effects of Supplementation with the Standardized Extract of Saffron (Affron) on the Kynurenine Pathway and the Synthesis of Melatonin in Rats.” Antioxidants (Basel) 12 (8): 1619. https://doi.org/10.3390/antiox12081619.

De Monte, Celeste, Simone Carradori, Paola Chimenti, Daniela Secci, Luisa Mannina, Federica Alcaro, Anél Petzer, Chunderika N’Da, et al. 2014. “New Insights into the Biological Properties of Crocus sativus l.: Chemical Modifications, Human Monoamine Oxidases Inhibition and Molecular Modeling.” European Journal of Medicinal Chemistry 82: 164–71. https://doi.org/10.1016/j.ejmech.2014.05.038.

Debourdeau, Antoine, Jean-Michel Gonzalez, Florence Mathias, Christophe Prost, Marc Barthet, and Véronique Vitton. 2024. “Gastric Volumetry for the Assessment of Fundic Compliance and Visceral Hypersensitivity in Patients with Gastroparesis: A Retrospective Comparative Study.” Scandinavian Journal of Gastroenterology 59 (3): 254–59. https://doi.org/10.1080/00365521.2023.2279928.

DecodeME Consortium, Chris P Ponting, et al. 2025. “Initial Findings from the DecodeME Genome-Wide Association Study of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” medRxiv. https://doi.org/10.1101/2025.08.06.25333109v1.

Dodge-Kafka, Kimberly L., Matthew G. Turcotte, Stephanie M. Possidento, et al. 2026. “Β-Adrenergic Receptors: Not Always Outside-in.” Physiology 41 (4). https://doi.org/10.1152/physiol.00026.2025.

Domingo, Joan Carles, Federica Battistini, Begona Cordobilla, Maria Cleofe Zaragoza, Ramon Sanmartin-Sentanes, Jose Alegre-Martin, Trinitat Cambras, and Jesus Castro-Marrero. 2024. “Association of Circulating Biomarkers with Illness Severity Measures Differentiates Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post-COVID-19 Condition: A Prospective Pilot Cohort Study.” Journal of Translational Medicine 22 (1): 343. https://doi.org/10.1186/s12967-024-05148-0.

Due Bruun, Karin, Robin Christensen, Kirstine Amris, Henrik Bjarke Vaegter, Morten Rune Blichfeldt-Eckhardt, L. Bye-Møller, Anders Holsgaard-Larsen, and Palle Toft. 2024. “Naltrexone 6 Mg Once Daily Versus Placebo in Women with Fibromyalgia: A Randomised, Double-Blind, Placebo-Controlled Trial.” The Lancet Rheumatology 6 (1): e31–39. https://doi.org/10.1016/S2665-9913(23)00278-3.

Duffy, Brynne M, James F Staples, and Shannon N Tessier. 2022. “Arousal from Torpor Increases Oxidative Damage in the Hibernating Thirteen-Lined Ground Squirrel (Ictidomys Tridecemlineatus).” Physiological and Biochemical Zoology 95 (3): 229–38. https://doi.org/10.1086/719931.

Eaton-Fitch, Natalie, and Sonya Marshall-Gradisnik. 2026. “Australian Registry Reports Poor Health and Wellbeing in People Living with ME/CFS.” Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08618-9.

Eckey, Macy, Peng Li, Brett Morrison, Jonas Bergquist, Ronald W. Davis, and Wenzhong Xiao. 2025. “Patient-Reported Treatment Outcomes in ME/CFS and Long COVID.” Proceedings of the National Academy of Sciences 122 (28): e2426874122. https://doi.org/10.1073/pnas.2426874122.

Eggelbusch, Moritz, Braeden T. Charlton, Alessandra Bosutti, Bergita Ganse, Ifigeneia Giakoumaki, Anita E. Grootemaat, Paul W. Hendrickse, et al. 2024. “The Impact of Bed Rest on Human Skeletal Muscle Metabolism.” Cell Reports Medicine 5 (1): 101372. https://doi.org/10.1016/j.xcrm.2023.101372.

Eriksson, Peter S., Ekaterina Perfilieva, Thomas Björk-Eriksson, Ann-Marie Alborn, Claes Nordborg, Daniel A. Peterson, and Fred H. Gage. 1998. “Neurogenesis in the Adult Human Hippocampus.” Nature Medicine 4 (11): 1313–17. https://doi.org/10.1038/3305.

Esteban, David J., Brynn Conrad, Autumn Cullinan, Sharon Luong, Jason Albaum, and Victoria Wilk. 2026. “Tryptophan Metabolism and Aryl-Hydrocarbon Receptor Agonists in the Gut Microbiome of People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” MicrobiologyOpen 15 (3): e70333. https://doi.org/10.1002/mbo3.70333.

Everly, Michael J., Pamela C. Heaton, and Jr. Cluxton Robert J. 2004. “Beta-Blocker Underuse in Secondary Prevention of Myocardial Infarction.” Annals of Pharmacotherapy 38 (2): 286–93. https://doi.org/10.1345/aph.1C472.

Faber, Chelsea L., Jennifer D. Deem, Bao Anh Phan, Tammy P. Doan, Kayoko Ogimoto, Zaman Mirzadeh, Michael W. Schwartz, and Gregory J. Morton. 2021. “Leptin Receptor Neurons in the Dorsomedial Hypothalamus Regulate Diurnal Patterns of Feeding, Locomotion, and Metabolism.” eLife 10: e63671. https://doi.org/10.7554/eLife.63671.

Fatt, Scott J., Jessica E. Beilharz, Michelle Joubert, Chloe Wilson, Andrew R. Lloyd, Ute Vollmer-Conna, and Erin Cvejic. 2020. “Parasympathetic Activity Is Reduced During Slow-Wave Sleep, but Not Resting Wakefulness, in Patients with Chronic Fatigue Syndrome.” Journal of Clinical Sleep Medicine 16 (1): 19–28. https://doi.org/10.5664/jcsm.8114.

Feng, Yuqing, and Yun Lu. 2021. “Immunomodulatory Effects of Dopamine in Inflammatory Diseases.” Frontiers in Immunology 12: 663102. https://doi.org/10.3389/fimmu.2021.663102.

Fernández-Castañeda, Anthony, Peiwen Lu, Anna C. Geraghty, Eric Song, Myoung-Hwa Lee, Jamie Wood, Michael R. O’Dea, et al. 2022. “Mild Respiratory COVID Can Cause Multi-Lineage Neural Cell and Myelin Dysregulation.” Cell 185 (14): 2452–68. https://doi.org/10.1016/j.cell.2022.06.008.

Fernández-Garibay, Xavi, Manuel Gómez-Florit, Rui M. A. Domingues, Manuela E. Gomes, Juan M. Fernández-Costa, and Javier Ramón-Azcón. 2022. “Xeno-Free Bioengineered Human Skeletal Muscle Tissue Using Human Platelet Lysate-Based Hydrogels.” Biofabrication 14 (4). https://doi.org/10.1088/1758-5090/ac8dc8.

Fesharaki-Zadeh, Arman, Timothy Belliveau, Robert H. Pietrzak, and Amy Arnsten. 2025. “A Novel Multimodal Pharmacologic Approach Using Guanfacine, N-Acetylcysteine, and Donepezil in Severe TBI: A Case Series.” Frontiers in Rehabilitation Sciences 6: 1648002. https://doi.org/10.3389/fresc.2025.1648002.

Fesharaki-Zadeh, Arman, Naomi Lowe, and Amy F. T. Arnsten. 2023. “Clinical Experience with the $\alpha$2A-Adrenoceptor Agonist, Guanfacine, and N-Acetylcysteine for the Treatment of Cognitive Deficits in Long-COVID19.” Neuroimmunology Reports 3: 100154. https://doi.org/10.1016/j.nerep.2022.100154.

Finlay, David B., Stephen B. Duffull, and Michelle Glass. 2020. “100 Years of Modelling Ligand–Receptor Binding and Response: A Focus on GPCRs.” British Journal of Pharmacology 177 (7): 1501–20. https://doi.org/10.1111/bph.14907.

Fleury, Samantha T., Xuanyi Lin, Peter D. Rios, Christopher Olker, Eun Joo Song, Alejandra Cobos Perez, Cody Fell, et al. 2026. “Encapsulated Leptin-Producing Cells Facilitate Entrainment of Circadian Rhythms in Rodents and Nonhuman Primates.” Advanced Science, e77191. https://doi.org/10.1002/advs.77191.

Fluge, Øystein, Olav Mella, Ove Bruland, Kristin Risa, Sissel E. Dyrstad, Kine Alme, Ingrid G. Rekeland, et al. 2016. “Metabolic Profiling Indicates Impaired Pyruvate Dehydrogenase Function in Myalgic Encephalopathy/Chronic Fatigue Syndrome.” JCI Insight 1 (21): e89376. https://doi.org/10.1172/jci.insight.89376.

Fu, Qi, Tiffany B VanGundy, Shigeki Shibata, Richard J Auchus, Gordon H Williams, and Benjamin D Levine. 2010. “Menstrual Cycle Affects Renal-Adrenal and Hemodynamic Responses During Prolonged Standing in the Postural Orthostatic Tachycardia Syndrome.” Hypertension 56 (1): 82–90. https://doi.org/10.1161/HYPERTENSIONAHA.110.151787.

Galbo, Henrik, and Lisbeth Kall. 2016. “Circadian Variations in Clinical Symptoms and Concentrations of Inflammatory Cytokines, Melatonin, and Cortisol in Polymyalgia Rheumatica Before and During Prednisolone Treatment: A Controlled, Observational, Clinical Experimental Study.” Arthritis Research & Therapy 18: 174. https://doi.org/10.1186/s13075-016-1072-4.

Gao, Jingwei, Cong Lin, Lehua Deng, Hongshuang Wang, and Xiaohui Wang. 2025. “Nanomolar TLR4 Antagonist CIAC101 Derived from (+)-Naltrexone Blocks Microglial Activation and Methamphetamine Addiction.” Journal of Medicinal Chemistry 68 (23): 25469–84. https://doi.org/10.1021/acs.jmedchem.5c02596.

García-Abellán, J. et al. 2021. “Antibody Response to SARS-CoV-2 Is Associated with Long-Term Clinical Outcome in Patients with COVID-19: A Longitudinal Study.” Journal of Clinical Immunology 41 (7): 1490–1501. https://doi.org/10.1007/s10875-021-01077-7.

Germain, Arnaud, Katherine A. Glass, Mary A. Eckert, Ludovic Giloteaux, and Maureen R. Hanson. 2025. “Temporal Dynamics of the Plasma Proteomic Landscape Reveals Maladaptation in ME/CFS Following Exertion.” Molecular & Cellular Proteomics 24 (12): 101467. https://doi.org/10.1016/j.mcpro.2025.101467.

Gerolymos, Cyril, Enzo Saddier, Laurent Boyer, and Guillaume Fond. 2026. “Cognitive and Affective Effects of l-Theanine: A Systematic Review and Meta-Analysis of 31 Randomized Trials.” Molecular Psychiatry. https://doi.org/10.1038/s41380-026-03727-9.

Gimbach, Silke, Daniel Vogel, Rainer Fried, Stephen V. Faraone, Tobias Banaschewski, Jan Buitelaar, Manfred Döpfner, and Ruth Ammer. 2024. “ADHD Medicine Consumption in Europe After COVID-19: Catch-up or Trend Change?” BMC Psychiatry 24 (1): 112. https://doi.org/10.1186/s12888-024-05505-9.

Giménez-Orenga, Karen, Eva Martín-Martínez, Lubov Nathanson, and Elisa Oltra. 2025. “HERV Activation Segregates ME/CFS from Fibromyalgia While Defining a Novel Nosologic Entity.” eLife 14: RP104441. https://doi.org/10.7554/eLife.104441.

Godlewska, Beata R., Amy L. Sylvester, Uzay E. Emir, Ann L. Sharpley, William T. Clarke, Stephen R. Williams, Ana Jorge Gonçalves, and Philip J. Cowen. 2025. “Brain and Muscle Chemistry in Myalgic Encephalitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID: A 7T Magnetic Resonance Spectroscopy Study.” Molecular Psychiatry 30: 5215–26. https://doi.org/10.1038/s41380-025-03108-8.

Goebel, A., K. Busch, R. Riedl, and C. Sommer. 2021. “Passive Transfer of Fibromyalgia IgG Induces Pain and Fatigue in Mice.” Pain 162 (4): 893–904. https://doi.org/10.1097/j.pain.0000000000002134.

Granerod, Julia, Nicholas W. S. Davies, Parashar P. Ramanuj, Ava Easton, David W. Brown, and Sara L. Thomas. 2017. “Increased Rates of Sequelae Post-Encephalitis in Individuals Attending Primary Care Practices in the United Kingdom: A Population-Based Retrospective Cohort Study.” Journal of Neurology 264 (2): 407–15. https://doi.org/10.1007/s00415-016-8316-8.

Grover, Madhusudan, Gianrico Farrugia, Matthew S. Lurken, Cheryl E. Bernard, Maria-Simonetta Faussone-Pellegrini, et al. 2011. “Cellular Changes in Diabetic and Idiopathic Gastroparesis.” Gastroenterology 140 (5): 1575–1585.e8. https://doi.org/10.1053/j.gastro.2011.01.046.

Guarnotta, Valentina, Roberta Amodei, and Carla Giordano. 2021. “Metabolic Comorbidities of Adrenal Insufficiency: Focus on Steroid Replacement Therapy and Chronopharmacology.” Current Opinion in Pharmacology 60: 123–32. https://doi.org/10.1016/j.coph.2021.07.003.

Gürbüzer, Nazan, Ahmet Ozkaya, and Filiz Mercantepe. 2026. “The SIRT-1/Nrf-2/HO-1 Antioxidant Defense Axis in Adult Attention-Deficit/Hyperactivity Disorder.” Metabolic Brain Disease 41 (1). https://doi.org/10.1007/s11011-026-01845-5.

Habermann-Horstmeier, Lotte, and Lukas M. Horstmeier. 2025. “Symptom Clusters in ME/CFS Reflect Distinct Neuroimmune and Autonomic Pathophysiological Mechanisms: A Translational Model.” Journal of Translational Medicine 24 (1): 606. https://doi.org/10.1186/s12967-026-08159-1.

Hadanny, Amir, Shani Zilberman-Itskovich, Marat Catalogna, Keren Elman-Shina, Elad Lang, Shachar Finci, Natalie Polak, Rachel Shorer, Yonatan Parag, and Shai Efrati. 2024. “Long Term Outcomes of Hyperbaric Oxygen Therapy in Post Covid Condition: Longitudinal Follow-up of a Randomized Controlled Trial.” Scientific Reports 14 (1): 3604. https://doi.org/10.1038/s41598-024-53091-3.

Hadidchi, Ramin, Bonny Patel, Jay Madan, Andrew Liu, Sean Henry, and Tim Q. Duong. 2025. “Elevated Risk of New-Onset Chronic Fatigue Syndrome/Myalgic Encephalomyelitis up to Four Years After SARS-CoV-2 Infection.” Journal of Translational Medicine 23 (1): 815. https://doi.org/10.1186/s12967-025-06625-w.

Hajhashemy, Zahra, Mohammad Bagherniya, and Omid Sadeghi. 2026. “The Effect of Saffron Supplementation on Indices of Oxidative Stress, Inflammation, Mental Health, and Quality of Life in Patients with Parkinson’s Disease.” Food & Function 17 (2): 889–901. https://doi.org/10.1039/d5fo01924a.

Hanson, Aimee L., Matthew P. Mulè, Hélène Ruffieux, Federica Mescia, Laura Bergamaschi, Victoria S. Pelly, Lorinda Turner, et al. 2024. “Iron Dysregulation and Inflammatory Stress Erythropoiesis Associates with Long-Term Outcome of COVID-19.” Nature Immunology 25 (3): 471–82. https://doi.org/10.1038/s41590-024-01754-8.

Hazrati, Ebrahim, Seyed Parsa Eftekhar, Reza Mosaed, et al. 2024. “Understanding the Kynurenine Pathway: A Narrative Review on Its Impact Across Chronic Pain Conditions.” Molecular Pain 20: 17448069241297714. https://doi.org/10.1177/17448069241297714.

He, Jiabao, Kieren G. Hollingsworth, Julia L. Newton, and Andrew M. Blamire. 2013. “Cerebral Vascular Control Is Associated with Skeletal Muscle pH in Chronic Fatigue Syndrome Patients Both at Rest and During Dynamic Stimulation.” NeuroImage: Clinical 2: 168–73. https://doi.org/10.1016/j.nicl.2012.12.006.

Heneka, Michael T., Wiesje M. van der Flier, Frank Jessen, Jeroen Hoozemans, Dietmar R. Thal, Delphine Boche, Frederic Brosseron, Charlotte Teunissen, Henrik Zetterberg, et al. 2025. “Neuroinflammation in Alzheimer Disease.” Nature Reviews Immunology 25 (5): 321–52. https://doi.org/10.1038/s41577-024-01104-7.

Heneka, Michael T., Markus P. Kummer, Andrea Stutz, Andrea Delekate, Stephanie Schwartz, Ana Vieira-Saecker, Angelika Griep, et al. 2013. “NLRP3 Is Activated in Alzheimer’s Disease and Contributes to Pathology in APP/PS1 Mice.” Nature 493 (7434): 674–78. https://doi.org/10.1038/nature11729.

Heng, Ruiwen Benjamin, Bavani Gunasegaran, Shivani Krishnamurthy, Sonia Bustamante, Ananda Staats, Sharron Chow, Seong Beom Ahn, et al. 2025. “Mapping the Complexity of ME/CFS: Evidence for Abnormal Energy Metabolism, Altered Immune Profile, and Vascular Dysfunction.” Cell Reports Medicine 6 (12): 102514. https://doi.org/10.1016/j.xcrm.2025.102514.

Hermida, Ramón C, Michael H Smolensky, Howard Balan, Richard J Castriotta, Juan J Crespo, Yaron Dagan, Sherine El-Toukhy, et al. 2021. “Guidelines for the Design and Conduct of Human Clinical Trials on Ingestion-Time Differences — Chronopharmacology and Chronotherapy — of Hypertension Medications.” Chronobiology International 38 (1): 1–26. https://doi.org/10.1080/07420528.2020.1850468.

Hickie, Ian, Tracey Davenport, Denis Wakefield, Ute Vollmer-Conna, Barbara Cameron, Suzanne D Vernon, William C Reeves, and Andrew Lloyd. 2006. “Post-Infective and Chronic Fatigue Syndromes Precipitated by Viral and Non-Viral Pathogens: Prospective Cohort Study.” BMJ 333 (7568): 575. https://doi.org/10.1136/bmj.38933.585764.AE.

Hoel, August, Fredrik Hoel, Sissel Elisabeth Dyrstad, Henrique Chapola, Ingrid Gurvin Rekeland, Kristin Risa, Kine Alme, et al. 2026. “Charting the Circulating Proteome in ME/CFS Using Cross-System Profiling to Uncover Mechanistic Insights.” Cell Reports Medicine 7 (March): 102647. https://doi.org/10.1016/j.xcrm.2026.102647.

Horvath, Audrey E, Miriam Grozis, Peter R S Baker, et al. 2026. “Saffron Alters Microbial Amino Acid Metabolism and Neurotransmitter Production in a Defined Gut Consortium.” Food Science & Nutrition 14 (4): e71694. https://doi.org/10.1002/fsn3.71694.

Hrvatin, S, S Sun, O F Wilcox, H Yao, A J Lavin-Peter, M Cicconet, E G Assad, et al. 2020. “Neurons That Regulate Mouse Torpor.” Nature 583 (7814): 115–21. https://doi.org/10.1038/s41586-020-2387-5.

Hunstiger, Moriah, Maren M Johannsen, and Shawn R Oliver. 2023. “Non-Shivering Thermogenesis Is Differentially Regulated During the Hibernation Season in Arctic Ground Squirrels.” Frontiers in Physiology 14: 1207529. https://doi.org/10.3389/fphys.2023.1207529.

Hunter, Ewan, Heba Alshaker, Oliver Bundock, Cicely Weston, Shekinah Bautista, Abel Gebregzabhar, Anya Virdi, et al. 2025. “Development and Validation of Blood-Based Diagnostic Biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Using EpiSwitch® 3-Dimensional Genomic Regulatory Immuno-Genetic Profiling.” Journal of Translational Medicine 23 (1): 1010. https://doi.org/10.1186/s12967-025-07203-w.

Institute of Medicine. 2015. “Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness.” The National Academies Press. https://doi.org/10.17226/19012.

Ising, Christina, Carmen Venegas, Shuangshuang Zhang, Hannah Scheiblich, Susanne V. Schmidt, Ana Vieira-Saecker, Stephanie Schwartz, et al. 2019. “NLRP3 Inflammasome Activation Drives Tau Pathology.” Nature 575 (7784): 669–73. https://doi.org/10.1038/s41586-019-1769-z.

Jahanshahi, Arash, Sina Mohammadi, Mohammad Amin Salehi, Mahsa Dolatshahi, et al. 2026. “Brain Microstructural Alterations in COVID-19: A Systematic Review of Diffusion Weighted Imaging Studies.” Brain Imaging and Behavior 20 (2): 49. https://doi.org/10.1007/s11682-026-01084-3.

Jason, L. A., W. J. McGarrigle, and R. C. W. Vermeulen. 2024. “The Head-up Tilt Table Test as a Measure of Autonomic Functioning Among Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Personalized Medicine 14 (3): 238. https://doi.org/10.3390/jpm14030238.

Jason, Leonard A, Jasmine A Dorri, Benjamin H Natelson, Lucinda Bateman, and Suzanne D Vernon. 2025. “Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A RECOVER-Adult Study.” Journal of General Internal Medicine. https://doi.org/10.1007/s11606-024-09290-9.

Jason, Leonard A., Meredyth Evans, Suzanna So, Jodie Scott, and Abigail Brown. 2015. “Problems in Defining Post-Exertional Malaise.” Journal of Prevention and Intervention in the Community 43 (1): 20–31. https://doi.org/10.1080/10852352.2014.973239.

Javonillo, Dominic I., S. Furman, L. Le, K. Fernandez, J. Mulford, V. Singla, R. Jha, et al. 2026. “Characterization of Effects of a Neurotropic Murine Coronavirus Infection on Alzheimer’s Disease Neuropathology of 5xFAD Mice.” bioRxiv. https://doi.org/10.64898/2026.02.23.707587.

Jensen, Federico, Mariana Woudwyk, Ana Teles, Katja Woidacki, Florin Taran, Sonia Costa, Sara F Malfertheiner, and Ana Claudia Zenclussen. 2010. “Estradiol and Progesterone Regulate the Migration of Mast Cells from the Periphery to the Uterus and Induce Their Maturation and Degranulation.” PLoS ONE 5 (12): e14409. https://doi.org/10.1371/journal.pone.0014409.

Jobava, Raul, Yuanhui Mao, Bo-Jhih Guan, Dawei Hu, Dawid Krokowski, Chih-Wei Chen, Xing-En Shu, et al. 2021. “Adaptive Translational Pausing Is a Hallmark of the Cellular Response to Severe Environmental Stress.” Molecular Cell 81 (20): 4191–4208.e8. https://doi.org/10.1016/j.molcel.2021.09.029.

Johnston, K. J. A., R. Signer, and L. M. Huckins. 2025. “Chronic Overlapping Pain Conditions and Nociplastic Pain.” HGG Advances 6 (1): 100381. https://doi.org/10.1016/j.xhgg.2024.100381.

Joseph, Phillip, Claudia Arevalo, Rudolf K. F. Oliveira, Mariana Faria-Urbina, Aaron B. Waxman, and David M. Systrom. 2021. “Insights from Invasive Cardiopulmonary Exercise Testing of Patients with ME/CFS.” Chest 160 (2): 642–51. https://doi.org/10.1016/j.chest.2021.01.082.

Jovanovic, Hristina, Per Karlsson, Asa Cerin, Christer Halldin, and Anna-Lena Nordström. 2009. “5-HT(1A) Receptor and 5-HTT Binding During the Menstrual Cycle in Healthy Women Examined with [(11)C] WAY100635 and [(11)C] MADAM PET.” Psychiatry Research: Neuroimaging 172 (1): 31–37. https://doi.org/10.1016/j.pscychresns.2008.07.002.

Kahathuduwa, Chanaka N., Sarah Wakefield, Blake D. West, Jessica Blume, Tharaka Lagath Dassanayake, Vajira S. Weerasinghe, and Ann Mastergeorge. 2020. “Effects of l-Theanine-Caffeine Combination on Sustained Attention and Inhibitory Control Among Children with ADHD: A Proof-of-Concept Neuroimaging RCT.” Scientific Reports 10 (1): 13072. https://doi.org/10.1038/s41598-020-70037-7.

Kavyani, Bahar, Seong Beom Ahn, Daniel Missailidis, Sarah J. Annesley, Paul R. Fisher, Richard Schloeffel, Gilles J. Guillemin, David B. Lovejoy, and Benjamin Heng. 2024. “Dysregulation of the Kynurenine Pathway, Cytokine Expression Pattern, and Proteomics Profile Link to Symptomology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Molecular Neurobiology 61 (7): 3771–87. https://doi.org/10.1007/s12035-023-03784-z.

Kavyani, Behrouz, Seong Beom Ahn, Daniel Missailidis, Sarah J. Annesley, Paul R. Fisher, Gilles J. Guillemin, et al. 2024. “Dysregulation of the Kynurenine Pathway, Cytokine Expression Pattern, and Proteomics Profile Link to Symptomology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Molecular Neurobiology 61 (7): 4728–48. https://doi.org/10.1007/s12035-023-03756-w.

Kavyani, Zahra, Ekua W Brenu, Donald R Staines, and Sonya M Marshall-Gradisnik. 2022. “Kynurenine Pathway Metabolites in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review.” Journal of Translational Medicine 20 (1): 512. https://doi.org/10.1186/s12967-022-03712-3.

Kerrebijn, Isabel, Gyda Bjornsdottir, Keon Arbabi, Lea Urpa, Hele Haapaniemi, Gudmar Thorleifsson, Lilja Stefansdottir, et al. 2026. “The Genetic Architecture of Fibromyalgia Across 2.5 Million Individuals.” Nature Medicine 32 (8): 3060–70. https://doi.org/10.1038/s41591-026-04492-6.

Khasnavis, Siddharth, Timothy Belliveau, Amy Arnsten, and Arman Fesharaki-Zadeh. 2024. “Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury.” Neurotrauma Reports 5 (1): 226–31. https://doi.org/10.1089/neur.2023.0124.

Kielland, Anne, Jing Liu, and Leonard A. Jason. 2023. “Do Diagnostic Criteria for ME Matter to Patient Experience with Services and Interventions? Key Results from an Online RDS Survey Targeting Fatigue Patients in Norway.” Journal of Health Psychology 28 (13): 1189–1203. https://doi.org/10.1177/13591053231169191.

Kim, Hyeonwoo, Christiane D. Wrann, Mark Jedrychowski, Sara Vidoni, Yukiko Kitase, Kenichi Nagano, Chenhe Zhou, et al. 2018. “Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors.” Cell 175 (7): 1756–1768.e17. https://doi.org/10.1016/j.cell.2018.10.025.

Klein, Jon, Jamie Wood, Jillian R. Jaycox, Rahul M. Dhodapkar, Peiwen Lu, Jeff R. Gehlhausen, Alexandra Tabachnikova, et al. 2023. “Distinguishing Features of Long COVID Identified Through Immune Profiling.” Nature 623 (7985): 139–48. https://doi.org/10.1038/s41586-023-06651-y.

Knadler, Mary Pat, Evelyn Lobo, Jill Chappell, and Richard Bergstrom. 2011. “Duloxetine: Clinical Pharmacokinetics and Drug Interactions.” Clinical Pharmacokinetics 50 (5): 281–94. https://doi.org/10.2165/11539240-000000000-00000.

Komaroff, Anthony L, and Robert Dantzer. 2025. “Causes of Symptoms and Symptom Persistence in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Cell Reports Medicine 6 (8): 102259. https://doi.org/10.1016/j.xcrm.2025.102259.

Koonce, Rachel M., and Bradley C. Martin. 2024. “The Association Between Suspected Long-COVID and Stimulant Prescribing in the United States.” Psychiatry Research 331: 115686. https://doi.org/10.1016/j.psychres.2023.115686.

Krishnan, Kalpana, Ying Lin, Kim R. M. Prewitt, and David A. Potter. 2022. “Multidisciplinary Approach to Brain Fog and Related Persisting Symptoms Post COVID-19.” Journal of Health Service Psychology 48 (1): 31–38. https://doi.org/10.1007/s42843-022-00056-7.

Kuczyk, Christina, Martina Nöhre, Christoph Herrmann-Lingen, Maike Stolz, Christian Krauth, Elmar Brähler, Leonard A. Jason, and Martina de Zwaan. 2025. “Reliability and Validity of the German Version of the DePaul Symptom Questionnaire Post-Exertional Malaise (DSQ-PEM).” Frontiers in Psychiatry 16: 1647040. https://doi.org/10.3389/fpsyt.2025.1647040.

Kuring, J. K., J. L. Mathias, L. Ward, and G. Tachas. 2023. “Inflammatory Markers in Persons with Clinically-Significant Depression, Anxiety or PTSD: A Systematic Review and Meta-Analysis.” Journal of Psychiatric Research 168: 279–92. https://doi.org/10.1016/j.jpsychires.2023.10.009.

———. 2026. “Inflammatory Markers Associated with Dementia: A Systematic Review and Meta-Analysis.” Journal of Psychiatric Research 197: 26–40. https://doi.org/10.1016/j.jpsychires.2026.02.044.

Kurmashev, Rustem. 2026. “UBE3A Dosage Imbalance as a Molecular Framework Linking Angelman Syndrome and Dup15q-Associated Autism Phenotypes.” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. https://doi.org/10.1002/ajmg.b.70025.

Le, T., H. J. Kim, Y. Chen, Q. Zhang, X. Wang, Y. Liu, M. Zhou, J. Wu, S. Li, and Z. Xu. 2025. “The eIF2alpha-ATF4 Axis Regulates Mitochondrial Dynamics and Bioenergetics During ER Stress.” Cell Metabolism 35 (4): 678–695.e8. https://doi.org/10.1016/j.cmet.2025.01.012.

Lee, Eui-Cheol, Keon Kim, Sojin Kim, Minju Kim, and Hyoung-Pyo Kim. 2025. “3D Enhancer Architecture Coordinated by CTCF Determines Immune-Related Gene Expression Patterns via RNA Polymerase II Pause-Release in CD4+ T Cells.” Nucleic Acids Research 53 (22): gkaf1404. https://doi.org/10.1093/nar/gkaf1404.

Lee, Ji-Sook, Eliana Lacerda, Caroline Kingdon, Erik Abken, Gaia Susannini, Hazel M. Dockrell, Luis Nacul, and Jacqueline M. Cliff. 2025. “Abnormal T-Cell Activation and Cytotoxic T-Cell Frequency Discriminate Symptom Severity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Translational Medicine 23: 669. https://doi.org/10.1186/s12967-025-07507-x.

Lee, Soo-Yeon, Soo-Jin Oh, Kyung-Uk Yun, Ho-Min Kim, Bong-Hee Kim, Kiho Lee, and Sang-Kyum Kim. 2012. “Expression of Hepatic and Ovarian Cytochrome P450 During Estrous Cycle in Rats.” Archives of Toxicology 86 (1): 75–85. https://doi.org/10.1007/s00204-011-0730-1.

Leemburg, Simone, Andrea Kala, Amita Nataraj, Petra Karkusova, et al. 2025. “LPS-Induced Systemic Inflammation Disrupts Brain Activity in a Region- and Vigilance-State Specific Manner.” Brain, Behavior, and Immunity 120: 12–24. https://doi.org/10.1016/j.bbi.2025.05.002.

Lévi, Francis A, Alper Okyar, Eva Hadadi, Pasquale F Innominato, and Annabelle Ballesta. 2024. “Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy.” Annual Review of Pharmacology and Toxicology 64: 89–114. https://doi.org/10.1146/annurev-pharmtox-051920-095416.

Lim, Eun-Jin, and Chang-Gue Son. 2020. “Review of Case Definitions for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Journal of Translational Medicine 18 (1): 289. https://doi.org/10.1186/s12967-020-02455-0.

Lin, L., Y. Li, F. Ji, J. Lin, M. Zhu, D. Liang, M. Cao, G. Fu, and Y. Fu. 2026. “Shared Latent Genetic Liability Across Fibromyalgia and Psychiatric Traits: Novel Insights from Genomic Structural Equation Modeling.” PLoS Genetics 22 (1): e1012034. https://doi.org/10.1371/journal.pgen.1012034.

Lipworth, Brian J., and Allison Grove. 1997. “Evaluation of Partial Beta-Adrenoceptor Agonist Activity.” British Journal of Clinical Pharmacology 43 (1): 9–14. https://doi.org/10.1111/j.1365-2125.1997.tb00025.x.

Liu, Philip Z., David M. Raizen, Carsten Skarke, Thomas G. Brooks, and Ron C. Anafi. 2025. “Genetic Variants Associated with Chronic Fatigue Syndrome Predict Population-Level Fatigue Severity and Actigraphic Measurements.” Sleep 48 (2): zsae243. https://doi.org/10.1093/sleep/zsae243.

Livieratos, Achilleas, Steven W Lockley, and Sotirios Tsiodras. 2025. “Post Infectious Fatigue and Circadian Rhythm Disruption in long-COVID and Other Infections: A Need for Further Research.” EClinicalMedicine 80: 103073. https://doi.org/10.1016/j.eclinm.2025.103073.

Locci, Andrea, and Graziano Pinna. 2017. “Neurosteroid Biosynthesis down-Regulation and Changes in GABA(A) Receptor Subunit Composition: A Biomarker Axis in Stress-Induced Cognitive and Emotional Impairment.” British Journal of Pharmacology 174 (19): 3226–41. https://doi.org/10.1111/bph.13843.

Lu, Yuanqing, Xiang Li, Daoying Geng, Nan Mei, et al. 2020. “Cerebral Micro-Structural Changes in COVID-19 Patients – an MRI-Based 3-Month Follow-up Study.” EClinicalMedicine 25: 100484. https://doi.org/10.1016/j.eclinm.2020.100484.

Maccallini, P. 2026. “Biological Insights from Genome-Wide Association Studies and Whole Genome Sequencing of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome.” Research Square [Preprint], June. https://doi.org/10.21203/rs.3.rs-9702020/v1.

Machado, N L S, N Lynch, L H A Costa, D Melville, H Kucukdereli, S Kaur, et al. 2025. “Preoptic EP3R Neurons Constitute a Two-Way Switch for Fever and Torpor.” Nature 644 (8076): 463–72. https://doi.org/10.1038/s41586-025-09056-1.

Maguire, Cole, Jing Chen, Nadine Rouphael, Brinkley A. Morse, Annmarie Hoch, Harry Pickering, Hoang Van Phan, et al. 2026. “Virus Reactivation in Acute and Long COVID-19.” Nature.

Mahad, Don H., Bruce D. Trapp, and Hans Lassmann. 2015. “Pathological Mechanisms in Progressive Multiple Sclerosis.” Lancet Neurology 14 (2): 183–93. https://doi.org/10.1016/S1474-4422(14)70256-X.

Maksoud, Reem, Stanley du Preez, Natalie Eaton-Fitch, Kiran Thapaliya, Leighton Barnden, Hélène Cabanas, Donald Staines, and Sonya Marshall-Gradisnik. 2020. “A Systematic Review of Neurological Impairments in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Using Neuroimaging Techniques.” PLoS One 15 (4): e0232475. https://doi.org/10.1371/journal.pone.0232475.

Malatji, Bontle G., Helgard Meyer, Shayne Mason, Udo F. H. Engelke, Ron A. Wevers, Mari van Reenen, and Carolus J. Reinecke. 2017. “A Diagnostic Biomarker Profile for Fibromyalgia Syndrome Based on an NMR Metabolomics Study of Selected Patients and Controls.” BMC Neurology 17 (1): 88. https://doi.org/10.1186/s12883-017-0863-9.

Markussen, Fredrik Andreas Falkenberg, Fernando Cázarez-Márquez, Vebjørn Jacobsen Melum, David G Hazlerigg, and Shona H Wood. 2024. “C-Fos Induction in the Choroid Plexus, Tanycytes and Pars Tuberalis Is an Early Indicator of Spontaneous Arousal from Torpor in a Deep Hibernator.” Journal of Experimental Biology 227 (10): jeb247224. https://doi.org/10.1242/jeb.247224.

Maughan, Ronald J., and Susan M. Shirreffs. 2019. “Muscle Cramping During Exercise: Causes, Solutions, and Questions Remaining.” Sports Medicine 49 (Suppl 2): 115–24. https://doi.org/10.1007/s40279-019-01162-1.

May, Marcella, Sara F. Milrad, Dolores M. Perdomo, Sara J. Czaja, Mary Ann Fletcher, Devika R. Jutagir, Daniel L. Hall, Nancy Klimas, and Michael H. Antoni. 2020. “Post-Exertional Malaise Is Associated with Greater Symptom Burden and Psychological Distress in Patients Diagnosed with Chronic Fatigue Syndrome.” Journal of Psychosomatic Research 129: 109893. https://doi.org/10.1016/j.jpsychores.2019.109893.

McManimen, Stephanie L., Madison L. Sunnquist, and Leonard A. Jason. 2019. “Deconstructing Post-Exertional Malaise: An Exploratory Factor Analysis.” Journal of Health Psychology 24 (2): 188–98. https://doi.org/10.1177/1359105316664139.

Merzon, Eugene, Michael Weiss, Brian Krone, Shira Cohen, Galia Ilani, Shlomo Vinker, Avivit Cohen-Golan, et al. 2022. “Clinical and Socio-Demographic Variables Associated with the Diagnosis of Long COVID Syndrome in Youth: A Population-Based Study.” International Journal of Environmental Research and Public Health 19 (10): 5993. https://doi.org/10.3390/ijerph19105993.

Minzenberg, Michael J, and Cameron S Carter. 2008. “Modafinil: A Review of Neurochemical Actions and Effects on Cognition.” Neuropsychopharmacology 33 (7): 1477–1502. https://doi.org/10.1038/sj.npp.1301534.

Moffitt, Terrie E, Renate Houts, Philip Asherson, Daniel W Belsky, David L Corcoran, et al. 2015. “Is Adult ADHD a Childhood-Onset Neurodevelopmental Disorder? Evidence from a Four-Decade Longitudinal Cohort Study.” American Journal of Psychiatry 172 (10): 967–77. https://doi.org/10.1176/appi.ajp.2015.14101266.

Moghimi Dehkordi, Zohreh, Jamshid Salamzadeh, Maria Tavakoli-Ardakani, Atefeh Abedini, and Farzaneh Dastan. 2026. “Efficacy of a Saffron-Based (Crocus sativus l.) Herbal Supplement on Sleep Disturbances in Pulmonary Sarcoidosis Patients.” Iranian Journal of Pharmaceutical Research 25 (1): e169041. https://doi.org/10.5812/ijpr-169041.

Mohammadi, Sajad, Mostafa Naseri, Niloofar Faridi, Parisa Zareie, Leila Zare, Javad Mirnajafi-Zadeh, and S. Zahra Bathaie. 2023. “Saffron Carotenoids Reversed the UCMS-Induced Depression and Anxiety in Rats: Behavioral and Biochemical Parameters, and Inhibition of NMDA Receptor.” Phytomedicine 119: 154989. https://doi.org/10.1016/j.phymed.2023.154989.

Moldofsky, Harvey, and John Patcai. 2011. “Chronic Widespread Musculoskeletal Pain, Fatigue, Depression and Disordered Sleep in Chronic Post-SARS Syndrome; a Case-Controlled Study.” BMC Neurology 11: 37. https://doi.org/10.1186/1471-2377-11-37.

Monchaux de Oliveira, Caroline, Adrien Vignault, Angèle Guille, et al. 2026. “Exploring the Neurofunctional Potential of Saffron Bioactives: From Mood-Related Behavioral Modulation to Brain Access of Its Compounds.” Food & Function 17 (6): 2800–2818. https://doi.org/10.1039/d5fo04830c.

Montalvo, Mithil, Priya Nallapaneni, Sara Hassan, Samuel Nurko, Sean J. Pittock, et al. 2022. “Autoimmune Gastrointestinal Dysmotility Following SARS-CoV-2 Infection Successfully Treated with Intravenous Immunoglobulin.” Neurogastroenterology and Motility 34 (7): e14314. https://doi.org/10.1111/nmo.14314.

Montoya, Jose G, Tyson H Holmes, Jill N Anderson, Holden T Maecker, Yael Rosenberg-Hasson, Ian J Valencia, Lily Chu, Jarred W Younger, Cristina M Tato, and Mark M Davis. 2017. “Cytokine Signature Associated with Disease Severity in Chronic Fatigue Syndrome Patients.” Proceedings of the National Academy of Sciences 114 (34): E7150–58. https://doi.org/10.1073/pnas.1710519114.

Mueller, Chantal, James C. Lin, Sulaiman Sheriff, Andrew A. Maudsley, and Jarred W. Younger. 2020. “Evidence of Widespread Metabolite Abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome: Assessment with Whole-Brain Magnetic Resonance Spectroscopy.” Brain Imaging and Behavior 14 (2): 562–72. https://doi.org/10.1007/s11682-018-0029-4.

Mughal, Sheeza, Félix Andújar-Sánchez, Maria Sabater-Arcis, Glòria Garrabou, Joaquim Fernández-Solà, Jose Alegre-Martin, Ramon Sanmartin-Sentañes, et al. 2025. “Metabolic Adaptation and Fragility in Healthy 3D in Vitro Skeletal Muscle Tissues Exposed to Chronic Fatigue Syndrome and Long COVID-19 Sera.” Biofabrication 17 (4). https://doi.org/10.1088/1758-5090/adf66c.

Muñoz-Cruz, Samira, Yadira Mendoza-Rodríguez, Karen E Nava-Castro, Lilian Yepez-Mulia, and Jorge Morales-Montor. 2015. “Gender-Related Effects of Sex Steroids on Histamine Release and Fc$\epsilon$RI Expression in Rat Peritoneal Mast Cells.” Journal of Immunology Research 2015: 351829. https://doi.org/10.1155/2015/351829.

Murrough, James W., Xiangling Mao, Katherine A. Collins, Crystal Kelly, George Andrade, Paul Nestadt, Susan M. Levine, Sanjay J. Mathew, and Dikoma C. Shungu. 2010. “Increased Ventricular Lactate in Chronic Fatigue Syndrome Measured by 1H MRS Imaging at 3.0 t. II: Comparison with Major Depressive Disorder.” NMR in Biomedicine 23 (6): 643–50. https://doi.org/10.1002/nbm.1512.

Nakatomi, Yasuhito, Kei Mizuno, Akemi Ishii, Yasuhiro Wada, Masaaki Tanaka, Shusaku Tazawa, Kayo Onoe, et al. 2014. “Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study.” Journal of Nuclear Medicine 55 (6): 945–50. https://doi.org/10.2967/jnumed.113.131045.

Narita, Shin-ichiroh, Randall M Goldblum, Cheryl S Watson, Edward G Brooks, D Mark Estes, Edward M Curran, and Terumi Midoro-Horiuti. 2007. “Environmental Estrogens Induce Mast Cell Degranulation and Enhance IgE-Mediated Release of Allergic Mediators.” Environmental Health Perspectives 115 (1): 48–52. https://doi.org/10.1289/ehp.9378.

Natelson, B. H. et al. 2017. “Elevations of Ventricular Lactate Levels Occur in Both Chronic Fatigue Syndrome and Fibromyalgia.” Fatigue: Biomedicine, Health & Behavior 5 (1): 15–20. https://doi.org/10.1080/21641846.2017.1280114.

Nawarathna, Gayani Shashikala, Dinesh Ishara Ariyasinghe, Nadeeka Balasooriya, Asha Fernando, and Tharaka Lagath Dassanayake. 2026. “Effects of l-Theanine-Caffeine Combination on Selective Attention Among Adolescents with Attention-Deficit Hyperactivity Disorder: A Double-Blind, Placebo-Controlled, Crossover Study.” Nutritional Neuroscience, 1–14. https://doi.org/10.1080/1028415X.2026.2659148.

Neu, Daniel, Olivier Mairesse, Paul Verbanck, and Olivier Le Bon. 2015. “Slow Wave Sleep in the Chronically Fatigued: Power Spectra Distribution Patterns in Chronic Fatigue Syndrome and Primary Insomnia.” Clinical Neurophysiology 126 (10): 1926–33. https://doi.org/10.1016/j.clinph.2014.12.016.

Nielsen, Maria Juul, Henrik Bjarke Vaegter, and Karin Due Bruun. 2026. “Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial.” Pain Management Nursing. https://doi.org/10.1016/j.pmn.2026.07.020.

Nilsson, Ida, Jeremy Palmer, Eirini Apostolou, Carl G. Gottfries, Muhammad Rizwan, Charlotte Dahle, and Anders Rosén. 2020. “Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-Mitochondrial Antibodies.” Frontiers in Medicine 7: 108. https://doi.org/10.3389/fmed.2020.00108.

Novak, P., D. M. Systrom, A. Witte, S. P. Marciano, D. Felsenstein, J. M. Milunsky, A. Milunsky, J. Krier, and M. C. Fishman. 2026. “Shared Autonomic Phenotype of Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” PLoS One 21 (1): e0341278. https://doi.org/10.1371/journal.pone.0341278.

Ohdo, Shigehiro. 2021. “Chrono-Drug Discovery and Development Based on Circadian Rhythm of Molecular, Cellular and Organ Level.” Biological & Pharmaceutical Bulletin 44 (6): 747–61. https://doi.org/10.1248/bpb.b21-00277.

Okamoto, L. E., V. Urechie, S. Rigo, J. J. Abner, M. Giesecke, J. A. S. Muldowney, R. Furlan, et al. 2024. “Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine.” Hypertension 81 (11): 2237–47. https://doi.org/10.1161/HYPERTENSIONAHA.124.23035.

Okyar, Alper, Dilek Ozturk Civelek, Yasemin Kubra Akyel, Saliha Surme, Zeliha Pala Kara, and Ibrahim Halil Kavakli. 2024. “The Role of the Circadian Timing System on Drug Metabolism and Detoxification: An Update.” Expert Opinion on Drug Metabolism & Toxicology 20 (6): 503–17. https://doi.org/10.1080/17425255.2024.2356167.

Ologunowa, Adaeze, Mary N Otoo, Aisling R Caffrey, Ashley Buchanan, Uchenna J Eze, and Amisha Vyas. 2025. “Efficacy of Low-Dose Naltrexone in Treating Patients with Fibromyalgia: Systematic Review and Meta-Analysis.” Journal of Pain & Palliative Care Pharmacotherapy 39 (3): 363–73. https://doi.org/10.1080/15360288.2025.2496526.

Ortelli, Paola, Francesco Benso, Davide Ferrazzoli, et al. 2022. “Global Slowness and Increased Intra-Individual Variability Are Key Features of Attentional Deficits and Cognitive Fluctuations in Post COVID-19 Patients.” Scientific Reports 12: 13123. https://doi.org/10.1038/s41598-022-17463-x.

Osorio-Mendoza, Jazmin, Jana-Thabea Kiehn, Sarah Stenger, Keno O. Heinen, Laura Griewahn, Christiane E. Koch, Undine Haferkamp, et al. 2025. “Regulation of Hedonic Feeding Rhythms by Circadian Clocks in Leptin-Receptive Neurons.” Molecular Metabolism 100: 102221. https://doi.org/10.1016/j.molmet.2025.102221.

Pajuelo, D., M. Dezortova, M. Hajek, M. Ibrahimova, and I. Ibrahim. 2024. “Metabolic Changes Assessed by 1H MR Spectroscopy in the Corpus Callosum of Post-COVID Patients.” MAGMA 37 (5): 937–46. https://doi.org/10.1007/s10334-024-01171-w.

Palacios, Natalia, Samantha Molsberry, Kathryn C. Fitzgerald, and Anthony L. Komaroff. 2023. “Different Risk Factors Distinguish Myalgic Encephalomyelitis/Chronic Fatigue Syndrome from Severe Fatigue.” Scientific Reports 13 (1): 2469. https://doi.org/10.1038/s41598-023-29329-x.

Palma, Jose-Alberto, and Horacio Kaufmann. 2020. “Management of Orthostatic Hypotension.” Continuum (Minneapolis, Minn.) 26 (1): 154–77. https://doi.org/10.1212/CON.0000000000000816.

Panov, Josif, Liron Simchi, Yaron Feuermann, and Hanoch Kaphzan. 2020. “Bioinformatics Analyses of the Transcriptome Reveal Ube3a-Dependent Effects on Mitochondrial-Related Pathways.” International Journal of Molecular Sciences 21 (11): 4156. https://doi.org/10.3390/ijms21114156.

Papadopoulos, Andrew S., and Anthony J. Cleare. 2012. “Hypothalamic-Pituitary-Adrenal Axis Dysfunction in Chronic Fatigue Syndrome.” Nature Reviews Endocrinology 8 (1): 22–32. https://doi.org/10.1038/nrendo.2011.153.

Peng, Madeleine S., Jialin Jiang, Lucia Polizzi, Tiancheng Shi, Rakshitha Ramkumar, Victor O. Anosike, Giulia Guasoni, et al. 2026. “Dysregulated Adult Hippocampal Neurogenesis in Major Depressive Disorders.” Nature Medicine 32. https://doi.org/10.1038/s41591-026-04571-8.

Peppercorn, Katie, Sayan Sharma, Christina D. Edgar, Peter A. Stockwell, Euan J. Rodger, Aniruddha Chatterjee, and Warren P. Tate. 2025. “Comparing DNA Methylation Landscapes in Peripheral Blood from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Patients.” International Journal of Molecular Sciences 26 (14): 6631. https://doi.org/10.3390/ijms26146631.

Petersen, Nicole, Andrea J Rapkin, Kyoji Okita, Kelly R Kinney, Toshihiko Mizuno, Mark A Mandelkern, and Edythe D London. 2021. “Striatal Dopamine D(2)-Type Receptor Availability and Peripheral 17β-Estradiol.” Molecular Psychiatry 26 (6): 2038–47. https://doi.org/10.1038/s41380-020-01000-1.

Petrov, Steliyan, Martina Bozhkova, Mariya Ivanovska, Teodora Kalfova, Dobrina Dudova, Ralitsa Nikolova, Kalina Vaseva, et al. 2025. “Comparable Immune Alterations and Inflammatory Signatures in ME/CFS and Long COVID.” Biomedicines 13 (12): 3001. https://doi.org/10.3390/biomedicines13123001.

Petter, Elisabeth, Carmen Scheibenbogen, Peter Linz, Christian Stehning, Klaus Wirth, Titus Kuehne, and Marcus Kelm. 2022. “Muscle Sodium Content in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Translational Medicine 20 (1): 580. https://doi.org/10.1186/s12967-022-03616-z.

Phetsouphanh, Chansavath, Brendan Jacka, Samantha Ballouz, Katherine J L Jackson, Daniel B Wilson, Bikash Manandhar, Vera Klemm, et al. 2024. “Improvement of Immune Dysregulation in Individuals with Long COVID at 24-Months Following SARS-CoV-2 Infection.” Nature Communications 15 (1): 3315. https://doi.org/10.1038/s41467-024-47720-8.

Pinggal, Elaine, Paul M. Dockree, Redmond G. O’Connell, Mark A. Bellgrove, and Thomas Andrillon. 2022. “Pharmacological Manipulations of Physiological Arousal and Sleep-Like Slow Waves Modulate Sustained Attention.” Journal of Neuroscience 42 (43): 8113–24. https://doi.org/10.1523/JNEUROSCI.0836-22.2022.

Pinggal, Elaine, James Jackson, Anneke Kusztor, David Chapman, Jennifer Windt, Sean P. A. Drummond, Tim J. Silk, Mark A. Bellgrove, and Thomas Andrillon. 2026. “Sleep-Like Slow Waves During Wakefulness Mediate Attention and Vigilance Difficulties in Adult Attention-Deficit/Hyperactivity Disorder.” Journal of Neuroscience 46 (15): e1694252025. https://doi.org/10.1523/JNEUROSCI.1694-25.2025.

Ponticelli, Claudio, Gabriella Moroni, and Francesco Reggiani. 2023. “Autophagy and Podocytopathy.” Nephrology Dialysis Transplantation 38 (9): 1931–39. https://doi.org/10.1093/ndt/gfad024.

Qu, Shen, Jinjing Wang, Xiaoqian Guan, Caijun Song, and Xiaoyun Wang. 2024. “Sleep Disturbance in Angelman Syndrome Patients.” Orphanet Journal of Rare Diseases 19 (1): 146. https://doi.org/10.1186/s13023-024-03154-5.

Raijmakers, R, M Roerink, S Keijmel, L Joosten, M Netea, J van der Meer, H Knoop, H Klein, C Bleeker-Rovers, and J Doorduin. 2021. “No Signs of Neuroinflammation in Women with Chronic Fatigue Syndrome or q Fever Fatigue Syndrome Using TSPO Ligand [(11)c]-PK11195.” Neurology Neuroimmunology and Neuroinflammation 9 (1): e1113. https://doi.org/10.1212/NXI.0000000000001113.

Rassoulpour, Asma, Hui-Qiu Wu, Sergi Ferré, and Robert Schwarcz. 2005. “Nanomolar Concentrations of Kynurenic Acid Reduce Extracellular Dopamine Levels in the Striatum.” Journal of Neurochemistry 93 (3): 762–65. https://doi.org/10.1111/j.1471-4159.2005.03134.x.

Ray, Urvi, Antje Schulze Selting, Roshan Priyarangana Perera, Zhiqi Yang, Vladislav Lysenkov, Siri Göpel, Michael Bitzer, et al. 2026. “Dysregulated NK-Cell Gene Expression Defines the Enduring Symptoms of Long COVID-19.” Frontiers in Immunology 17: 1720551. https://doi.org/10.3389/fimmu.2026.1720551.

Rayhan, R. U., and J. N. Baraniuk. 2021. “Submaximal Exercise Provokes Increased Activation of the Anterior Default Mode Network During the Resting State as a Biomarker of Postexertional Malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Frontiers in Neuroscience 15: 748426. https://doi.org/10.3389/fnins.2021.748426.

Razumovsky, A. Y., K. DeBusk, H. Calkins, S. Snader, K. E. Lucas, P. Vyas, D. F. Hanley, and P. C. Rowe. 2003. “Cerebral and Systemic Hemodynamics Changes During Upright Tilt in Chronic Fatigue Syndrome.” Journal of Neuroimaging 13 (1): 57–67.

Rizor, Elizabeth J, Viktoriya Babenko, Neil M Dundon, Renee Beverly-Aylwin, Alexandra Stump, Margaret Hayes, Lauren Herschenfeld-Catalan, Emily G Jacobs, and Scott T Grafton. 2024. “Menstrual Cycle-Driven Hormone Concentrations Co-Fluctuate with White and Gray Matter Architecture Changes Across the Whole Brain.” Human Brain Mapping 45 (11): e26785. https://doi.org/10.1002/hbm.26785.

Roberts, David D., Sukhbir Kaur, and Jeffrey S. Isenberg. 2017. “Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.” Antioxidants & Redox Signaling 27 (12): 874–911. https://doi.org/10.1089/ars.2017.7140.

Rogers, Natasha M., Maryam Sharifi-Sanjani, Gábor Csányi, Patrick J. Pagano, and Jeffrey S. Isenberg. 2014. “Thrombospondin-1 and CD47 Regulation of Cardiac, Pulmonary and Vascular Responses in Health and Disease.” Matrix Biology 37: 92–101. https://doi.org/10.1016/j.matbio.2014.01.002.

Rothhammer, Veit, and Francisco J. Quintana. 2019. “The Aryl Hydrocarbon Receptor: An Environmental Sensor Integrating Immune Responses in Health and Disease.” Nature Reviews Immunology 19 (3): 184–97. https://doi.org/10.1038/s41577-019-0125-8.

Samms, Gemma Louise, and Chris P Ponting. 2025. “Unequal Access to Diagnosis of Myalgic Encephalomyelitis in England.” BMC Public Health 25 (1): 1417. https://doi.org/10.1186/s12889-025-22603-9.

Sarkar, Chinmoy, Basabi Basu, Debanjan Chakroborty, Partha S. Dasgupta, and Sujit Basu. 2010. “The Immunoregulatory Role of Dopamine: An Update.” Brain, Behavior, and Immunity 24 (4): 525–28. https://doi.org/10.1016/j.bbi.2009.10.015.

Schacterle, Richard S, and Anthony L Komaroff. 2004. “A Comparison of Pregnancies That Occur Before and After the Onset of Chronic Fatigue Syndrome.” Archives of Internal Medicine 164 (4): 401–4. https://doi.org/10.1001/archinte.164.4.401.

Schreiner, Philipp, Thomas Harrer, Carmen Scheibenbogen, Stephanie Lamer, Andreas Schlosser, Robert K. Naviaux, and Bhupesh K. Prusty. 2020. “Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Immunohorizons 4 (4): 201–15. https://doi.org/10.4049/immunohorizons.2000006.

Schwarcz, Robert, John P. Bruno, Paul J. Muchowski, and Hui-Qiu Wu. 2012. “Kynurenines in the Mammalian Brain: When Physiology Meets Pathology.” Nature Reviews Neuroscience 13 (7): 465–77. https://doi.org/10.1038/nrn3257.

Sellers, Katherine, Pooja Raval, and Deepak P Srivastava. 2015. “Molecular Signature of Rapid Estrogen Regulation of Synaptic Connectivity and Cognition.” Frontiers in Neuroendocrinology 36: 72–89. https://doi.org/10.1016/j.yfrne.2014.08.001.

Shadani, Sarah, Kyna Conn, Zane B Andrews, and Claire J Foldi. 2024. “Potential Differences in Psychedelic Actions Based on Biological Sex.” Endocrinology 165 (8): bqae083. https://doi.org/10.1210/endocr/bqae083.

Shankar, Vishnu, Julie Wilhelmy, Ellis J. Curtis, Basil Michael, Layla Cervantes, Vamsee A. Mallajosyula, Ronald W. Davis, et al. 2025. “Oxidative Stress Is a Shared Characteristic of ME/CFS and Long COVID.” Proceedings of the National Academy of Sciences U.S.A. 122 (28): e2426564122. https://doi.org/10.1073/pnas.2426564122.

Shimaoka, Haruka, Tomoya Kawaguchi, Kana Morikawa, Yuuki Sano, Kiyotada Naitou, Hiroyuki Nakamori, Takahiko Shiina, and Yasutake Shimizu. 2018. “Induction of Hibernation-Like Hypothermia by Central Activation of the A1 Adenosine Receptor in a Non-Hibernator, the Rat.” Journal of Physiological Sciences 68 (4): 425–30. https://doi.org/10.1007/s12576-017-0543-y.

Shkalim Zemer, Vered, Iris Manor, Abraham Weizman, Herman A. Cohen, Moshe Hoshen, Nehama M. Caspi, Shlomo Cohen, Stephen V. Faraone, and Nily Shahar. 2024. “The Influence of COVID-19 on Attention-Deficit/Hyperactivity Disorder Diagnosis and Treatment Rates Across Age, Gender, and Socioeconomic Status: A 20-Year National Cohort Study.” Psychiatry Research 339: 116077. https://doi.org/10.1016/j.psychres.2024.116077.

Sibley, Margaret H, Luis Augusto Rohde, James M Swanson, Lily T Hechtman, Brooke S G Molina, John T Mitchell, L Eugene Arnold, et al. 2018. “Late-Onset ADHD Reconsidered with Comprehensive Repeated Assessments Between Ages 10 and 25.” American Journal of Psychiatry 175 (2): 140–49. https://doi.org/10.1176/appi.ajp.2017.17030298.

Simchi, Liron, Pratiksha K. Gupta, Yaron Feuermann, and Hanoch Kaphzan. 2023. “Elevated ROS Levels During the Early Development of Angelman Syndrome Alter the Apoptotic Capacity of the Developing Neural Precursor Cells.” Molecular Psychiatry 28 (6): 2382–97. https://doi.org/10.1038/s41380-023-02038-7.

Skiba, Meredith A., and Andrew C. Kruse. 2021. “Autoantibodies as Endogenous Modulators of GPCR Signaling.” Trends in Pharmacological Sciences 42 (3): 135–50. https://doi.org/10.1016/j.tips.2020.11.013.

Slack, Emma, Katrina Anne Pears, Judith Rankin, Julia L Newton, and Mark Pearce. 2023. “Identifying, Synthesising and Appraising Existing Evidence Relating to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Pregnancy: A Mixed-Methods Systematic Review.” BMJ Open 13 (10): e070366. https://doi.org/10.1136/bmjopen-2022-070366.

Snyder, Jason S., Amelie Soumier, Michelle Brewer, James Pickel, and Heather A. Cameron. 2011. “Adult Hippocampal Neurogenesis Buffers Stress Responses and Depressive Behaviour.” Nature 476 (7361): 458–61. https://doi.org/10.1038/nature10287.

Sonnweber, Thomas, Philipp Grubwieser, Sabina Sahanic, Anna K. Böhm, Alex Pizzini, Anna Luger, Christoph Schwabl, et al. 2022. “The Impact of Iron Dyshomeostasis and Anaemia on Long-Term Pulmonary Recovery and Persisting Symptom Burden After COVID-19: A Prospective Observational Cohort Study.” Metabolites 12 (6): 546. https://doi.org/10.3390/metabo12060546.

Sorrells, Shawn F., Mercedes F. Paredes, Arantxa Cebrian-Silla, Kadellyn Sandoval, Dashi Qi, Kevin W. Kelley, David James, et al. 2018. “Human Hippocampal Neurogenesis Drops Sharply in Children to Undetectable Levels in Adults.” Nature 555 (7696): 377–81. https://doi.org/10.1038/nature25975.

Sorrells, Shawn F., Mercedes F. Paredes, Zicong Zhang, Gina Kang, Olaya Pastor-Alonso, Sara Biagiotti, Chelsea E. Page, et al. 2021. “Positive Controls in Adults and Children Support That Very Few, If Any, New Neurons Are Born in the Adult Human Hippocampus.” Journal of Neuroscience 41 (12): 2554–65. https://doi.org/10.1523/JNEUROSCI.0676-20.2020.

Souma, Bernard, Wesam Elremaly, Marie-Yvonne Akoume, Mohamed Elbakry, Christian Godbout, and Alain Moreau. 2026. “Irisin Signaling Resistance in Myalgic Encephalomyelitis: A Proposed Mechanistic Framework for Post-Exertional Malaise Involving the TSP-1–HSP90α–Αvβ5 Axis.” International Journal of Molecular Sciences 27 (11): 4770. https://doi.org/10.3390/ijms27114770.

Spanoghe, Martin, Tomaso Antonacci, Nicole Schneider, and Thomas H. J. Molmans. 2026. “Viewpoint: Linking Long Covid and AD(H)D Through Neuroimmune Dysfunction: A Translational Framework Proposal for Precision Medicine.” Brain, Behavior, and Immunity 131: 106181. https://doi.org/10.1016/j.bbi.2025.106181.

Stewart, J., A. Weldon, N. Arlievsky, K. Li, and J. Munoz. 1998. “Neurally Mediated Hypotension and Autonomic Dysfunction Measured by Heart Rate Variability During Head-up Tilt Testing in Children with Chronic Fatigue Syndrome.” Clinical Autonomic Research 8 (4): 221–30. https://doi.org/10.1007/BF02267785.

Stickford, Abigail S, Tiffany B VanGundy, Benjamin D Levine, and Qi Fu. 2015. “Menstrual Cycle Phase Does Not Affect Sympathetic Neural Activity in Women with Postural Orthostatic Tachycardia Syndrome.” The Journal of Physiology 593 (9): 2131–43. https://doi.org/10.1113/JP270088.

Strawbridge, Rebecca, Maria Laura Sartor, Fiona Scott, and Anthony J Cleare. 2019. “Inflammatory Proteins Are Altered in Chronic Fatigue Syndrome–a Systematic Review and Meta-Analysis.” Neuroscience and Biobehavioral Reviews 107: 69–83. https://doi.org/10.1016/j.neubiorev.2019.08.011.

Stussman, Barbara, Nicolas Camarillo, Gina McCrossin, Mary Stockman, Gina Norato, Caryn S. Vetter, Anamaria Ferrufino, et al. 2025. “Post-Exertional Malaise in Long COVID: Subjective Reporting Versus Objective Assessment.” Frontiers in Neurology 16: 1534352. https://doi.org/10.3389/fneur.2025.1534352.

Su, Hui, Wei Fan, Pinar E. Coskun, Jouni Vesa, Jeffrey A. Gold, Yong-hui Jiang, Prasanth Potluri, Douglas C. Wallace, Jane Gibson, and Virginia E. Kimonis. 2011. “Mitochondrial Dysfunction in CA1 Hippocampal Neurons of the UBE3A Deficient Mouse Model for Angelman Syndrome.” Neuroscience Letters 487 (2): 129–33. https://doi.org/10.1016/j.neulet.2009.06.079.

Sunami, Yutaro, Kazushi Sugaya, and Kazushi Takahashi. 2025. “G Protein-Coupled Receptors Related to Autoimmunity in Postural Orthostatic Tachycardia Syndrome.” Immunological Medicine 48 (1): 1–11. https://doi.org/10.1080/25785826.2025.2457613.

Tanaka, Masaru, Ákos Szabó, Eleonóra Spekker, Helga Polyák, Fanni Tóth, and László Vécsei. 2022. “Mitochondrial Impairment: A Common Motif in Neuropsychiatric Presentation? The Link to the Tryptophan–Kynurenine Metabolic System.” Cells 11 (16): 2607. https://doi.org/10.3390/cells11162607.

Tang, Qijun, Elizabeth Godschall, Charles D. Brennan, Qi Zhang, Ruei-Jen Abraham-Fan, Sydney P. Williams, Taha Bugra Gungul, et al. 2023. “Leptin Receptor Neurons in the Dorsomedial Hypothalamus Input to the Circadian Feeding Network.” Science Advances 9 (34): eadh9570. https://doi.org/10.1126/sciadv.adh9570.

Thapaliya, Kiran, Sonya Marshall-Gradisnik, James Baraniuk, Natalie Eaton-Fitch, and Leighton Barnden. 2022. “Brainstem Neuroimaging Reveals Structural Abnormalities in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Frontiers in Neuroscience 16: 828014. https://doi.org/10.3389/fnins.2022.828014.

Thapaliya, Kiran, Sonya Marshall-Gradisnik, Markus Barth, Natalie Eaton-Fitch, and Leighton Barnden. 2023. “Brainstem Volume Changes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Patients.” Frontiers in Neuroscience 17: 1125208. https://doi.org/10.3389/fnins.2023.1125208.

Thapaliya, Kiran, Sonya Marshall-Gradisnik, Maira Inderyas, and Leighton Barnden. 2025. “Altered Brain Tissue Microstructure and Neurochemical Profiles in Long COVID and Recovered COVID-19 Individuals: A Multimodal MRI Study.” Brain, Behavior, & Immunity – Health 50: 101142. https://doi.org/10.1016/j.bbih.2025.101142.

Thapaliya, Kiran, Sonya Marshall-Gradisnik, Donald Staines, and Leighton Barnden. 2021. “Diffusion Tensor Imaging Reveals Neuronal Microstructural Changes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” European Journal of Neuroscience 54 (6): 6214–28. https://doi.org/10.1111/ejn.15413.

Thirugnanam, Siva, Alison R. Van Zandt, Alexandra B. McNally, Victoria A. Hart, Isabelle Berthelot, Cecily C. Midkiff, Lara A. Doyle-Meyers, et al. 2026. “Dietary Indoles Influence the AHR-RORgt Axis and Mucosal Immune Homeostasis in ART-Treated SIV Infection.” JCI Insight 11 (10): e201258. https://doi.org/10.1172/jci.insight.201258.

Thomas, Natalie, Caroline Gurvich, Katherine Huang, Paul R Gooley, and Christopher W Armstrong. 2022. “The Underlying Sex Differences in Neuroendocrine Adaptations Relevant to Myalgic Encephalomyelitis Chronic Fatigue Syndrome.” Frontiers in Neuroendocrinology 66: 100995. https://doi.org/10.1016/j.yfrne.2022.100995.

Thomas, Natalie, Katherine Huang, Elena K Schneider-Futschik, Beth Pollack, Michal C Tal, David Fineberg, X Wang, et al. 2026. “Systems Neuroendocrinology in ME/CFS and Long COVID: A Chronobiological Framework for Hormone-Based Research.” Frontiers in Neuroendocrinology 82: 101268. https://doi.org/10.1016/j.yfrne.2026.101268.

Thornton, Emily J., Lawrence D. Hayes, Daniel S. Goodwin, Nicholas Sculthorpe, Yeliz Prior, and Nilihan E. M. Sanal-Hayes. 2025. “Managing Energy, and Shaping Care: Insights from Adults with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through Co-Production Workshops.” American Journal of Medicine 138 (6): 1001–9. https://doi.org/10.1016/j.amjmed.2025.02.008.

Tomas, C. et al. 2017. “Cellular Bioenergetics Is Impaired in Patients with Chronic Fatigue Syndrome.” PLoS One 12 (10): e0186802. https://doi.org/10.1371/journal.pone.0186802.

Torrelli-Diljohn, Alex, Bhargavi Kulkarni, and Dario A. Vitturi. 2026. “Cell Signaling by Tryptophan Catabolism.” Biochemistry 65 (9): 1366–94. https://doi.org/10.1021/acs.biochem.6c00179.

Trapp, Bruce D., and Peter K. Stys. 2009. “Virtual Hypoxia and Chronic Necrosis of Demyelinated Axons in Multiple Sclerosis.” Lancet Neurology 8 (3): 280–91. https://doi.org/10.1016/S1474-4422(09)70043-2.

Tsilioni, Irene, Benjamin Natelson, and Theoharis C. Theoharides. 2022. “Exosome-Associated Mitochondrial DNA from Patients with ME/CFS Stimulates Human Microglia to Release IL-1$\beta$.” European Journal of Neuroscience 56 (10): 5784–94. https://doi.org/10.1111/ejn.15828.

Tsuchida, T. et al. 2022. “Relationship Between Changes in Symptoms and Antibody Titers After a Single Vaccination in Patients with Long COVID.” Journal of Medical Virology 94 (7): 3416–20. https://doi.org/10.1002/jmv.27725.

Tuomaala, J, M Saraste, E Smith, M Kuusi, E Westerberg, E Honkonen, R Kargar, et al. 2026. “Association Between Post-COVID-19 Neuropsychiatric Symptoms and Persistent Glial Activation in the Limbic System: A TSPO PET Study.” Journal of Neurology 273 (5): 298. https://doi.org/10.1007/s00415-026-13842-w.

Unger, Elizabeth R., Jin-Mann S. Lin, Lauren E. Wisk, Huihui Yu, Michelle L’Hommedieu, Helen Lavretsky, Juan Carlos C. Montoy, et al. 2024. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection.” JAMA Network Open 7 (7): e2423555. https://doi.org/10.1001/jamanetworkopen.2024.23555.

Van Dongen, Hans P. A. 2025. “Local Versus Global Sleep Organization and the Quest to Determine Sleep Function.” Neurobiology of Sleep and Circadian Rhythms 18 (Suppl): 100117. https://doi.org/10.1016/j.nbscr.2025.100117.

Van Elslande, J. et al. 2021. “Longitudinal Follow-up of IgG Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infected Patients up to Eight Months After Infection.” Journal of Clinical Virology 136: 104765. https://doi.org/10.1016/j.jcv.2021.104765.

Vatvani, Akhil D, Priya Patel, Timotius Ivan Hariyanto, and Theo Audi Yanto. 2024. “Efficacy and Safety of Low-Dose Naltrexone for the Management of Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis.” The Korean Journal of Pain 37 (4): 367–78. https://doi.org/10.3344/kjp.24202.

Vu, Quan M., Annette L. Fitzpatrick, Jennifer R. Cope, Jeanne Bertolli, Nona Sotoodehnia, Thomas E. West, Nikki L. Gentile, and Elizabeth R. Unger. 2024. “Estimates of Incidence and Predictors of Fatiguing Illness After SARS-CoV-2 Infection.” Emerging Infectious Diseases 30 (3): 539–47. https://doi.org/10.3201/eid3003.231194.

Walitt, Brian, Komudi Singh, Samuel R LaMunion, Mark Hallett, Sandra Jacobson, Kong Chen, Yoshihisa Enose-Akahata, et al. 2024. “Deep Phenotyping of Post-Infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Nature Communications 15 (1): 907. https://doi.org/10.1038/s41467-024-45107-3.

Wang, Lu, Peng Chen, Qian Gao, Ying Men, Quanyuan Yun, Qiang Zhang, Xin Xing, et al. 2026. “A Telomere-to-Telomere Genome Reveals Arachidonic Acid as a Key Regulator of Hepatic Lipid Metabolism During Hibernation.” Communications Biology. https://doi.org/10.1038/s42003-026-10625-x.

Wang, X.-Y., J. D. Huizinga, J. Diamond, and L. W. C. Liu. 2009. “Loss of Intramuscular and Submuscular Interstitial Cells of Cajal and Associated Enteric Nerves Is Related to Decreased Gastric Emptying in Streptozotocin-Induced Diabetes.” Neurogastroenterology and Motility 21 (10): 1095–e92. https://doi.org/10.1111/j.1365-2982.2009.01336.x.

Ward, Anna I, Jose I de Las Heras, Eric C Schirmer, and Ariberto Fassati. 2025. “Memory CD4+ T Cells Sequentially Restructure Their 3D Genome During Stepwise Activation.” Frontiers in Cell and Developmental Biology 13: 1514627. https://doi.org/10.3389/fcell.2025.1514627.

Watanabe, Makoto, Takuya Goto, Riko Miyoshi, Shohei Nakakubo, Yumiko Hiramatsu, Ryosuke Nakajima, Akihiko Kondo, Kazuki Higashiyama, and Kazuhiro Yamakawa. 2026. “Region-Dependent Differences in Tonic Inhibition Underlie Epileptic Features in Angelman Syndrome Model Mice.” Epilepsia. https://doi.org/10.1002/epi.70307.

Wauquier, Fabien, Line Boutin-Wittrant, Line Pourtau, David Gaudout, Benjamin Moras, Adrien Vignault, Caroline Monchaux De Oliveira, Julien Gabaston, et al. 2022. “Circulating Human Serum Metabolites Derived from the Intake of a Saffron Extract Protect Human Neurons from Oxidative Stress-Induced Neurotoxicity.” Nutrients 14 (7): 1511. https://doi.org/10.3390/nu14071511.

Wei, Ke, Rui Li, Xuan Zhao, Bing Xie, Tong Xie, Qiu Sun, Yi Chen, et al. 2025. “TRIM28 Is an Essential Regulator of Three-Dimensional Chromatin State Underpinning CD8+ T Cell Activation.” Nature Communications 16 (1): 750. https://doi.org/10.1038/s41467-025-56029-z.

Williams, Graham, Jim Waterhouse, Javier Mugarza, et al. 2002. “Therapy of Circadian Rhythm Disorders in Chronic Fatigue Syndrome: No Symptomatic Improvement with Melatonin or Phototherapy.” European Journal of Clinical Investigation 32 (11): 831–37. https://doi.org/10.1046/j.1365-2362.2002.01081.x.

Wirth, Klaus J., and Carmen Scheibenbogen. 2026. “Imbalance of Excitatory and Inhibitory Neurotransmitter Systems in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International Journal of Molecular Sciences 27 (9): 4041. https://doi.org/10.3390/ijms27094041.

Wirth, Klaus J., and Jürgen M. Steinacker. 2025. “The Potential Causes of Myasthenia and Fasciculations in Severely Ill ME/CFS Patients: The Role of Disturbed Electrophysiology.” Frontiers in Physiology 16: 1693589. https://doi.org/10.3389/fphys.2025.1693589.

Woo, Tae-Won, Yoo-Jin Choi, Ji-Yeon Kim, Jin-Seok Lee, and Chang-Gue Son. 2026. “Neuroendocrine Signature of ME/CFS: Meta-Analytic Evidence for Bioactive Cortisol Deficit and Exaggerated Feedback Sensitivity.” Molecular Psychiatry. https://doi.org/10.1038/s41380-026-03608-1.

Wu, Cheng-Wei, and Kenneth B Storey. 2021. “mTOR Signaling in Metabolic Stress Adaptation.” Biomolecules 11 (5): 681. https://doi.org/10.3390/biom11050681.

Wu, Kai, Zhiliang Wu, Siyuan Feng, Tianci Zhou, Yuping Ning, Kuangshi Li, and Hongxiao Jia. 2026. “Microstructural White Matter Impairments in Chronic Fatigue Syndrome: Evidence of Segmental Injury in the Cingulum Bundle.” Brain Research Bulletin 234: 111671. https://doi.org/10.1016/j.brainresbull.2025.111671.

Xiong, Ruoyun, Elizabeth Aiken, Ryan Caldwell, Suzanne D. Vernon, Lina Kozhaya, Courtney Gunter, Lucinda Bateman, Derya Unutmaz, and Julia Oh. 2025. “AI-Driven Multi-Omics Modeling of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Nature Medicine 31 (9): 2991–3001. https://doi.org/10.1038/s41591-025-03788-3.

Xiong, Ruoyun, Courtney Gunter, Elizabeth Fleming, Suzanne D. Vernon, Lucinda Bateman, Derya Unutmaz, and Julia Oh. 2023. “Multi-’omics of Gut Microbiome-Host Interactions in Short- and Long-Term Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients.” Cell Host & Microbe 31 (2): 273–287.e5. https://doi.org/10.1016/j.chom.2023.01.001.

Xu, Wen-Tao, Xian-Bin An, Mei-Jun Chen, Jie Ma, Xue-Qin Wang, Jia-Nan Yang, Qiang Wang, et al. 2025. “A Gene Cluster of Mitochondrial Complexes Contributes to the Cognitive Decline of COVID-19 Infection.” Molecular Neurobiology 62 (6): 6869–83. https://doi.org/10.1007/s12035-024-04471-3.

Zagon, Ian S, and Patricia J McLaughlin. 2018. “Intermittent Blockade of OGFr and Treatment of Autoimmune Disorders.” Experimental Biology and Medicine (Maywood) 243 (17-18): 1323–30. https://doi.org/10.1177/1535370218817746.

Zaitsu, Munehiro, Shin-ichiroh Narita, Kenneth C Lambert, James J Grady, D Mark Estes, Edward M Curran, Edward G Brooks, Cheryl S Watson, Randall M Goldblum, and Terumi Midoro-Horiuti. 2007. “Estradiol Activates Mast Cells via a Non-Genomic Estrogen Receptor-Alpha and Calcium Influx.” Molecular Immunology 44 (8): 1977–85. https://doi.org/10.1016/j.molimm.2006.09.030.

Zaki, Nevin F W, Mohamed Yousif, Ahmed S BaHammam, David Warren Spence, Vijay K Bharti, Perumal Subramanian, and Seithikurippu R Pandi-Perumal. 2019. “Chronotherapeutics: Recognizing the Importance of Timing Factors in the Treatment of Disease and Sleep Disorders.” Clinical Neuropharmacology 42 (3): 80–87. https://doi.org/10.1097/WNF.0000000000000341.